

CURRICULUM VITAE

PERSONAL HISTORY:

Name: Anthony David Elias

Current Position: Professor of Medicine, University of Colorado School of Medicine

Office Address: University of Colorado Anschutz Medical Center
Mail Stop F724, ACP 5310
1665 Aurora Court
Aurora, CO 80045

Home Address: 6565 E. 6th Avenue, Denver, CO 80220

Email: Anthony.Elias@cuanschutz.edu

Fax: 303-724-3889

Phone: 720-848-0347

Clinic: 720-848-3532

Place of Birth: New York, New York

EDUCATION:

Medical School:
1976 A.B. (cum laude) Princeton University, Princeton, NJ
1980 M.D. New York University School of Medicine, New York, NY

Internship and Residency:
1980-1981 Intern in Medicine, Johns Hopkins Hospital, Baltimore, MD
1981-1982 Junior Assistant Resident, Johns Hopkins Hospital, Baltimore, MD
1982-1983 Senior Assistant Resident, Johns Hopkins Hospital, Baltimore, MD

Clinical Fellowships:
1983-1986 Clinical Fellow in Medicine,
Harvard Medical School, Boston, MA
1983-1986 Fellow in Medical Oncology,
Dana-Farber Cancer Institute, Boston, MA
1983-1986 Clinical Fellow in Medicine,
Brigham & Women's Hospital, Boston, MA

ACADEMIC APPOINTMENTS:

1986-1990 Instructor in Medicine, Harvard Medical School, Boston, MA
1990-2000 Assistant Professor in Medicine, Harvard Medical School, Boston, MA
2000 Associate Professor in Medicine, Harvard Medical School, Boston, MA
2000-2006 Associate Professor in Medicine, University of Colorado, Aurora, CO
2006-present Professor in Medicine, University of Colorado, Aurora, CO
2008-present Martha Cannon Dear Chair for Breast Cancer Research, University of Colorado,
Aurora, CO
2014 Tenure

HOSPITAL, GOVERNMENT OR OTHER PROFESSIONAL POSITIONS:

1986-2000	Associate in Medicine, Beth Israel Hospital, Boston, MA
1986-1990	Associate Physician, Brigham and Women's Hospital, Boston, MA
1986-1990	Clinical Associate in Medicine, Dana-Farber Cancer Institute, Boston, MA
1990-1992	Assistant Physician, Dana-Farber Cancer Institute, Boston, MA
1992-2000	Assistant Professor of Medicine, Dana-Farber Cancer Institute, Boston, MA
2000	Associate Professor of Medicine, Dana-Farber Cancer Institute, Boston, MA
2000-2006	Associate Professor of Medicine, University of Colorado, Aurora, CO
2004-2010	Attending Physician, Montrose Medical Center, Montrose, CO
2006-present	Professor of Medicine, University of Colorado, Aurora, CO with tenure (7/2014)
2006-2011	Associate with Clinical Privileges, Vail Valley Medical Center, Vail, CO
2010-2016	Provisional Consulting Staff, St. Mary's Hospital & Medical Center, Grand Junction, CO

HONORS, SPECIAL RECOGNITIONS AND AWARDS:

1980-present	Alpha Omega Alpha
1980	Andrew Friedland Memorial Prize for Internal Medicine
1980	Alpha Omega Alpha Prize for Scholastic Achievement
1985-1986	Aid for Cancer Research Fellowship
1986-1989	American Cancer Society Physician's Research Training Fellowships:
1989-1992	American Cancer Society Career Development Award
1990-present	Fellow - American College of Physicians
2001-present	Selected for "Best Doctors in America" (Castle Connolly, etc)
2008-present	Who's Who in America (Marquis)
2011-present	Top Doctor, US News & World Report
2012	Patient's Choice, American Registry
2013-present	Best Doctors for Executives (ColoradoBiz)
2013-present	Regional Top Doctor (Castle Connolly)
2013-2021	May; BCLS/ACLS certification
2013-	Vitals Top 10 Doctor, American Registry
2013-present	America's Top Physicians for Cancer
2014	America's Top Physicians
2014	Foundations in Medicine Golden Stethoscope Award for Patient/Physician Communication
2015	Top Oncologist (International Association of Oncologists (IAO))
2015	Top Doctor in Newsweek (Castle Connolly)
2017	America's Most Honored Businesses 2016 – top 10%
2020	Teaching Award: Medical Oncology Fellows

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS:

1982-present	American College of Physicians (FACP)
1985-present	American Association for the Advancement of Science
1987-present	American Society of Clinical Oncology
1991-2000	International Association for the Study of Lung Cancer
1992-2000	Cancer and Leukemia Group B Investigator (3295)
1993-2002	International Society for Hematotherapy & Graft Engineering (174)
1993-2002	American Society for Blood and Marrow Transplantation
1994-present	American Association for Cancer Research
2001-present	Southwest Oncology Group Investigator (17675)

2001-present NSABP/NRG Investigator (14758)
2008-present SARC Investigator

Major Service Responsibilities:

Department of Medicine: Dana-Farber Cancer Institute, Harvard University
1987-2000 Member Lung Cancer Planning/TOP Steering Committee, DFCI
1997-2000 Member Breast Cancer Working Committee, DFCI

University of Colorado
12/2002-2/2003 Interim Chief, Medical Oncology, University of Colorado School of Medicine
2004-2005 Member, Search Committee BMT Head
2004-2005 Chair, Search Committee BMT Physician
2004-2005 Member, Incentive Committee, Department of Medicine
2004-present Member, Medical Oncology Fellowship Committee
2006-present Member, Medical Oncology Steering Committee
2006-present Member, Medical Oncology Clinical Affairs Committee
2009-2011 Member, BMT Oversight Committee
2009-2015 Member, Professional Promotions and Tenure Committee

University:
Dana-Farber Cancer Institute, Harvard University
1995-2000 Project Leader, STAMP PO1, DFCI
1998-2000 Principal Investigator, STAMP PO1, DFCI

University of Colorado
2000-2015 Program Leader for Breast Cancer, UCCC
2000-present Member, University of Colorado Cancer Center
2000-2015 Member, Hormone-Related Malignancies Program, UCCC
2000-present Member, Developmental Therapeutics Program, UCCC
2001-2002 Interim Co-Leader, Hormone-Related Malignancies Program, UCCC
2001-2012 Associate Director of Cancer Center (Clinical Sciences), UCCC
2001-present Member, COMIRB (IRB)
2000-2012 Member, Management Committee, University of Colorado Cancer Center
2002-2004 Interim Director, Clinical Investigations Core, UCCC
2001-2004, 2005-2012 Chair, PQASC Committee UCHSC (Data Safety & Monitoring)
2012-2015 Member, UCCC Data Safety & Monitoring Committee
2001-2004 Chair, CIC Reorganization Committee, UCCC
2002-2007 Chair/Member, Informatics Reorganization Committee, UCCC
2002-present Member, Protocol Review and Monitoring Committee, UCCC
2002-2014 Principal Investigator, University of Colorado SWOG grant
2003-2004 Member/Chair, Search Committee Medical Director, CIC
2003-2004 Member, Search Committee Associate Director for Basic Science, Endowed
Chair School of Pharmacy
2004 Chair, Dean's Review Committee, School of Pharmacy (Dr. Vandenberg
promotion)
2003-2004 Scientific Advisory Board, Women's Health Program, University of Colorado
Health Sciences Center (PI: Margaret Neville)
2002-2007 Member, Space Committee, UCCC
2002-2012 Chair, Data Sharing Committee, UCCC
2006-2008 Member, Search Committee for Division Chief of Pediatric Heme/Onc/BMT
2006-2007 Member, Search Committee for Associate Director for Administration, UCCC
2006-2009 Member, Faculty Senate, University of Colorado
2006-2015 Director, Sarcoma Clinic

2008 Chair, Search Committee for Associate Director for Outreach, UCCC
 2008-2015 Member, Outreach Committee, UCCC
 2008-present Member, BIRCWH K12 Committee
 2008-present Member, UCCC-ACS K12 Committee
 2008-present Member, UCCC Biobanking Committee
 2009-2010 Member, Search Committee for Associate Director for Population Science, UCCC
 2009-present Reviewer, CCTSI grant panel
 2010 Member, Internal Advisory Board NCI TREC grant
 2011-2012 Member, Search Committee for C-TRIC director, Department of Radiology
 2011-present Member, Research Advisory Council
 2012-2015 Member, Scientific Advisory Board; R25 Cancer Education Grant (Overholser, PI)
 2013-2020 Member, Clinical Translational Research Advisory Committee (CTRAC)
 2014-2019 Principal Investigator, University of Colorado LAPS U10 grant
 2019-2025 Principal Investigator, University of Colorado LAPS UG1 grant

Hospital:

Dana-Farber Cancer Institute, Harvard University

1985-1994 Member Sarcoma Subspecialty Clinic, DFCI
 1986-2000 Bone Marrow Transplant Attending - 3-6 months/year, DFCI/BWH/BIDMC
 1987-2000 Member Lung Cancer Subspecialty Clinic, DFCI
 1997-2000 Member Breast Cancer Subspecialty Clinic, DFCI
 1987-1991 Director of Cryopreservation Laboratory for Autologous Transplantation, DFCI
 1993-2000 Clinical Director, Dana-Farber Cancer Institute/Beth Israel Hospital Solid Tumor Autologous Marrow Program
 1997 JV Audit subcommittee, Partners Joint Venture
 1997-2000 BMT Care Improvement Team, DFCI
 1998 Pt/Family Reunion Committee, DFCI

University of Colorado

2000-present Medical Director Breast Cancer Research Program, University of Colorado
 2000-present Co-director, Breast Center, University of Colorado
 2004-2005 Interim Director, Adult BMT Program, UCHSC
 2004-2005 Interim Clinical Director, Stem Cell Laboratory, UCH
 2003-2004 Member, Oncology Inpatient Floor Planning Committee
 2011-present Member, Cancer Committee, UCH

State and National Committees:

1992 ASCO Program Committee
 1992 ACS Epidemiology, Diagnosis and Therapy Committee
 1993-1995 Principal Investigator - Phase III trial CALGB 9134
 1994-1997 Principal Investigator - phase II trial CALGB 9331
 1994-2000 CALGB Transplant Committee
 1996-2001 National Comprehensive Cancer Network SCLC Guidelines
 1998-2001 Chairperson, NCCN SCLC Guideline Committee
 2001-present Member, SWOG Breast Committee
 2004-present Member, SWOG Breast Working Group
 2011-present Co-chair, SWOG Breast Working Group Her2+ subcommittee
 2002-2004 ASCO Education and Program Committee
 2004 Chair, ASCO Breast Cancer Program Committee Track
 2004 ASCO Foundation Advanced Research Grant Committee
 2008-2012 ASCO IDEA mentor
 2008 Komen IIR and Career Catalyst Research Grant Committee

2009	Komen PG-1 Peer Review Panel
2009	DOD Breast Cancer Research Program Peer Review Panel
2010	DOD Breast Cancer Research Program Peer Review Panel
2011	DOD Breast Cancer Research Program Peer Review Panel
2011-present	Member, SWOG, Symptom Control and Quality of Life and Molecular Epidemiology Committee
2012	ASCO BC ACRA review committee
2012	DOD Breast Cancer Research Program Peer Review Panel
2013	ASCO BC ACRA Review Committee
2013	NCI P50 SPORE III Review Committee
2013-present	Member, NCCN Breast Panel
2013	Member, Scientific Advisory Board, Emory University Breast Cancer SPORE application
2013	DOD Breast Cancer Research Program Breakthrough reviewer
2013	DOD Breast Cancer Research Program Integration Panel
2014	ASCO BC ACRA Review Committee
2015	DOD Breast Cancer Research Program Peer Review Panel
2015	NCCN Foundation YIA Grants Selection Review Committee
2018-2020	ASCO CCF Award
2018	DOD Breast Cancer Research Program panel
2019	DOD Sarcoma/Rare Tumors Research Program panel
2020	DOD Breast Research Program panel (chair)
2020	DOD Sarcoma/Rare Tumors Research Program panel
2021	ASCO YIA Sarcoma panel (chair)
2021	DOD Sarcoma/Rare Tumors Research Program panel
2021	DOD BCRP panel
International Committee:	
2009-2014	Member, BIG NABCG Metastatic Breast Cancer Panel
2010-present	EORTC Protocol Review Committee

MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES:

Department of Medicine:

Dana-Farber Cancer Institute, Harvard University

1987-2000	Member Lung Cancer Planning/TOP Steering Committee, DFCI
1997-2000	Member Breast Cancer Working Committee, DFCI

University of Colorado

2002-2003	Interim Chief, Medical Oncology, University of Colorado School of Medicine
2004-2005	Member, Search Committee BMT Head
2004-2005	Chair, Search Committee BMT Physician
2004-2005	Member, Incentive Committee, Department of Medicine
2004-present	Member, Medical Oncology Fellowship Committee
2006-present	Member, Medical Oncology Steering Committee
2006-present	Member, Medical Oncology Clinical Affairs Committee
2009-2011	Member, BMT Oversight Committee
2009-2015	Member, Professorial Promotions and Tenure Committee
2015-2018	Member, Post-Tenure Committee

University:

Dana-Farber Cancer Institute, Harvard University

1995-2000.1 Project Leader, STAMP PO1, DFCI
1998-2000 Principal Investigator, STAMP PO1, DFCI

University of Colorado

2000-2014 Program Leader for Breast Cancer, UCCC
2000-present Member, University of Colorado Cancer Center
2000-2016 Member, Hormone-Related Malignancies Program, UCCC
2000-present Member, Developmental Therapeutics Program, UCCC
2001-2002 Interim Co-Leader, Hormone-Related Malignancies Program, UCCC
2001-2012 Associate Director of Cancer Center (Clinical Sciences), UCCC
2001-present Member, COMIRB (IRB)
2000-2012 Member, Management Committee, University of Colorado Cancer Center
2002-2004 Interim Director, Clinical Investigations Core, UCCC
2001-2004, 2005-2014 Chair, PQASC Committee UCHSC (Data Safety & Monitoring)
2001-2004 Chair, CIC Reorganization Committee, UCCC
2002-2007 Chair/Member, Informatics Reorganization Committee, UCCC
2002-present Member, Protocol Review and Monitoring Committee, UCCC
2002-2014 Principal Investigator, University of Colorado SWOG grant
2003-2004 Member/Chair, Search Committee Medical Director, CIC
2003-2004 Member, Search Committee Associate Director for Basic Science, Endowed
Chair School of Pharmacy
2004 Chair, Dean's Review Committee, School of Pharmacy (Dr. Vandenberg
promotion)
2003-2004 Scientific Advisory Board, Women's Health Program, University of Colorado
Health Sciences Center (PI: Margaret Neville)
2002-2007 Member, Space Committee, UCCC
2002-2012 Chair, Data Sharing Committee, UCCC
2006-2008 Member, Search Committee for Division Chief of Pediatric Heme/Onc/BMT
2006-2007 Member, Search Committee for Associate Director for Administration, UCCC
2006-2009 Member, Faculty Senate, University of Colorado
2008 Chair, Search Committee for Associate Director for Outreach, UCCC
2008-2018 Member, Outreach Committee, UCCC
2008-present Member, BIRCWH K12 Committee
2008-present Member, UCCC-ACS K12 Committee
2008-2018 Member, UCCC Biobanking Committee
2009-2010 Member, Search Committee for Associate Director for Population Science,
UCCC
2009-present Reviewer, CCTSI grant panel
2010 Member, Internal Advisory Board NCI TREC grant
2011-2012 Member, Search Committee for C-TRIC director, Department of Radiology
2011-2018 Member, Research Advisory Council
2012-2014 Member, Scientific Advisory Board; R25 Cancer Education Grant (Overholser,
PI)
2018-present Member of Executive Committee, Protocol Review and Monitoring Committee
2020-2021 Interim Medical Director, Cancer Center Clinical Trials Office

Hospital:

Dana-Farber Cancer Institute, Harvard University

1985-1994 Member Sarcoma Subspecialty Clinic, DFCI
1986-2000 Bone Marrow Transplant Attending - 3-6 months/year, DFCI/BWH/BIDMC
1987-2000 Member Lung Cancer Subspecialty Clinic, DFCI
1997-2000 Member Breast Cancer Subspecialty Clinic, DFCI
1987-1991 Director of Cryopreservation Laboratory for Autologous Transplantation, DFCI

1993-2000	Clinical Director, Dana-Farber Cancer Institute/Beth Israel Hospital Solid Tumor Autologous Marrow Program
1997	JV Audit Subcommittee, Partners Joint Venture
1997-2000	BMT Care Improvement Team, DFCI
1998	Patient Family Reunion Committee, DFCI
University of Colorado	
2000-2014	Medical Director Breast Cancer Research Program, University of Colorado
2000-2014	Co-director, Breast Center, University of Colorado
2004-2005	Interim Director, Adult BMT Program, UCHSC
2004-2005	Interim Clinical Director, Stem Cell Laboratory, UCH
2003-2004	Member, Oncology Inpatient Floor Planning Committee
2009-2011	Member, Faculty Senate
2011-present	Member, Cancer Committee, UCH
2013-present	Chair (2013-2016) and member, Breast Cancer Joint Operating Committee
National:	
1992	ASCO Program Committee
1992	ACS Epidemiology, Diagnosis and Therapy Committee
1993-1995	Principal Investigator - Phase III trial CALGB 9134
1994-2000	Principal Investigator - Phase II trial CALGB 9331
1994-2000	CALGB Transplant Committee
1996-2001	National Comprehensive Cancer Network SCLC Guidelines
1998-2001	Chairperson
2001-present	Member, SWOG Breast Committee
2004-present	Member, SWOG Breast Working Group
2011-present	Co-chair, SWOG Breast Working Group Her2+ subcommittee
2002-2004	ASCO Education and Program Committee
2004	Chair, Breast Cancer Program Committee Track
2004	ASCO Foundation Advanced Research Grant Committee
2008-2012	ASCO IDEA mentor
2008	Komen IIR and Career Catalyst Research Grant Committee
2009	Komen PG-1 Peer Review Panel
2009	DOD Breast Cancer Research Program Peer Review Panel
2010	DOD Breast Cancer Research Program Peer Review Panel
2011	DOD Breast Cancer Research Program Peer Review Panel
2012	ASCO BC ACRA review committee
2012	DOD Breast Cancer Research Program Peer Review Panel
2013	ASCO BC ACRA Review Committee
2013	NCI P50 SPORE III Review Committee
2013-present	NCCN Breast Cancer Panel
2013	DOD Breast Cancer Research Program Breakthrough reviewer
2014	ASCO BC ACRA Review Committee
2014-2019	Principal Investigator, University of Colorado LAPS U10 grant
2019-2025	Principal Investigator, University of Colorado LAPS UG1 grant
2015	DOD Breast Cancer Research Program Peer Review Panel
2018	ASCO YIA review panel
2018	DOD Breast Cancer Research Program Peer Review Panel
2018-2020	ASCO CCF grant review
2019	DOD Sarcoma/Rare Tumors Research Program panel
2020	DOD Breast Cancer Research Program Peer Review Panel (chair)
2020	NCI STEEP 2.0 committee
2021	ASCO YIA Sarcoma panel (chair)
2021	DOD Sarcoma/Rare Tumors Research Program panel

2021 ASCO Use of Biomarkers to Guide Decisions on Systemic Therapy for Women
With Metastatic Breast Cancer Guideline.

International:

2009-2019 Member, BIG NABCG Metastatic Breast Cancer Panel
2010-present EORTC Protocol Review Committee

LICENSURE AND BOARD CERTIFICATION:

1983-2001 Massachusetts License Registration
1983 American Board of Internal Medicine
1985 American Board of Internal Medicine, Oncology Subspecialty Boards
1997, 1999, 2013, 2015, 2017, 2019 Advanced Cardiac Life Support Certification
2000-present Colorado License Registration

INVENTIONS, INTELLECTUAL PROPERTY AND PATENTS HELD OR PENDING:

2011 Patent pending: Duncan M, Weitzel L, Byers T, Elias A.
Title: Biomarkers for Diagnosis of Breast Cancer

REVIEW AND REFEREE WORK:

Editorial Boards:

HPCLive (editorial advisor)
Oncology (advisory board)
The Breast Journal (editorial board 2015-present)
Targeted Therapies in Oncology (editorial board 2017-2020)
Annals of Breast Surgery (editorial board 2018-2020)

Ad Hoc Reviews:

Journal of Clinical Oncology
Cancer
Journal of the National Cancer Institute
Blood
Clinical Cancer Research
NEJM
J Hematotherapy
Bone Marrow Transplantation
European J Cancer
Lung Cancer
BBMT
Cancer Investigation
Breast Cancer Res Treat
Oncologist
Brit J Cancer
Int J Cancer
Cancer Biotherapy & Radiopharmaceuticals
BMC Systematic Reviews
Pharmacogenomics
Molecular Therapeutics
International J Molecular Medicine
Cancer Medicine
J NCCN

INVITED EXTRAMURAL LECTURES, PRESENTATIONS AND VISITING PROFESSORSHIPS:

Local:

1. Skarin AT, Elias AD. "Small Cell Lung Cancer - Clinical and Research." Clinical Trials in Cancer Management Conference, DFCI Boston, MA, 3/14/86.
2. Elias A, Antman K. "Sarcoma, Ifosfamide Trials." Clinical Trials in Cancer Management Conference, DFCI, Boston, MA, 3/11/87.
3. Elias A, Eder JP, Shea T, Antman K. "ABMT in Breast Cancer." Beth Israel Hospital, Boston, 3/8/88.
4. Elias A. "Smoking - facts and decisions." Presentation to 5th grade classes at the Agassiz School, Jamaica Plain, Boston, MA, 3/89.
5. Elias A, "New Approach to Small Cell Lung Carcinoma of the Lung." Postgraduate Medical Series Oncology session, Beth Israel Hospital, Boston, MA, 3/17/89.
6. Elias A, "Clinical Uses of Colony Stimulating Factors." Postgraduate Medical Education Oncology Series, Harvard Medical School, Beth Israel Hospital, Boston, MA, 10/27/89.
7. Elias A, "Non-Small Cell Lung Cancer - Innovative Therapeutic Approaches", Continuing Medical Education Course, Harvard Medical School (Multimodality Therapy of NSCLC: 1989 Update). The Westin Hotel, Boston, MA, 11/17/89.
8. Elias AD, Skarin AT, Herman T, Hunt M, Ayash L, Wheeler C, Schwartz G, Tepler I, Schnipper L, Frei E, Antman K. Intensive Multimodality Therapy for Small Cell Lung Cancer Using Intensification with High Dose Chemotherapy and Autologous Bone Marrow Support. An International Conference on Lung Cancer, Boston University Medical Center, Boston, MA, 11/9/90.
9. Elias A. GM-CSF Stimulated Peripheral Blood Stem Cells as Hematopoietic Support in Breast Cancer Therapy. Oncology Research Seminar, DFCI, Boston, MA, 3/25/91.
10. Elias A. GM-CSF in Breast Cancer Treatment. Boston VA Hematology-Oncology lecture series, Boston, MA, 4/29/91.
11. Elias A. Utilization of Growth Factors and Peripheral Stem Cells in BMT. Symposium on Clinical Applications of Bone Marrow Transplantation (BMT). Harvard Medical School. Boston, MA 6/28/91.
12. Elias AD. Chemotherapy and Radiotherapy for Advanced Non-Small Cell Lung Cancer. Multimodality Therapy of Chest Malignancies - Update '92. Harvard Medical School, Boston, MA, 4/9-11/92.
13. Elias AD. Role of Bone Marrow Transplantation for Small Cell Lung Cancer. Multimodality Therapy of Chest Malignancies - Update '92. Harvard Medical School, Boston, MA, 4/9-11/92.
14. Elias AD. Dose intensive therapy for Small Cell Lung Cancer. Issues in the Management of Small Cell Lung Cancer. Boston University School of Medicine Symposium, Colonnade Hotel, Boston, MA, 11/20/92.
15. Elias A. The management of inoperable stage III NSCLC. BWH Thoracic Surgery Seminar. Boston, MA, 3/5/93.
16. Elias A. Use of cytokines to mobilize peripheral blood progenitor cells. Pediatric Oncology lecture series, DFCI, Boston, MA, 3/22/93.
17. Elias AD. New chemotherapy drugs in lung cancer. DFCI Lung Clinic Conference, Boston, MA, 11/17/93.
18. Elias AD. Chemotherapy in the management of lung cancer. Thoracic Surgery Lecture Series, Brigham and Women's Hospital, Boston, MA, 4/1/94.
19. Elias AD. Dose intensive therapy for small cell lung cancer. Multimodality Therapy of Chest Malignancies - Update '94, Boston, MA, 4/7/94.
20. Elias AD. Minimal Residual Tumor Detection: Future Directions. Countway Library, Boston, MA, 9/28/94.
21. Elias AD. High Dose Therapy for SCLC: Cure and near-cure. Bone Marrow Transplant Lecture Series, DFCI, Boston, MA, 1/19/95.
22. Elias AD. Management of SCLC. Thoracic Surgical Rounds. Brigham & Women's Hospital. Boston, MA, 4/7/95.
23. Elias AD. High dose therapy for SCLC. TOP Seminar Series, DFCI, 11/21/95.
24. Elias AD. Management of SCLC: Update 1996. Multimodality Therapy of Chest Malignancies - Update '96, Boston, MA, 3/28-3/29/96.
25. Elias AD. Management of Small Cell Lung Cancer. TOP Seminar Series, DFCI, 7/96.

26. Elias AD, Marks EJ. Acute and chronic pneumonitis after high dose chemotherapy with hematopoietic stem cell support. Case Presentation Conference, Massachusetts General Hospital Boston, MA, 7/18/96. *New Engl J Med*.
27. Elias AD. Dose intensive therapy for SCLC. BMT Lecture Series. DFCI, Boston, MA, 5/27/97.
28. Elias AD. Dose intensive therapy for SCLC. BMT Symposium: The role of hematopoietic stem cell transplant in the management of common malignancies. Boston, MA 6/25/97.
29. Elias AD. Management of SCLC: 1997. TOP Lecture series. DFCI 10/7/97.
30. Elias AD. Case Presentation Conference: SCLC. TOP Lecture series. DFCI, Boston, MA, 10/21/97.
31. Elias A. Peripheral blood cell mobilization. Hematopoietic Stem Cell Transplantation: Current Practice and Future Trends. Boston, MA, 10/1/98.
32. Elias A. High dose chemotherapy in breast cancer. BMT Symposium Series. Dana-Farber Cancer Institute, Boston, MA, 12/3/98.
33. Elias A. High dose chemotherapy: an overview for solid tumors. Dental Resident Teaching Conference. Boston, MA, 12/11/98.
34. Elias A. High dose approaches for breast cancer. Hematology/Oncology Rounds, Jamaica Plains VA Medical Center, Boston, MA, 1/25/99.
35. Elias A. High dose therapy for solid tumors. Lecture, dental residents, Harvard School of Dental Medicine, Boston, MA, 8/13/99.
36. Elias A. Management of SCLC. TOP Lecture Series. DFCI, Boston, MA, 10/5/99.
37. Elias A. Management of the Elderly Patient with SCLC. Multimodality Therapy of Chest Malignancies - Update '00, Boston, MA, 4/1/00.
38. Elias A. Review of the DFCI/BIDMC experience with high dose chemotherapy for metastatic breast cancer. BIDMC, Boston, MA. 8/22/00.
39. Elias A. Adjuvant Therapy for T1a and T1b Breast Cancers. UCHSC, Aurora, CO. 3/13/01.
40. Elias A. Taking Aim: Genetic and Molecular targets in breast cancer research. 20th Annual Denver Day of Caring, Denver, CO. 5/12/01.
41. Elias A. Chemotherapy for Metastatic Breast Cancer. UCHSC Fellows Conference. Aurora, CO. 8/18/01.
42. Elias A. Breast Cancer Update, 2001. University of Colorado Medical Grand Rounds. Denver, CO. 11/14/01.
43. Elias A. What's New in Breast Cancer. Denver, CO. 12/15/01
44. Elias A. Overview of Breast Cancer Management. Pathology Residents series. Denver, CO. 1/3/02.
45. Elias A. Breast Cancer. Med6000 course. University of Colorado School of Medicine. Denver, CO. 1/29/02.
46. Elias A. The Clinical Significance of Growth Factor Receptors in Breast Cancer. Pathology Grand Rounds. Denver, CO 4/4/02.
47. Elias A. Management of Breast Cancer. Hormone Related Malignancies Program Seminar Series. Denver, CO. 4/23/02.
48. Singh M, Finlayson C, Lewin J, Rabinovitch R, Elias A. Case Presentation of Breast Cancer. Pathology. University of Colorado School of Medicine. Denver, CO. 5/9/02.
49. Elias A. Media controversies in breast cancer research. 21th Annual Denver Day of Caring, Denver, CO. 5/11/02.
50. Singh M, Finlayson C, Lewin J, Rabinovitch R, Elias A. Management of breast cancer. Pathology6000 course, University of Colorado Health Science Center, Denver, CO. 5/5/03.
51. Elias A. Organizer/Moderator. Breast Diseases 2004, Aurora, CO 5/1/04.
52. Elias A. Moderator, Q & A for Breast Cancer. Day of Caring, Denver, CO. 5/8/04.
53. Elias A. Her2/EGFR signaling in breast cancer. Brown Palace, Denver, CO. 5/13/04.
54. Elias A. Treatment of metastatic breast cancer. Fellows' Educational Series. Aurora, CO. 10/4/04.
55. Elias A. Management of breast cancer. Residents' lecture series. Denver Health Medical Center. Denver, CO. 1/24/05.
56. Singh M, Finlayson C, Isaacs P, Rabinovitch R, Elias A. Management of breast cancer. Pathology6000 course, University of Colorado Health Science Center, Denver, CO. 4/28/05.
57. Elias A. New agents in the treatment of breast cancer. 24th Annual Denver Day of Caring, Denver, CO. 4/30/05.

58. Elias A. Breast cancer and its management. CHA/PA student lecture. UCHSC. Aurora, CO. 10/14/05.
59. Elias A. Inflammatory Breast Cancer. Fellows' Educational Series. Aurora, CO. 1/6/06.
60. Elias A. Organizer/Moderator. Breast Diseases 2006, Aurora, CO. 2/11/06.
61. Elias A. Management of the breast cancer survivor: Her2 and trastuzumab. Breast Diseases 2006, Aurora, CO. 2/11/06.
62. Elias A. Management of soft tissue sarcomas. Fellows' Educational Series. Aurora, CO. 4/17/06.
63. Elias A. Endocrine therapy and prevention of breast cancer. Fellows' Educational Series. Aurora, CO. 9/25/06.
64. Elias A. Metastatic breast cancer. Fellows' Educational Series. Aurora, CO. 10/16/06.
65. Singh M, Finlayson C, Isaacs P, Rabinovitch R, Elias A. Management of breast cancer. Pathology6000 course, University of Colorado Health Science Center, Aurora, CO. 2/8/07.
66. Elias A. Management of Sarcomas. CIC. Aurora, CO 2/12/07.
67. Elias A. Emerging Trends. Denver, CO 6/23/07.
68. Elias A. Decision making and breast cancer biology. Colorado Cancer Day. Aurora, CO. 9/29/07.
69. Elias A. Management of Metastatic Breast Cancer. Colorado Cancer Day. Aurora, CO. 9/29/07.
70. Elias A. Breast Cancer Journal Club. Fellows. Aurora, CO. 10/8/07.
71. Singh M, Finlayson C, Hardesty L, Rabinovitch R, Elias A. Management of breast cancer. Life Cycle IDPT 6003 course, University of Colorado Health Science Center, Denver, CO. 2/1/08.
72. Elias A. Management of breast cancer. UC Medical School. Aurora, CO. 2/15/08.
73. Elias A. Decision-Making Regarding Cancer Treatment in Early Breast Cancer. Colorado Cancer Day, UC Medical School. Aurora, CO, 9/20/08.
74. Elias A. Management of Metastatic Breast Cancer. Kaiser Permanente, Denver, CO, 9/25/08.
75. Elias A. Management of Early Stage Breast Cancer. Fellows, Division Medical Oncology, Aurora, CO, 10/20/08.
76. Elias A. Highlights of Breast Cancer Advances. Many Faces of Breast Cancer, Mile High Stadium, Denver, CO, 11/18/08.
77. Elias A. Advances in Breast Cancer. Clinical Investigations Core, UCCC, Aurora, CO, 11/20/08.
78. Elias A. Management of Soft Tissue Sarcomas. Professor's Rounds. Denver Children's Hospital. Aurora, CO, 1/9/09.
79. Elias A. Overview of Breast Cancer: Med8029 course, UC School of Medicine. Aurora, CO. 2/24/09.
80. Elias A. Management of Sarcomas. Clinical Investigations Core, Aurora, CO. 4/9/09.
81. Elias A. Breast Cancer. PLCO Clinical Investigations Team, 5 Aurora, CO. /14/09.
82. Elias A. Sarcomas. Fellow's talk. Aurora, CO. 6/15/09.
83. Elias A. Decision Making in Breast Cancer – Lay Presentation. Colorado Cancer Day, Aurora, CO. 9/26/09.
84. Elias A. Overview of Breast Cancer: Med8029 course, UC School of Medicine. Aurora, CO. 2/25/10.
85. Elias A. The I-SPY2 trial. RIP conference. Medical Oncology, UCCC, Aurora, CO. 4/8/10.
86. Elias A. The management of metastatic breast cancer. Fellows, Division Medical Oncology, Aurora, CO, 9/20/10.
87. Elias A. Decision Making in Breast Cancer – Lay Presentation. Colorado Cancer Day, Aurora, CO. 11/6/10.
88. Panel Discussion “The Evolution of Cancer Therapy.” 2nd Annual Cancer Biology Retreat. UCCC, Aurora, CO. 1/10/11.
89. Elias A. Sarcomas. Fellow's talk. Aurora, CO. 2/14/11.
90. Elias A. Predictive biomarkers and biologicals in breast cancer. Biomedicine roundtable: innovation, safety, access. UC AMC, Aurora, CO. 7/12/11.
91. Elias A. ER+ BC: from metastatic to adjuvant. Fellows, Division Medical Oncology, Aurora, CO, 9/9/11.
92. Elias A. Overview of Breast Cancer: Med8029 course, UC School of Medicine. Aurora, CO. 2/2/12.
93. Elias A. Sarcomas. Fellow's talk. Aurora, CO. 5/4/12.
94. Elias A. ER+ BC: from metastatic to adjuvant. Fellows, Division Medical Oncology, Aurora, CO, 9/10/12.
95. Elias A. Overview of Breast Cancer: Med8029 course, UC School of Medicine. Aurora, CO. 2/21/13.
96. Elias A. The management of soft tissue sarcomas. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/6/13.

97. Elias A. The Gist of GIST. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/6/13.
98. Elias A. The management of ER+ breast cancer. Fellow's talk. Division Medical Oncology, Aurora, CO, 9/6/13.
99. Elias A. Soft Tissue Sarcomas. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/9/14.
100. Elias A. The Gist of GIST. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/16/14.
101. Elias A. The management of ER+ breast cancer. Fellow's talk. Division Medical Oncology, Aurora, CO, 9/5/14.
102. Elias A. Samples, Patients, and Communities: How to Establish Trust. 5th Annual CCTSI Research Ethics Conference, Aurora, CO, 10/9/14.
103. Elias A. Case studies in sarcoma. Fellow's talk. Division Medical Oncology, Aurora, CO, 4/23/15.
104. Elias A. The management of ER+ breast cancer. Fellow's talk. Division Medical Oncology, Aurora, CO, 10/6/15.
105. Elias A. Presentation to the State of Colorado legislative committee on clinical trials. 12/18/15.
106. Elias A. The Gist of GIST. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/16/16.
107. Elias A. The management of ER+ breast cancer. Fellow's talk. Division Medical Oncology, Aurora, CO, 9/22/16.
108. Elias A. The Gist of GIST. Fellow's talk. Division Medical Oncology, Aurora, CO, 12/3/16.
109. Elias A. The Role of AR in Breast Cancer. Dept of Medicine, Aurora, CO, 2/2/17.
110. Elias A. The Best of ASCO: Breast. Fellow's talk. Division Medical Oncology, Aurora, CO, 6/27/17.
111. Elias A. Management of ER+ BC. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/18/18.
112. Elias A. The Best of ASCO: Sarcomas. Fellow's talk. Division Medical Oncology, Aurora, CO, 6/22/18.
113. Elias A. Management of metastatic ER+ BC. Fellow's talk. Division Medical Oncology, Aurora, CO, 3/1/19.
114. Elias A. Best of ASCO 2019 for breast cancer. Fellow's talk. Division Medical Oncology, Aurora, CO, 7/12/19.
115. Elias A. Preoperative management of breast cancer. Fellow's talk. Division Medical Oncology, Aurora, CO, 2/21/20.
116. Elias A. Management of metastatic ER+ BC. Fellow's talk. Division Medical Oncology, Aurora, CO, 5/8/21.
117. Elias A. Management of metastatic ER+ BC. Fellow's talk. Division Medical Oncology, Aurora, CO, 10/9/22.

Regional:

1. Elias A, Socinski M, Antman K, Griffin J. "Use of rhGM-CSF to Ameliorate Chemotherapy Induced Myelosuppression in Sarcoma Patients." Tumor Board Conference Consultant, Eastern Maine Medical Center, Bangor, ME, 3/16/88.
2. Elias A. "ABMT in Solid Tumors." Grand Rounds, Glover Hospital, Needham, MA, 5/4/88 & St. Johns Hospital, Lowell, MA, 6/24/88 & Charleton Memorial Hospital, 11/10/88.
3. Elias A. "ABMT in SCLC and Breast Cancer." Grand Rounds, Baystate Medical Center, Worcester, MA. 10/5/88.
4. Elias A. "ABMT in SCLC". Tumor Board Conference Consultant, Eastern Maine Medical Center, Bangor, ME, 12/14/88.
5. Elias A. "Ifosfamide: Clinical Trials with a Novel Agent". New Directions in Chemotherapy Conference at Sturbridge, Baystate Medical Center, Worcester, MA. 11/9/88.
6. Elias A, "Management of Soft Tissue Sarcomas," Grand Rounds, Lowell General Hospital, Lowell, MA 4/4/90.
7. Elias A, "Chemotherapy of Sarcomas," Tumor Board Conference, Dartmouth Hitchcock Medical Center, White River Junction, NH. 4/19/90.
8. Elias A, "Sarcomas," Tumor Conference, AtlantiCare, Lynn, MA, 4/23/90.
9. Elias A. The use of ABMT in the treatment of Small Cell Lung Cancer. Topics in Lung Cancer, Maine Medical Center, Portland, ME. 7/9/90.
10. Elias A. The role of chemotherapy in the management of non-small cell lung cancer. Medical Grand Rounds, Salem Hospital, Salem, MA. 7/27/90.

11. Elias A. Multimodality Strategies in the Treatment of Stage IIIA NSCLC. Tumor Board Conference, Eastern Maine Medical Center, Bangor, ME, 1/16/91.
12. Elias A. Principles and Advances in ABMT Technology. Medical Grand Rounds, Cardinal Cushing Hospital, Brockton, MA. 9/16/91.
13. Elias AD. High Dose Chemotherapy With Chest Radiotherapy as Consolidation for Limited-Stage Small-Cell Lung Cancer. Controversies in Lung Cancer. Rhode Island Hospital, Providence, RI, 3/24/92.
14. Elias AD. The Role of Stem Cell in BMT. Bone Marrow Transplant in Solid Tumors. St. Vincent's Medical Center, Bridgeport, CT, 4/29/92.
15. Elias AD. Autologous bone marrow transplantation in breast cancer. New England Cancer Society, Mystic, CT, 11/14/92.
16. Elias AD. Visiting Professor, Eastern Maine Medical Center, Bangor, ME, 1/29/97.
17. Elias AD. High dose therapy for breast cancer. Oncology Grand Rounds. Cape Cod Hospital. Hyannis, MA, 6/26/97.
18. Elias A. Management of small cell lung cancer: focus on high dose therapy. Medical Grand Rounds, Deaconess-Waltham Hospital, Waltham, MA, 11/6/98.
19. Elias A. Management of SCLC. Medical Grand Rounds. Charleton Memorial Hospital, Fall River, MA, 2/23/99.
20. Elias A. Management of SCLC. Oncology Rounds, U Mass Medical Center, Worcester, MA 3/27/00.
21. Elias A. Adjuvant Therapy for Breast Cancer. Ft. Collins Country Club, Ft. Collins, CO. 2/21/01.
22. Elias A. Management of Early Breast Cancer. Poudre Valley Hospital, Ft. Collins, CO. 5/15/01.
23. Elias A. Management of Breast Cancer and Risk. Grand Rounds. Memorial Hospital, Colorado Springs, CO. 4/24/02.
24. Elias A. New Issues in Breast Cancer. Novartis Speaking Engagement. Denver, CO. 4/26/02.
25. Elias A. Management of Breast Cancer and Risk. Grand Rounds. St. Mary's Medical Center, Grand Junction, CO. 4/30/02.
26. Elias A. Neoadjuvant endocrine therapy. St. Anthony's Hospital, Denver, CO. 2/13/03.
27. Elias A, Borges V. Aromatase inhibitors in the treatment of breast cancer. Broomfield, CO. 9/23/03.
28. Elias A. The adjuvant treatment of breast cancer. Pikes Peak Nursing Society, Colorado Springs, CO. 10/22/03.
29. Elias A. Adjuvant trastuzumab: candidates and practical management. Current Trends in Breast Cancer. Hotel Monaco, Denver, CO 2/25/06.
30. Elias A. Advances in breast cancer management. Young Women's Association. Adams Mark, Denver, CO. 2/25/06.
31. Elias A. Q&A for breast cancer. Day of Caring. Denver, CO 5/13/06.
32. Elias A. Adjuvant endocrine therapy of breast cancer. Aurora South Hospital. Aurora, CO. 9/22/06.
33. Elias A. New developments in Adjuvant Chemotherapy of breast cancer. Current Trends in Breast Cancer. PER. Denver, CO. 2/17/07.
34. Elias A, Hardenbergh P. Organizer, Co-directors. 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/5/07-4/7/07.
35. Elias A. Should axillary lymph node dissection be completed for patients with N1mic on SLN? Yes. 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/6/07.
36. Elias A. Use of Gene Expression Profiling for decision making. 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/6/07.
37. Elias A. Risk-adjusted chemotherapy intensity. 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/6/07.
38. Elias A. What is the role of bevacizumab in the standard treatment of metastatic breast cancer? 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/7/07.
39. Elias A. Is raloxifene ready for prime time as a chemoprevention agent? 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/7/07.
40. Elias A, Paul D. Oncology Best Practices. PER. Delfrisco's Steakhouse. Denver, CO. 4/12/07.
41. Elias A, Royce M. Best of ASCO. PER. Albuquerque, NM. 9/5/07.
42. Elias A, Hardenbergh P. Organizer, Co-directors. 2nd International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/3/08-4/5/08.

43. Elias A. Adjuvant Endocrine Therapy and Molecular Predictors of Outcome and Treatment Benefit. 2nd International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/4/08.
44. Elias A. Management of Bone Metastases. 2nd International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/5/08.
45. Elias A. Brain and CNS metastases. 2nd International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO. 4/5/08.
46. Elias AD, Bush SE, Course Co-directors. Women's Cancer and Survivorship Symposium. Durango, CO. 5/16-17, 2008.
47. Elias AD. Lung screening and smoking cessation. Women's Cancer and Survivorship Symposium. Durango, CO. 5/17/08.
48. Elias A. What's new in breast cancer. Lay Public. Women's Cancer and Survivorship Symposium. Durango, CO. 5/17/08.
49. Elias A. Young Women's Breast Cancer – what's different and why? Loveland, CO, 4/23/10.
50. Elias A. Management of metastatic breast cancer. PER, Denver, CO 10/26/10.
51. Elias A. Controversies in the management of metastatic breast cancer. Oncology Grand Rounds. St. Mary's Hospital, Grand Junction, CO, 12/2/10.
52. Elias A. The latest in breast cancer. 1st Annual Western Slope Oncology Conference. Montrose Memorial Hospital. Montrose, CO 5/6/11.
53. Elias A. SABCS 2011 Updates. RMOS, Denver, CO. 1/12/12.
54. Elias A. Emerging treatment strategies for advanced and metastatic ER+ breast cancer: the clinical potential of CDK 4/6 inhibitors. St. Joseph's Hospital, Denver, CO. 4/27/15.
55. Elias A. Targeted therapies: Updates in breast cancer. Total Health Targeted Therapies. Denver, CO, 3/21/19.
56. Elias A. Triple negative breast cancer. Evolving Treatments for the Oncology Practice. Denver, CO, 9/24/22.

National:

1. Elias AD. "Management of Soft Tissue Sarcoma." Grand Rounds, Jacksonville Hospital, Jacksonville, FL, 5/6/86.
2. Elias AD, Ryan L, Aisner J, Antman KH. "Doxorubicin, Ifosfamide, and DTIC (AID) for Advanced Untreated Sarcomas. ASCO 5/86.
3. Elias AD, Cohen BF, Weinberg K, Bernal SD. "The Cytokeratins of Small Cell Lung Cancer (SCLC): Evidence for Epithelial Origin." Poster session, AACR 27: C-169, 1986.
4. Elias AD. "Update of SCLC research at the DFCI -- ABMT and antibody serum and bone marrow assays." SCLC Limited Disease Workshop at NCI, 5/8/87.
5. Elias AD, Antman KH, Eder JP, Shea T, Schryber S, Bernal SD, Skarin, AT, Schnipper L, Frei E III. Consolidation of responding small cell lung cancer (SCLC) with high dose combination alkylating agents and autologous bone marrow transplant (ABMT): A pilot study. Bone Marrow Transplant Group, CALGB meeting 10/23/87.
6. Elias A. "The Clinical Applications of Colony Stimulating Factors." Englewood Hospital, NJ, 2/9/89.
7. Elias A, Antman K, Eder J, Frei E III. High-Dose Ifosfamide (IFF) with mesna uroprotection: Phase I Study. Proc ASCO 8: C-264, 1989.
8. Elias AD, Pap S, Bernal SD. Use of Magnetic Bead Immunoconjugates to Remove Bone Marrow Contamination with Small Cell Lung Cancer Cell Lines. Proc AACR, 1989.
9. Elias A, "Management of Sarcomas"; "ABMT for solid tumors"; "Clinical Uses of Ifosfamide", Tumor Board, Parkland Hospital, Univ of Texas at Dallas, 11/29-11/30, 1989.
10. Elias A, Ayash L, Wheeler C, Deary J, Schryber S, Critchlow J, Hunt M, Eder JP, Frei E III, Antman K. High-Dose Ifosfamide (IFX) with escalating doses of carboplatin (Cb) and Autologous Bone Marrow Support (ABMT). Proc ASCO 9: 11 (C-35), 1990. Poster presentation. 5/90
11. Elias A. Management of Sarcomas, Nashville Oncology Society Dinner; ABMT for Solid Tumors, Baptist Hospital; Vanderbilt Journal Club, 6/5-6/90.
12. Elias AD. Current Treatment in Advanced Sarcomas. Oncology Update, University of South Florida, Saddlebrook, 7/27-29/90.

13. Elias A. The Chemotherapy of Sarcomas. University of South Florida Ifosfamide Symposium. Tampa, 10/19/90.
14. Elias A, et al. The use of GM-CSF Stimulated Peripheral Blood Progenitor Cells as Autologous Stem Cell support for patients with breast cancer undergoing high dose chemotherapy. Hematopoietic Growth Factors in Breast Cancer, Immunex Symposium, San Antonio Breast Cancer Meetings, 11/1/90.
15. Elias A. Sarcomas. Current Perspectives in Cancer Treatment. The Illinois Cancer Council, Chicago, 11/2/90.
16. Elias A, et al. Recruitment of Peripheral Blood Progenitor Cells with GM-CSF for use as Autologous Stem Cell support. Recent Advances in the Use of Colony Stimulating Factors. University of Medicine and Dentistry of New Jersey. New Brunswick, NJ, 11/4/90.
17. Elias AD, Ayash L, Anderson K, Wheeler C, Schwartz G, Tepler I, Lynch C, Hunt M, Pap S, Schryber S, Deary J, Pelaez J, Schnipper L, Griffin J, Frei III E, Antman KH. Hematologic Support During High Dose Intensification for Breast Cancer: Recruitment of Peripheral Blood Progenitor Cells (PBPC) by GM-CSF & Chemotherapy. ASH, Boston, Poster presentation, 12/3/90.
18. Elias A. Current and Future Approaches to Soft Tissue Sarcomas. Tumor Board, Hospital of the University of Pennsylvania, Philadelphia, PA, 1/23/91.
19. Elias A. Advances in the Field of Bone Marrow Transplant for Solid Tumors. Medical Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, PA, 1/23/91.
20. Elias A, et al. The use of Peripheral Blood Progenitor Cells (PBPC) in Support of High Dose Intensification for Breast Cancer. "Clinical Applications of Hematopoietic Growth Factors" Symposium, Indiana University and Immunex Corp., Indianapolis, IN, 3/9/91.
21. Elias A. GM-CSF: Uses in Chemotherapy-Induced Myelosuppression. Colony-Stimulating Factors: Uses in Clinical Practice Symposium, The Cleveland Clinic Cancer Center and Immunex Corp., Cleveland OH, 3/27/91.
22. Elias A. Peripheral Stem Cell Transplant and Growth Factors in High Dose Chemotherapy. The Emerging Role of Hematopoietic Growth Factors. Fox Chase Cancer Center and Immunex Corp., Philadelphia, PA, 4/10/91.
23. Elias A. GM-CSF in the Treatment of Breast Cancer. Beth Israel Hospital Tumor Board, Newark NJ, 6/7/91.
24. Elias A. Bone Marrow Transplantation and Peripheral Stem Cell Transplantation. Colony Stimulating Factors in Hematology and Oncology" Symposium. Georgetown University Medical Center, Washington DC. 10/3/91.
25. Elias A. High Dose chemotherapy with stem cells support for solid tumors. Medical Grand Rounds, University of Medicine and Dentistry of New Jersey, Newark, NJ. 10/4/91.
26. Elias A. The ICE regimen at transplant doses. New York Medical College at Valhalla, NY, 10/12/91.
27. Elias A. Adjuvant Therapy in Osteosarcomas and Soft Tissue Sarcomas. Recent Advances in Adjuvant Therapy in Cancer. Yale University School of Medicine, New Haven, 10/22/91.
28. Elias et al. Hematostimulation by GM-CSF during high dose chemotherapy of breast cancer after bone marrow transplantation. Advances in Innovative Oncology: Biomodulation, chemoimmunotherapy and selected phase II drugs. The Chemotherapy Foundation & Mt. Sinai School of Medicine. New York, 11/7/91.
29. Elias A, Ayash L, Anderson K, Wheeler C, Mazanet R, Schwartz G, Tepler I, Reich E, Hunt M, Pap S, Pelaez J, Lynch C, Schnipper L, Griffin J, Frei E III, Antman K. GM-CSF-Mobilized Peripheral Blood Progenitor Cells (PBPC) Support After High Dose Chemotherapy for Breast Cancer: Effect of GM-CSF Post Reinfusion. ASH, Denver, CO, 12/10/91.
30. Elias AD. Bone Marrow Transplantation for Germ Cell and other Solid Tumors. 9th Annual Symposium on Bone Marrow Transplantation. New York Medical College, Valhalla, NY, 3/9/92.
31. Elias AD. Primary Management of Soft Tissue Sarcomas: A Multimodality Approach. Current Perspectives in Cancer Therapy - The Multi-modal Approach. Case Western Reserve University, Cleveland, OH, 3/18/92.
32. Elias AD. When is Tumor Response Meaningful for Soft Tissue Sarcomas? ASCO Sarcoma Slide session, San Diego, CA, 5/19/92.
33. Elias AD, Ayash L, Wheeler C, Hunt M, Schwartz G, Mazanet R, Tepler I, Herman T, Skarin AT, Frei E III, Antman K. High-dose Combination Alkylating Agents Supported by Autologous Marrow with Chest

- Radiotherapy for Responding Limited-Stage Small Cell Lung Cancer. ASCO SCLC Slide session, San Diego, CA, 5/19/92.
34. Elias AD. Advances in ABMT for SCLC and the Use of PBPCs. Upstate Medical Center, Syracuse, NY, 6/11/92.
 35. Elias AD. The Role of Bone Marrow Transplants in Solid Tumors. Oncology Reimbursement: 1992. Upstate New York Society of Medical Oncology and Hematology/Assoc of Community Cancer Centers. Syracuse, NY, 6/11/92.
 36. Elias AD. Current status of ABMT for Solid Tumors. The Queen's Medical Center. Honolulu, HI, 9/3/92.
 37. Elias AD. Dose Intensive Therapy for Breast Cancer. Oncology and Hematology for the 1990's. Alta Bates Medical Center, Silverado, Napa, CA, 10/9/92.
 38. Elias AD. The management of soft tissue sarcomas. Heme/Oncol Grand Rounds, Cooper Hospital, Camden, NJ, 10/12/92.
 39. Elias AD. Cytokines and peripheral blood progenitor cells: the new frontier in high dose chemotherapy. Grand Rounds, Bryn Mawr Hospital, Bryn Mawr, PA, 11/12/92.
 40. Elias et al. Aggressive treatment of Small Cell Lung Cancer. 6th International Autologous Bone Marrow Transplantation Symposium, Houston, TX, 12/2/92.
 41. Elias et al. Autologous Marrow Transplantation in Metastatic Breast Cancer. 6th International Autologous Bone Marrow Transplantation Symposium, Houston, TX, 12/3/92.
 42. Elias et al. High dose ifosfamide, carboplatin, etoposide with hematologic stem cell support. Fox Chase Cancer Center Symposium on Carboplatin. Kona, Hawaii, 2/25-2/27/93.
 43. Elias A, et al. High-dose regimens in metastatic breast cancer: marrow and blood stem cells. Recent Advances in Hematopoietic stem cell transplantation -- clinical progress, new technologies and gene therapy. UCSD, San Diego, CA, 3/12/93.
 44. Elias A. Overview of Dose Intensive Therapy and Peripheral Stem Cell Transplantation. Shadyside Oncology Seminar, Pittsburgh, PA, 3/25/93.
 45. Elias A, Bearman S. The treatment of small cell lung cancer with high dose chemotherapy and autologous bone marrow support. South West Oncology Group Bone Marrow Transplant and Lung Committees, Denver, CO, 4/24-4/25/93.
 46. Elias A. The treatment of small cell lung cancer with high dose chemotherapy and autologous bone marrow support. Cancer & Leukemia Group B Lung, Radiation Oncology and Psycho-Oncology Committees, Baltimore, MD, 5/5-5/7/93.
 47. Elias A. Update on CALGB 9134 Stage IIIA N2 NSCLC. Cancer & Leukemia Group B Lung, Radiation Oncology and Psycho-Oncology Committees, Baltimore, MD, 5/5-5/7/93.
 48. Elias A, Kantoff P, Ayash L, Schwartz G, Wheeler C, Tepler I, Mazanet R, McCauley M, Warren D, Frei E III, Antman K. High-dose ifosfamide, carboplatin, & etoposide (ICE) with autologous marrow support for germ cell carcinoma. Proc ASCO 1993; 12: 231 (C-710). Poster discussion presentation, Orlando, FL, 5/17/93.
 49. Elias AD, Skarin AT, Strauss G, Lynch T, Shulman L, Frei E III, Jacobs C, Abner A, Mentzer S, Sugarbaker D. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Proc ASCO 1993; 12: 332 (C-1106). Poster presentation, Orlando, FL, 5/18/93.
 50. Small Cell Lung Cancer Strategy Meeting, NCI CTEP, Bethesda, MD, 9/27/93.
 51. Elias AD. Management of soft tissue sarcomas. Johns Hopkins Oncology Center Multidisciplinary Clinical Conference Series. Baltimore, MD, 1/27/94.
 52. Elias AD. High dose therapy for breast and lung cancer. Albany Medical Center, Albany, NY, 4/14/94.
 53. Elias AD. GM-CSF Priming and Mobilizing of peripheral blood progenitor cells. Central Ohio Society of Clinical Oncology, Worthington, OH, 4/19/94.
 54. Elias AD. Novel approaches to limited and extensive disease. Small Cell Lung Cancer: Current Therapeutic Approaches. American College of Physicians, Miami, FL, 4/22/94.
 55. Elias AD. Intensive multimodality therapy for small cell lung cancer. 7th World Conference on Lung Cancer, Colorado Springs, CO, 6/29/94.
 56. Elias AD. Role of chemotherapy in NSCLC. Albany Medical College. Propp Olsen Symposium. Albany, NY, 12/2/94.
 57. Elias AD. High Dose Therapy for SCLC. University of Colorado Medical Center, Denver, CO, 1/30/95.
 58. Elias AD. Management of NSCLC. Grand Rounds, Cornwall Hospital, Cornwall, NY, 3/10/95.

59. Elias AD. Cure and near cure: concepts in solid tumor high dose therapy. University of South Carolina, Richland Hospital, Columbia, SC, 4/28/95.
60. Elias A. Cure and near-cure for solid tumors: present and future strategies. "Future directions in stem cell transplantation symposium", Northern New Jersey Cancer Center, Teaneck, NJ, 5/12/95.
61. Elias AD. Role of chemotherapy in NSCLC: new agents and neoadjuvant approaches. Grand Rounds, Glens Falls Medical Center, Glens Falls, NY, 5/16/95.
62. Elias AD. High dose chemotherapy in lung cancer. 3rd International Conference on Cytokines & Growth Factors Symposium. Emory University School of Medicine, Ritz-Carlton, Atlanta, GA, 6/9/95.
63. Elias AD. Adjuvant Chemotherapy for soft tissue sarcomas. Panel Educational Meeting. ASTRO, Miami, FL, 10/10/95.
64. Elias AD. Management of soft tissue sarcomas: present and future. Hematology/Oncology Grand Rounds, Long Island Jewish Hospital, Great Neck, NY, 10/12/95.
65. Elias AD. High dose therapy for SCLC with stem cell support. Chemotherapy Foundation Symposium XIII: Innovative Cancer Therapy for Tomorrow. Mt Sinai School of Medicine, New York, NY, 11/3/95.
66. Elias AD. Dose intensive therapy for SCLC. International Symposium on Thoracic Malignancies. Pittsburgh, PA, 4/25-4/26/96.
67. Elias AD. FAHCT BMT Inspector Training Workshop. Omaha, NB, 9/9-9/10/96.
68. Elias AD, Herndon J, Kumar P, Sugarbaker D, Green MR. For the CALGB. A phase III comparison of "best local-regional therapy" with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results. Proc ASCO 1997; 16: 448a (A-1611). ASCO Poster Presentation: Highlights in Lung Cancer, 5/19/97.
69. Elias A, Negrin R, Shea T. High-dose therapy and growth factors: Poster discussion session ASCO, 5/20/97.
70. Elias AD. Dose intensive therapy in SCLC. Perspectives in Lung Cancer, MR Green, chairperson. Univ South Carolina, Charleston, SC. 9/19/97.
71. Elias AD. Management of SCLC. Karmanos Cancer Center, Detroit, MI, 11/10/97.
72. Elias AD, Wheeler C, Richardson P, Reich E, Hu P, Avigan D, Bunnell C, Demetri G, Joyce R, Levine J, Warren D, Teicher B, Ayash L, Frei E III. A Phase I trial of double transplant for metastatic breast cancer: sequence and interval considerations. ASBMT 1998, Poster presentation.
73. Elias A. Cytokines, Minimal Residual Disease, and Conditioning Regimens Poster Discussion. ASCO, May 19, 1998, poster discussion leader.
74. Elias A. High dose therapy for small cell lung cancer: future strategies. July 29, 1998. 9th International Symposium on Autologous Blood and Marrow Transplantation, Dallas, Texas.
75. Elias A, Demetri G. High dose liposomal daunorubicin (DaunoXome) for solid tumors. Chemotherapy Foundation Symposium XVI: Innovative Cancer Therapy for Tomorrow. New York, NY, 11/13/98.
76. Elias A. Tumor Board. Alexanian Medical Center. Elk Grove, IL 2/22/99.
77. Elias A. High dose therapy for SCLC. ASBMT meeting, Keystone, CO, 3/4/99.
78. Elias AD, Richardson P, Avigan D, Ibrahim J, Bunnell C, Joyce R, Demetri G, Levine J, Warren D, Hieng S, Reich E, Frei E. Phase I development of double cycle stem cell supported high dose chemotherapy (HDC) for metastatic breast cancer (BC): the DFCI/BIDMC experience. Proc ASCO 1999; 18: (A-466). Poster presentation. 5/16/99.
79. Rizzo D, Stiff P, Elias A. Autologous stem cell transplantation for small cell lung cancer. Proc ASCO 1999; 18: (A-1811). Poster presentation. 5/18/99.
80. Elias A. State of the Art Management of SCLC. Tumor Board. Provena Covenant Medical Center. Urbana, IL, 8/3/99.
81. Elias A. State-of-the-Science meeting: Lung Cancer. CTEP/NCI, Bethesda, MD, 9/14-9/15/99.
82. Elias A. Double transplant with short induction for metastatic breast cancer. Oncology Grand Rounds, Univ Colorado, 12/14/99.
83. Elias A for the CALGB. Strategy meeting for high dose therapy trials in breast cancer. CTEP/NCI, Bethesda, MD, 12/15/99.
84. Elias A. Double transplant with short induction for metastatic breast cancer. Oncology Grand Rounds, Karmanos Cancer Institute, 2/16/00.

85. Elias AD, Richardson P, Tretyakov O, Avigan D, Warren D, Arthur T, McCauley M, Wright J, Frei E. Amifostine with high dose ifosfamide, carboplatin, and etoposide (ICE) with hematopoietic stem cell support. Proc ASCO 2000; 19: 51a (197). Poster discussion session 5/20/00.
86. Elias A. Management of SCLC. Symposium. Union Memorial Hospital, Baltimore, MD, 6/1/00.
87. Elias A. High dose therapy for SCLC. 10th International Symposium on Autologous and Allogeneic Bone Marrow Transplantation. Dallas, TX, 7/12/00.
88. Elias A. High dose therapy for metastatic breast cancer. Swedish American Hospital Symposium, Rockford, IL. 11/1/00.
89. Elias A. Commentary on high-dose chemotherapy for breast cancer. ASCO, Chicago. 6/1/03.
90. Elias A. Case Presentations: North American Aromatase Inhibitor Educators Meeting, Washington, DC. 2/4/04.
91. Elias A. Poster Discussion, Breast Cancer Session ASCO, New Orleans, LA. 6/7/04.
92. Elias A. Adjuvant therapy of breast cancer. Thomson Educational Series. Stoneham, MA. 6/18/04.
93. Elias A. Hormonal therapy of metastatic breast cancer. New Orleans, LA. 1/13/05.
94. Elias A. Adjuvant hormonal therapy of breast cancer. San Diego, CA. 2/12/05.
95. Elias A. Overview of ASCO 2005: adjuvant hormonal therapy of breast cancer. San Francisco, CA. 6/9/05.
96. AD Elias, KD Miller, HJ Burstein, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, M Collier, BJ Adams, CM Baum. Sunitinib malate (SU11248), a multitargeted tyrosine kinase inhibitor: safety and efficacy as second-line therapy in metastatic breast cancer. Poster presentation: AACR: Advances in Breast Cancer Research: LaJolla, CA 9/23/05.
97. Elias A. Invited speaker. 1st Annual Great Debates in Breast Cancer. American School of Oncology. Lake Tahoe, NV, 10/28/05.
98. Elias A. Moderator and speaker; Bevacizumab and sunitinib in breast cancer. Sponsored by Pfizer. San Antonio, TX, 12/7/05.
99. Elias A. Invited speaker. 2nd Annual Great Debates in Breast Cancer. American School of Oncology. Las Vegas, NV, 10/13/06.
100. Elias A. New developments in Adjuvant Chemotherapy of breast cancer. Current Trends in Breast Cancer. PER. Boston, MA. 2/3/07.
101. Elias A, O'Regan R. Aromasin Regional Webcast Series. Web. 4/24/07.
102. Elias A. The role of trastuzumab for a small, node negative Her2 positive breast cancer. ASCO Breast. San Francisco, CA. 9/7/07.
103. Elias A. Best of ASCO. Updates on chemotherapy and endocrine therapy for breast cancer. PER. San Francisco, CA. 10/3/07.
104. Elias A. Novel Biologic Agents with Clinical Promise. Current Trends in Breast Cancer. PER. Boston, MA. 1/19/08.
105. Elias A. Adjuvant Her2-directed therapy: candidates and practical management. Current Trends in Breast Cancer. PER. Minneapolis, MN, 3/8/08.
106. Elias A. Future Directions in Breast Cancer Therapy. ODAC, FDA, Bethesda, MD, 8/11/08.
107. Elias A. Evolving Strategies in Metastatic Breast Cancer. PER, Dallas, TX, 11/7/08.
108. Elias A. Advances in Her2-Targeted Therapies for Early-Stage and Metastatic Breast Cancer. PER, Minneapolis, MN, 11/15/08.
109. Elias A. Advances in the Management of Metastatic Breast Cancer. Grand Rounds, Henry Ford Hospital, Detroit, MI. 4/2/09.
110. Elias A. Debate: Should patients with low risk node-positive disease have gene profiling performed to help with decision making? Great Debates in Breast Cancer. Imedex. San Francisco, CA 6/19/09.
111. Elias A. Clinical Applicability of available genomic profiling techniques. Great Debates in Breast Cancer. Imedex. San Francisco, CA 6/20/09.
112. Elias A. Updates from SABCS – Biomarkers in Breast Cancer. PER, Minneapolis, MN, 1/23/10.
113. Elias A. Adjuvant chemotherapy and molecular assays for individualizing treatment. Oncology Practice Reviews. Los Angeles, CA, 3/26/10.
114. Elias A. Management of small Her2+ breast cancers. In 'Controversies in adjuvant treatment of breast cancer'. ASCO Educational Session, Chicago, IL 6/1/12.

115. Elias A. Debate on bisphosphonates for the treatment of early-stage breast cancer. ASCO Breast Cancer Symposium. San Francisco, CA, 9/6/14.
116. Elias A. Debate on the use of neoadjuvant therapy for TNBC. Lynn Sage Breast Cancer Symposium. Chicago, IL, 10/10/14.
117. Elias A. What is the androgen receptor doing in breast cancer and can we target it? 14th Annual International Congress on the Future of Breast Cancer. PER. Huntington Beach, CA 7/17/15.
118. Elias A. An Evening Symposium: Incorporating emerging practice options for Her2 and ER+ breast cancer. Los Angeles, CA, 6/28/16.
119. Elias A. General approach to breast cancer and its treatment. Advances in Breast Cancer Research. Archer/Komen. Aurora, CO, 5/11/17.
120. Elias A. Panel discussion: Genomic medicine and population health. The Forum on Healthcare Innovation. Jackson Labs, Farmington, CT 10/25/17.
121. Elias A. The role of AR in breast cancer. 3rd Annual West Cancer Center Oncology Conference. Memphis, TN, 10/27/17.
122. Elias A. Breast Cancer: ASCO 2018 updates in local/regional and (neo)adjuvant therapy. Total Health Best of ASCO Denver, 8/4/2018.
123. Elias A. Luminal (ER+) biology: Late relapse, resistance, and new agents: updates from SABCS 2018. Best of SABCS – Chicago, 2/3/19.
124. Elias A. Breast Cancer: ASCO 2019 updates in metastatic disease. Total Health Best of ASCO Denver, 7/20/2019.
125. Elias A. Breast Cancer: ASCO 2020 updates in metastatic disease. Total Health Best of ASCO Denver, 7/20/2020.
126. Elias A. Breast Cancer: ASCO 2021 updates in metastatic disease. Total Health Best of ASCO Denver, 7/20/2021.
127. Elias A. Breast Cancer: ASCO 2022 updates in metastatic disease. Total Health Best of ASCO Denver, 7/30/2022.
128. Elias A. Antibody-drug conjugates in metastatic breast cancer. Total Health ESMO, Denver, CO 10/15/22.

International:

1. Elias AD, Cohen BF, Bernal SD. "Monoclonal Antibodies recognizing Cytoskeletal proteins of small cell lung carcinoma." 1st International Workshop on Small Cell Lung Cancer Antigens, Cancun, Mexico. 4/26/86.
2. Elias AD, Pap S, Bernal SD. Removal of Small Cell Lung Cancer Cell Lines (SCLC) from Bone Marrow (BM) by Magnetic Bead Immunoconjugates. 2nd International Bone Marrow Purging Conference, Cancun, Mexico, April 26-29, 1989.
3. Elias A, Eder JP, Ayash L, Wheeler C, Deary J, Weissman L, Schryber S, Critchlow J, Hunt M, Schnipper L, Frei E III, Antman K. A Phase I Study of Ifosfamide (IFX) and carboplatin (Cb) with Bone Marrow Transplantation. 15th International Cancer Congress, Hamburg, Germany, 8/19/90.
4. Elias A. Advances in the Treatment of Soft Tissue Sarcomas. Current Developments and Future Directions with Ifosfamide: An Update. Symposium, ESMO Meetings, Copenhagen, Denmark, 12/2/90.
5. Elias AD. High dose combined alkylating agents with ABMT for responding SCLC. Poster 6th World Conference on Lung Cancer. Melbourne, Australia, 11/11/91.
6. Elias AD. The Use of Peripheral Blood as a Source of Progenitor Cells for Sole Support of High Dose Chemotherapy. US-Japan Joint Seminar on Progress of Treatment of High Dose Chemotherapy with Autologous Stem Cell Transplantation. US- Japan Cooperative Cancer Research Program. Tokyo, Japan, 3/13-14/92.
7. Elias AD. Dose Intensity in SCLC and NSCLC. Today's Research, Tomorrow's Treatment Options: Focus on Lung Cancer, Vancouver, BC, Canada, 9/9/93.
8. Elias AD. The role of carboplatin in high dose therapy. Lecture series in Japan, Tokyo, Osaka, Nagoya, Hiroshima, 2/14-2/18/94.
9. Elias AD. High dose therapy in the management of breast cancer. National Cancer Institute of Japan, Tokyo, Japan, 2/14/94.
10. Elias AD. High-dose therapy with autologous stem cell support in lung cancer. In 12th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Nagoya, Japan, 10/5/97.

11. Elias AD. High dose therapy for sarcomas. Satellite Symposium on High Dose Therapy. ECCO, Hamburg, Germany. 9/16/97.
12. Elias A, Richardson P. Defibrotide (DF): A novel treatment for severe venoocclusive disease (VOD)-compassionate use results in efficacy without significant toxicity in a high risk population. 15th International Congress on Thrombosis. Antalya, Turkey, 10/17/98.
13. Elias A. High dose therapy for small cell lung cancer. Lausanne, Switzerland, 10/29/99.
14. Elias A. Breast cancer pathology by molecular analysis and its clinical relevance. 2nd Asia International Breast Cancer Summit. Hangzhou, China 7/12/08.
15. Elias A. Management of the Bones in Breast Cancer 2nd Asia International Breast Cancer Summit. Hangzhou, China 7/13/08.
16. Elias A. Breast Cancer Adjuvant Trials in the United States. 2nd Asia International Breast Cancer Summit. Hangzhou, China 7/13/08.
17. Elias A. Controversies in the management of metastatic breast cancer. NEMROCK/University of Cairo. Cairo, Egypt 9/30/10.
18. Elias A. Management of Small Breast Cancers. 3rd International Meeting on New drugs in Breast Cancer - Rome, 11/15/2013.
19. Elias A. New therapeutic targets in Sarcoma. 5th World Congress on Cancer Research & Therapy. London, England, 9/9/2019.

TEACHING RECORD:

1987-2000	BMT Attending and Medical Oncology attending DFCI/BWH/BIDMC 3-4 months per year with fellow and resident bedside teaching.
1989-1991	Pharmacology Course Tutor, Harvard Medical School (8-10 students; course duration ~8 weeks)
1989-1990	Post-graduate Medical Education Oncology Series - Harvard Medical School
1989	Course Co-director. Continuing Medical Education, Harvard Medical School: Multimodality Therapy of Non-Small Cell Lung Cancer: 1989 Update, 11/16-11/17/89.
1991-1994	Introduction to Clinical Medicine Tutor - HST Program School (2 students at a time; course duration ~8 weeks).
1992	Course Co-director. Continuing Medical Education, Harvard Medical School: Multimodality Therapy of Chest Malignancies -- Update '92
1993	Presenter - "One Step at a Time" BMT orientation video
1994	Course Co-director. Continuing Medical Education, Harvard Medical School: Multimodality Therapy of Chest Malignancies -- Update '94
1996	Course Co-director. Continuing Medical Education, Harvard Medical School: Multimodality Therapy of Chest Malignancies -- Update '96
1998	Course Co-director. Continuing Medical Education, Harvard Medical School: Multimodality Therapy of Chest Malignancies -- Update '98
1999	Faculty Preceptor: Outpatient Clinical Clerkship, HMS
2000	Course Co-director. Continuing Medical Education, Harvard Medical School: Multimodality Therapy of Chest Malignancies -- Update 2000
2001-	Medical Oncology attending UCH 1-2 months per year with fellow and resident bedside teaching
2001-	Director, Case Presentation and Clinical Research Series, Breast Cancer Clinic, USCHC
2002-2010	Lecture on Breast Cancer, Pathology 6000
2002	Co-organizer, Hormone Related Malignancies Minisymposium 3/15/02
2004	Director, Management of Breast Diseases and Symptoms for the Primary Care Provider 5/1/04
2004	Co-organizer, Hormone Related Malignancies Minisymposium 9/17/04
2005	Tutorial Leader, Pathophysiology Course, University of Colorado 4/18-4/22/05.
2006	Director, Management of Breast Diseases and Symptoms for the Primary Care Provider 2/11/06.
2007	Co-Course Director. 1st International Betty Ford Breast Cancer Treatment & Survivorship Symposium. Vail, CO 4/5-7/07.
2008	Co-Course Director. 1st International Betty Ford Breast Cancer Treatment & Survivorship

Symposium. Vail, CO 4/3-5/08.
 2008 Course Director. Durango Women's Cancer Days. Durango, CO 5/16-18/08.
 2008-2016 Lecture on Breast Cancer, MED8029 (one hour/year)
 2018 Course co-Director (with Manojkumar Bupathi): Total Health Best of ASCO 2018, 8/4-5/18.
 2019 Course co-Director (with Manojkumar Bupathi): Total Health Best of ASCO 2019, 7/20-21/19.
 2020 Course co-Director (with Manojkumar Bupathi): Total Health Best of ASCO 2020, 7/20-21/20 (video).
 2021 Course co-Director (with Manojkumar Bupathi): Total Health Best of ASCO 2021, 7/17-18/20 (video).

Mentoring:

Name: Paul Richardson, MD
 Prior Position: Instructor in Medical Oncology, Dana-Farber Cancer Institute
 Prior Degree: MD
 Current Position: Professor, Dana-Farber Cancer Institute, Harvard Medical School
 Training Duration: 1994-1999
 Achievements: Internationally reputed clinical translational investigator in multiple myeloma; lead investigator for thalidomide, lenalidomide, bortezomib, pomalidomide, panobinostat among others. Development of defibrotide for veno-occlusive disease. Clinical director of the Jerome Lipper Center for Multiple Myeloma at the DFCI since 2001. Over 200 articles in peer-reviewed journals including NEJM, Blood, JCO, Clin Cancer Res, Leukemia, and Br J Haemat.

Name: Alexander Urquhart, MD
 Prior Position: Medical Oncology Fellow
 Prior Degree: MD
 Current Position: Clinical Assistant Professor, University of Colorado
 Training Duration: 2006-2007
 Achievements: Development of protocols and a combined laboratory/clinical project in lobular carcinoma. Case presentation and review of literature on N1mic breast cancer published (2007). Successful clinical oncology practice at Vail Valley Shaw Regional Cancer Center

Name: Kimberley Roper, PhD
 Prior Position: Colorado Program in Aging and Cancer—PI Tim Byers, Robert Schwartz for Pilot Program
 Prior Degree: PhD
 Current Position: Assistant Professor in Medicine, UC
 Training Duration: 2007
 Achievements: Colorado Program in Aging and Cancer (PI Tim Byers, Robert Schwartz) Pilot project #5: The Caregiving Experience: Burden, Stress, and Hormones in Older Caregivers of Cancer Patients. Kim Roper PhD (Oncology PI), Mark Laudenslager PhD (Co-investigator), Anthony Elias MD (Oncology Mentor), Laurence Robbins MD (Geriatrics Mentor).

Name: Betsy Risendal, PhD
 Prior Position: University of Arizona graduate student
 Prior Degree: PhD
 Current Position: Associate Professor with tenure, University of Colorado
 Training Duration: 2009-2010

Achievements: Insulin-Like Growth Factors and Disparities in Breast Cancer Outcomes: K07 application. Oncology Mentor. Joint mentor with Tim Byers.
Co-Director of Lance Armstrong Foundation Center of Excellence at UC. PI of several grants on survivorship: CDPHE “Reducing the impact of cancer through exercise” and ACS “Quality of life and health behavior in long-term colon cancer patients”. National and state projects related to patient navigation. 24 publications mostly on breast cancer risk correlated with dietary and lifestyle risks and exercise.

Name: Virginia Borges, MD
Prior Position: Instructor, Beth Israel Deaconess Medical Center
Prior Degree: MD
Current Position: Professor with tenure, University of Colorado
Training Duration: 2003-2006
Achievements: R01, DOD, Komen, AACR-BCRF grants on pregnancy associated breast cancer; leader Young Women’s Breast Cancer Program

Name: Dan Bowles, MD
Prior Position: MSIV, UC
Prior Degree: BA
Current Position: Assistant Professor, University of Colorado
Training Duration: 2004-2008
Achievements: Chief Resident, Chief Fellow, Both at Denver VA and at UCH. In the Head & Neck Program as well as the Phase I program. Publications on patient derived xenografts as models to treat patients in parallel, a phase I on PX-866, scholarly reviews on various new oncologic agents.

Name: Alexander Menter, MD
Prior Position: Medical Oncology Fellow
Prior Degree: MD
Current Position: Kaiser Oncology, Denver
Training Duration:
Achievements: Development of protocols and a combined laboratory/clinical project in the function of TRAIL in stage II breast cancer. Grant application studying the mechanisms of resistance to SU011248 in breast cancer.
Currently Director of Oncology Clinical Trials at Kaiser Colorado

Name: Lindsay Weitzel, PhD
Prior Position: Graduate Student in the Department of Biometrics and Preventative Medicine, University of Colorado
Prior Degree: BA
Current Position: Post-doctoral PRA, Department of Cardiology, UC
Training Duration: July 2005 - 2012
Achievements: Awarded her PhD. Completed comparative proteomics on primary breast cancers and plasma samples before and after surgery. Published Weitzel L-R B, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Singh M, Duncan MW, Elias A. Discovery and verification of protein differences between ER positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Can Res Ther 2010; Jan 20 (epub). [PMID: 20087651](#)
Also author on a patent application for multiplex plasma protein markers of early stage breast cancer.

Name: Peter Kabos, MD
Prior Position: Medical Oncology Fellow
Prior Degree: MD

Current Position: Associate Professor, Division of Medical Oncology
Training Duration: 2008 to present
Achievements: ASCO Young Investigator Award, NCI K08 and R01. Runs a laboratory on the regulation of ER by non-coding RNA. Development of breast cancer patient-derived xenografts; cancer stem cell enrichment by preoperative chemotherapy. Multiple publications.

Name: Gabriel A. Brooks, MD
Prior Position: PGY2, UC
Prior Degree: MD
Current Position: Instructor, Harvard Medical School
Training Duration: 2008
Achievements: Case study published on small ER+/Her2+ breast cancer with review of literature, protocol development. Currently in the Gastrointestinal Oncology section at the DFCI just appointed to faculty after completing fellowship.

Name: Max Kullberg, PhD
Prior Position: Graduate student, University of Alaska
Prior Degree: PhD
Current Position: Assistant Professor, University of Alaska
Training Duration: 2011 - Present
Achievements: Development of targeting multifunctional liposomes for breast cancer. Several publications in Cancer Letters, J Drug Targeting, Mol Pharm

Name: Jennifer Diamond, MD
Prior Position: Fellow in Medical Oncology, University of Colorado School of Medicine
Prior Degree: MD
Current Position: Associate Professor of Medicine, University of Colorado
Training Duration: 2009 to present
Achievements: K12, R21, K23 awards. New agents in TNBC (ENMD2076 and others)

Name: Gail Stanley, MS II
Prior Position: MSII, University of Colorado School of Medicine
Prior Degree: BA
Current Position: Internal Medicine Resident, University of New Mexico
Training Duration: 2011-2014
Achievements: To graduate medical school with excellent bedside clinical skills

Name: Meredith McKean
Prior Position: PGY2 Internal Medicine, University of Colorado
Prior Degree: MD
Current Position: Asst Professor, U Tennessee
Training Duration: 2013 - 2015
Achievements: Developed protocol, collected tissue, IHC

Name: Victor Villalobos, MD, PhD
Prior Position: Assistant Professor of Medicine, University of Colorado
Prior Degree: MD, PhD
Current Position: Genzyme Medical Director
Training Duration: 2014 - 2020
Achievements: Director, Sarcoma Program; SWOG/HOPE Rare Cancer Fellow 2015-2017

Name: Carrye Cost, MD
Prior Position: Assistant Professor of Pediatrics, University of Colorado

Prior Degree: MD
Current Position: Assistant Professor of Pediatrics, University of Colorado
Training Duration: 2016 - Present
Achievements: Advisor on K12

Name: Justin Holmes, MS II
Prior Position: MSII, University of Colorado School of Medicine
Prior Degree: BA
Current Position: 4th Year MS
Training Duration: 2014-2017
Achievements: To graduate medical school with excellent bedside clinical skills

Name: Jessica Christenson, PhD
Prior Position: Postdoc, University of Colorado
Prior Degree: PhD
Current Position: Assistant Professor, University of Colorado
Training Duration: 2015 - Present
Achievements: Development of lung metastasis models in breast cancer

Name: Breelyn Wilky, MD
Prior Position: Asst Prof, University of Miami
Prior Degree: MD
Current Position: Assoc Professor, University of Colorado
Training Duration: 2018 - Present
Achievements: Development of novel immunotherapeutics for sarcoma

Name: Elaina Larson, MS I
Prior Position: MSI, University of Colorado School of Medicine
Prior Degree: BA
Current Position: 3rd Year MS
Training Duration: 2018-2021
Achievements: To graduate medical school with excellent bedside clinical skills

Name: Olivia Starich, MS I
Prior Position: MSI, University of Colorado School of Medicine
Prior Degree: BA
Current Position: 1st Year MS
Training Duration: 2020-2023
Achievements: To graduate medical school with excellent bedside clinical skills

GRANT SUPPORT:

Active

Title: **University of Colorado NTCN Lead Academic Participating Site (LAPS) UG1**
Role: Principal Investigator
Project Aims: To support the National Clinical Trials Network for the University of Colorado Health Systems.
Funding Agency: NCI
Funding Period: 3/1/19-2/28/25
Percent Effort: 8%
Total Cost: \$643,919

Title: **Targeting androgen receptor in breast cancer: enzalutamide as a novel breast cancer therapeutic**

Role Partnering Principal Investigator
Project Aims: To validate AR as a breast cancer target in the subtypes of breast cancer and to evaluate AR signaling inhibitors in the treatment of AR+ BC.
Funding Agency: DOD (Clinical Translational Research Award)
BC120183P1
Funding Period: 8/15/13 – 8/14/20
Percent Effort: 5-10%
Total Cost: \$3,817,628

Title: **10-0374: I-SPY2: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2**

Role PI
Project Aims: To determine the residual cancer burden for patients with stage 2/3 breast cancer treated with neoadjuvant therapy.
Funding Agency: FNIH/Quantum Leap
Funding Period: 3/15/10 to present
Percent Effort: 1%
Total Cost:

Title: **S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.**

Role PI
Project Aims: To determine the DFS of patients with ER+BC with high risk disease treated with adjuvant endocrine therapy +/- one year of everolimus.
Funding Agency: SWOG
Funding Period: 4/12/13 to 04/11/17
Percent Effort: 1%
Total Cost: \$27,000

Title: 19-1118: A Phase 1, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors.

Role PI
Project Aims: To determine the safety, MTD, and efficacy of ORIN1001 in metastatic breast cancer.
Funding Agency: Fosun Orinove, Inc
Funding Period: 8/8/19 to 8/5/24
Percent Effort: 1%
Total Cost: \$173,678

Title: **19-1337: A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally**

Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma.

Role PI
Project Aims: To determine the safety and efficacy of IPI-549 combined with nab-paclitaxel and atezolizumab in metastatic triple negative breast cancer.
Funding Agency: Infinity Pharmaceuticals, Inc
Funding Period: 8/12/19 to 2/22/24
Percent Effort: 1%
Total Cost: \$407,008

Title: **Infinity: 18-0685 A Phase 1/2 dose escalation and dose expansion study of A3021 in patients with advanced solid tumors.**

Role PI
Project Aims: To determine the toxicity and efficacy of IPI-549 added to nab-paclitaxel and atezolizumab for TNBC.
Funding Agency: Infinity
Funding Period: 12/23/19 to 2/22/23
Percent Effort: 1%
Total Cost:

Title: **BioAtla: 18-0685 A Phase 1/2 dose escalation and dose expansion study of A3021 in patients with advanced solid tumors.**

Role PI
Project Aims: To determine the toxicity and efficacy of an anti-ROR2 ADC.
Funding Agency: BioAtla
Funding Period: 9/7/18 to 9/6/23
Percent Effort: 1%
Total Cost: \$170,728

Title: **18-1856: A Phase 3, interventional, randomized, multicenter, open-label study of DCC-2618 vs sunitinib in patients with advanced GIST after treatment with imatinib.**

Role PI
Project Aims: To determine the toxicity and efficacy of DCC-2618 in second line treatment of GIST.
Funding Agency: Deciphera
Funding Period: 10/22/18 to 3/30/24
Percent Effort: 1%
Total Cost: \$438,856

PAST:

Title: **University of Colorado NTCN Lead Academic Participating Site (LAPS) U10**

Role: Principal Investigator
Project Aims: To support the National Clinical Trials Network for the University of Colorado Health Systems.
Funding Agency: NCI

Funding Period: 3/1/14-2/28/19
Percent Effort: 12%
Total Cost: \$ 4.2 million

Title: **17-0258 TRC105 vs pazopanib in advanced angiosarcoma**

Role: PI
Project Aims: As in title
Funding Agency: Tracon
Funding Period: 10/2/17 to 10/1/20
Percent Effort: 2%
Total Cost: \$150,422

Title: **15-2006 IMDZ-232: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY ESO-1**

Role: PI
Project Aims: As in title
Funding Agency: Immune Design
Funding Period: 3/22/16 to 3/21/19
Percent Effort: 2%
Total Cost: \$150,422

Title: **INO-VT-464-CL-006
15-1726 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.**

Role: PI
Project Aims: To determine the safety, PK, PD and efficacy of VT-464 in advanced breast cancer.
Funding Agency: Innocrin
Funding Period: 11/9/2015-9/15/2018
Percent Effort: 1%
Total Cost: \$280,000

Title: **14-1004 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy**

Role: PI
Project Aims: As in title
Funding Agency: CytRx
Funding Period: 9/16/14 to 9/15/17
Percent Effort: 2%
Total Cost: \$207,300

Title: **13-2892 A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of MDV3100 in Patients with Incurable Breast Cancer**
Role: PI
Project Aims: To determine the safety , PK and MTD of enzalutamide in breast cancer patients
Funding Agency: Medivation
Funding Period: 2/27/14 – 2/26/18
Percent Effort: 2%
Total Cost: \$276,400

Title: **12-0970 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination with Exemestane in Patients with Advanced Breast Cancer that is Estrogen or Progesterone Receptor-Positive and HER2-Normal**
Role: PI
Project Aims: To determine the efficacy of enzalutamide in breast cancer patients
Funding Agency: Medivation
Funding Period: 6/15/2012 – 6/14/2015
Percent Effort: 2%
Total Cost: \$93,569

Title: **17-0258 TRC105 vs pazopanib in advanced angiosarcoma**
Role: PI
Project Aims: As in title
Funding Agency: Tracon
Funding Period: 10/2/17 to 10/1/20
Percent Effort: 2%
Total Cost: \$150,422

Title: **13-1397 A Randomized, Open-label, Phase II Multicenter Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma**
Role: PI
Project Aims: As in title
Funding Agency: GSK
Funding Period: 6/6/13 to 6/5/16
Percent Effort: 1%
Total Cost: \$282,024

Title: **10-0754 A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone with the Immunological Adjuvant OPT-821 versus OPT-821 Alone in Metastatic Sarcoma Patients who are Rendered Disease Free.**

Role: PI
Project Aims: As in title
Funding Agency: MabVax
Funding Period: 9/13/10 to 4/1/16
Percent Effort: 1%
Total Cost: \$82,500

Title: **SWOG/HOPE Rare Cancer Fellow (V. Villalobos)**

Role: Mentor
Project Aims: To provide mentorship to Dr. Victor Villalobos.
Funding Agency: SWOG/HOPE Foundation
Funding Period: 5/1/15-4/30/17
Percent Effort: 5%
Total Cost: \$ 12,000

Title: **11-1225 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma**

Role: PI
Project Aims: As in title
Funding Agency: Eisai
Funding Period: 9/29/11 to 6/29/17
Percent Effort: 1%
Total Cost: \$167,000

Title: **MA.32: A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer**

Role: Principal Investigator
Project Aims: To determine if adjuvant metformin can improve survival and relapse in early stage BC
Funding Agency: NCICTG
Funding Period: 3/24/2011 – 3/23/2014
Percent Effort: 1%
Total Cost: \$20,000

Title: **PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR +, HER2 negative with known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146**

Role: Principal Investigator
Project Aims: To determine if PARP inhibition adds to cisplatin as postoperative treatment of TNBC who have residual disease after preoperative chemotherapy.
Funding Agency: Hoosier Oncology Group
Funding Period: 3/15/2010 – 4/1/2017
Percent Effort: 1%
Total Cost: \$90,000

Title: **09-0444 A phase I study of TDM1, paclitaxel and pertuzumab in metastatic breast cancer**
Role: PI
Project Aims: To determine the MTD and toxicity of the combination
Funding Agency: Genentech
Funding Period: 03/31/09-3/30/14
Percent Effort: 1%
Total Cost: \$468,502

Title: **10-1097 doxorubicin with or without palifosfamide for advanced soft tissue sarcoma**
Role: PI
Project Aims: To determine if palifosfamide improves PFS and OS when added to doxorubicin in metastatic sarcomas
Funding Agency: Ziopharm Oncology
Funding Period: 11/1/2010 – 8/31/2014
Percent Effort: 1%
Total Cost: \$334,815

Title: **A randomized phase II study of Imetelstat (GRN163L) in combination with Paclitaxel (with or without Bevacizumab) in patients with locally recurrent or metastatic breast cancer**
Role: PI
Project Aims: As in title
Funding Agency: Geron
Funding Period: 1/1/2011 – 12/31/2014
Percent Effort: 1%
Total Cost: \$150,000

Title: **10-1261 A Phase Ib/Randomized Phase II Study Evaluating the Efficacy of Doxorubicin With or Without a Human AntiPDGFR Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma.**
Role: PI
Project Aims: As in title
Funding Agency: ImClone
Funding Period: 10/19/10 to 12/31/15
Percent Effort: 1%
Total Cost: \$120,000

Title: **A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases**
Role: PI
Project Aims: To determine the safety and examine the efficacy of GRN1005 against brain metastases from BC.
Funding Agency: Geron
Funding Period: 1/3/2012 – 1/2/2015
Percent Effort: 1%
Total Cost: \$104,250

Title: **06-0026 A multicenter, open-label, single-arm study of Yondelis for subjects with locally advanced or metastatic soft tissue sarcoma who have relapsed or are refractory to standard of care treatment.**

Role: PI

Project Aims: To provide trabectedin to patients with refractory sarcomas

Funding Agency: Johnson & Johnson

Funding Period: 6/1/06-6/1/14

Percent Effort: 1%

Total Cost: \$34,920

Title: **11-0993 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide.**

Role: PI

Project Aims: As in title

Funding Agency: Johnson & Johnson

Funding Period: 9/22/2011 – 9/21/2016

Percent Effort: 1%

Total Cost: \$429,403

Title: **University of Colorado Southwest Oncology Group U10**

Role: Principal Investigator

Project Aims: To support the SWOG cooperative group trials at UCCC, including the network of institutions comprising our outreach.

Funding Agency: NIH/NCI U10 CA042777

Funding Period: 1/21/1998 – 12/31/2015

Percent Effort: 7%

Total Cost: \$141,659

Title: **University of Colorado Cancer Center Support Grant – Senior Leaders**

Role: Associate Director of Clinical Sciences

Project Aims: To serve as leadership for the University of Colorado Comprehensive Cancer Center

Funding Agency: NCI

Funding Period: 2/1/1998 - 1/31/2012

Percent Effort: 12%

Total Cost: \$ 191,869

Title: **Restoration of miR-200c: a Novel Therapy for Aggressive Breast Cancers**

Role: Collaborator (Richer PI)

Project Aims: To determine how miRNA-200c restores differentiation and chemosensitivity and if it can be used as a form of therapy for aggressive breast cancers

Funding Agency: Susan Komen

Funding Period: 02/26/2010- 02/25/2013

Percent Effort: < 1%
Total Cost: \$150,000

Title: **08-0138 A Phase Ib/IIa Trial of LBH589 in Combination with Trastuzumab in Adult Female Patients with HER2 Positive Metastatic Breast Cancer who Disease has Progressed During or Following Therapy with Trastuzumab.**

Role: PI
Project Aims: To determine the MTD of LBH589 with trastuzumab
Funding Agency: Novartis
Funding Period: 1/1/08 to 6/15/10
Percent Effort: 1%
Total Cost: \$137,597

Title: **08-0638 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib.**

Role: PI
Project Aims: To determine if IPI-504 can treat refractory GIST
Funding Agency: Infinity
Funding Period: 10/31/08 to 11/1/11
Percent Effort: 1%
Total Cost: \$137,220

Title: **08-0116 Five Tier Phase II Open Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients with Previously Treated Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET.**

Role: PI
Project Aims: To evaluate an IGF1R Ab in sarcomas
Funding Agency: Imclone
Funding Period: 4/1/08 to 4/1/10
Percent Effort: 1%
Total Cost: \$76,850

Title: **Androgen Receptors (AR) and Resistance to Current Endocrine Therapies: AR, hypoxia, and the "lipogenic phenotype"**

Role: Co-PI
Project Aims: To evaluate the role of AR and its regulation of the lipid metabolism on endocrine resistance.
Funding Agency: Susan G Komen Breast Cancer Foundation
Funding Period: 05/01/08 to 4/30/10
Percent Effort: <1%
Total Cost: \$100,000

Title: **Evaluation of the insulin-like growth factor-I receptor (IGF-IR) and its effect on tumor initiating cells; Phase II study of IGF-IR inhibitor in combo with chemo in new patients**

Role: PI/Mentor Young Investigator Award, ASCO 2009: Peter Kabos
Project Aims: Evaluation of the IGF1R's effect on tumor initiating cells – phase II study of IGF-1R inhibitor in combination with chemotherapy in locally advanced breast cancer patients.
Funding Agency: American Society of Clinical Oncology
Funding Period: 01/07/2009 - 06/30/2010

Percent Effort: 0%
Total Cost: \$ 47,500

Title: **A multiplexed panel of protein biomarkers for the early detection of breast cancer.**
Role: Co-Principal Investigator
Project Aims: To perform comprehensive proteomics on Stage I/II invasive breast cancers and determine if selected tumor-associated proteins circulate in the blood.
Funding Agency: Colorado Technology Transfer Office
Funding Period: 4/20/2005-3/19/2013
Percent Effort: 1%
Total Cost: \$88,420

Title: **06-0468 A Multi-center Phase II study of Sorafenib (BAY 43-9006) in Non-GIST sarcomas.**
Role: Co-PI
Project Aims: To evaluate sorafenib in sarcomas
Funding Agency: CTEP/MSKCC
Funding Period: 11/1/06-11/1/09
Percent Effort: 1%
Total Cost: \$21,860

Title: **05-0696 A randomized phase II study pf SU011248 vs. standard-of-care for patients with previously treated, advanced, triple receptor negative (ER,PR,and HER2) breast cancer.**
Role: PI
Project Aims: The goals of this study are to compare single agent sunitinib to single agent standard chemotherapy in the treatment of newly diagnosed metastatic triple negative breast cancer.
Funding Agency: Pfizer
Funding Period: 6/15/06-6/15/09
Percent Effort: 1%
Total Cost: \$118,676

Title: **A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma (AP23573-04-202)**
Role: PI
Project Aims: To evaluate ridaforolimus in sarcoma cohorts
Funding Agency: Ariad
Funding Period: 11/1/04-11/1/06
Percent Effort: 2%
Total Cost: \$62,958

Title: **01-543 A Controlled randomized, phase III, multicenter, open label study of ABI-007 (a cremophor-free, protein stabilized, nanoparticle paclitaxel) and taxol in patients with metastatic breast cancer.**
Role: PI
Project Aims: To compare ABI-007 to taxol in efficacy in BC.
Funding Agency: American BioScience, Inc.
Funding Period: 11/7/01-11/7/05
Percent Effort: 1%
Total Cost: \$34,020

Title: **03-977 A Phase II Study of the Efficacy and Safety of SU011248 in Patients with Anthracycline- and Taxane-Resistant Metastatic Breast Cancer**
Role: PI
Project Aims: To determine the efficacy and toxicity of sunitinib in BC
Funding Agency: Pfizer
Funding Period: 3/1/04-3/1/07
Percent Effort: 1%
Total Cost: \$305,947

Title: **03-178 H3E-US-JMEO, Phase II Trial of ALMITA and Gemzar in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy.**
Role: PI
Project Aims: To determine the efficacy and toxicity of pemetrexed plus gemcitabine in BC
Funding Agency: Lilly
Funding Period: 5/15/03-5/14/04
Percent Effort: 1%
Total Cost: \$34,072

Title: **03-478 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer**
Role: PI
Project Aims: To determine if a combined Her2/EGFR TKI will improve DFS of ER+ BC.
Funding Agency: GlaxoSmithKline
Funding Period: 6/1/2004 to 6/1/2007
Percent Effort: 1%
Total Cost: \$141,209

Title: **DAMD17-02-1-0353 (Richer)**
Role: Co-Principal Investigator
Project Aims: The goal of this project is to characterize breast cancer tissues obtained pre and post-treatment with anti-estrogen therapy by gene expression microarrays.
Funding Agency: DOD
Funding Period: 05/10/02 to 06/09/05
Percent Effort: 5%
Total Cost: \$ 76,000

Title: **Funding for faculty recruitment, seed grants, retreats, laser capture microscope, post-doctoral training, medical oncology fellow mentorship, and community outreach.**
Role: Co-Investigator
Project Aims: As per title
Funding Agency: Avon Breast Cancer Crusade Funds
Funding Period: 2001-2003
Percent Effort: 5%
Total Cost: \$ 2,500.000

Title: **Overcoming Age-Related Barriers to Early Phase Trials**
Role: Co-Investigator

Project Aims: To reduce barriers to accrual to phase I trials.
Funding Agency: NCI CA-03-501
Funding Period: 05/01/2003 to 04/30/04
Percent Effort: 5%
Total Cost:

Title: **Preoperative Hormone Therapy for Postmenopausal Women with ER+ or PR+ T2-3 Tumors: Exemestane with or without Tamoxifen, A Pilot Randomized Phase II Study.**

Role: Primary Investigator, Investigator initiated

Project Aims:
Funding Agency: Pharmacia & Upjohn
Funding Period: 3/1/02 - 3/1/05
Percent Effort: 5%
Total Cost: \$ 187,282

Title: **Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophospha Versus Docetaxel/Capecitabine Regimens in Patients with Large ER-Negative Breast Cancers**

Role: Primary Investigator, Investigator initiated

Project Aims: To discover pathways of resistance that overlap different mechanisms of chemotherapy

Funding Agency: Pharmacia
Funding Period: 7/1/2003 to 6/30/2006
Percent Effort: 2%
Total Cost: \$ 56,920

Title: **Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophospha Versus Docetaxel/Capecitabine Regimens in Patients with Large ER-Negative Breast Cancers**

Role: Primary Investigator, Investigator initiated

Project Aims: To discover pathways of resistance that overlap different mechanisms of chemotherapy

Funding Agency: Roche
Funding Period: 3/1/2003 to 6/30/2006
Percent Effort: 2%
Total Cost: \$ 56,920

Title: **COMIRB 00-1043 Phase II, Open-Label, Multi-Center Trial of Angiozyme in Patients with Metastatic Breast Cancer Who Have Failed at Least Once Course of Chemotherapy for Metastatic Disease**

Role: PI

Project Aims: The goal of this project is to determine the phase II activity of Angiozyme, an anti-VEGFR1 ribozyme, in breast cancer

Funding Agency: Ribozyme Pharmaceuticals
Funding Period: 03/20/2001 – 03/19/2004
Percent Effort: 1%
Total Cost: \$40,080

Title: **COMIRB 01-239 Phase II Study of Bevacizumab in Combination with Docetaxel in Patients with Advanced Breast Cancer**

Role: coPI

Project Aims: To determine the toxicity and efficacy of the combination in breast cancer
Funding Agency: CTEP/OSU

Funding Period: 4/1/03– 5/15/04
Percent Effort: 1%
Total Cost: \$49,000

Title: **COMIRB 01-889 A Phase III Adjuvant Trial of Sequenced EC+ Filgrastim + Epoetin Alfa Followed by Paclitaxel versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer**

Role: PI
Project Aims: The goal of this project is to determine which chemotherapy regimen is superior either in terms of time to progression or lesser toxicity for stage II breast cancer

Funding Agency: NCIC
Funding Period: 05/15/2001 – 05/15/2004
Percent Effort: 1%
Total Cost: \$19,842

Title: **Solid Tumor Autologous Marrow Program (STAMP), DFCI**
Role: Co-Primary Investigator, Project Leader, and Core Leader
Project Aims: This project involved high dose experimental therapy for breast cancer.
Funding Agency: NCI
Funding Period: 1994 - 1998
Percent Effort: 40%
Total Cost: \$300,000

Title: **Pharmacology of High Dose Ifosfamide with Etanidazole**
Role: Primary Investigator
Project Aims: The goal of this project was to characterize the Pharmacokinetics of high dose ifosfamide as part of a phase I study of high dose ifosfamide, carboplatin, and etoposide with etanidazole and stem cell support.
Funding Agency: Bristol Meyers Squibb
Funding Period: 1996-1998
Percent Effort: 5%
Total Cost: \$115,000

Title: **High Dose Alkylators with Amifostine**
Role: Primary Investigator
Project Aims: The goal of this project was to conduct a phase II study of high dose ifosfamide, carboplatin, and etoposide with amifostine and stem cell support with Pharmacokinetics of high dose ifosfamide.
Funding Agency: Alza Corporation
Funding Period: 1998 - 2000
Percent Effort: 5%
Total Cost: \$60,000

Title: **MRT in SCLC**
Role: Primary Investigator
Project Aims: The goal of this study was to determine the correlation of immunologically detected tumor contamination in bone marrow and blood of patients with limited state small cell lung cancer with time to progression.
Funding Agency: NCI R21 CA81324
Funding Period: 1999 - 2001

Percent Effort: 10%
Total Cost: \$ 150,000

Title: **MRT in Breast Cancer SPORE**
Role: Co-Primary Investigator of the Developmental Project
Project Aims: The goal of this study determine the correlation of circulating her2+ breast cancer cells with treatment with Herceptin containing therapy
Funding Agency: NCI
Funding Period: 2000 - 2001
Percent Effort: 10%
Total Cost: \$ 50,000

Many other clinical trials in sarcoma, lung cancer, BMT, and breast cancer (1986-2003)

BIBLIOGRAPHY:

Original Articles:

1. Elias AD, Antman KH. Doxorubicin, Ifosfamide, and Dacarbazine (AID) with Mesna uroprotection for advanced untreated sarcoma: a phase I study. *Cancer Treatment Reports* 1986; 70:827-33. [PMID: 3087617](#)
2. Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, Frei E III. High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. *J Clin Oncol* 1986; 4:1592-7. [PMID: 3534155](#)
3. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Bast R, Schnipper L, Frei E III, and the Solid Tumor Autologous Bone Marrow Team. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. *Cancer Treatment Reports* 1987; 71:119-25. [PMID: 3542208](#)
4. Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous infusion high-dose thioTEPA. *Cancer Treat Reports* 1987; 71:1043-7. [PMID: 3119200](#)
5. Elias AD, Cohen BF, Bernal SD. Keratin subtypes of small cell lung cancer (SCLC). *Cancer Res* 1988; 48:2724-9. [PMID: 2452011](#)
6. Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper L, Frei E III. Malignant melanoma treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. *Arch Dermatol* 1988; 124:878-84. [PMID: 3288124](#)
7. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. *Lancet* 1988; i:1194-8. [PMID: 2897009](#)
8. Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on granulocytes in vivo. *Blood* 1988; 72:691-7. [PMID: 3042045](#)
9. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E III, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression. *N Engl J Med* 1988; 319:593-8. [PMID: 3045544](#)
10. Eder JP, Antman K, Shea TC, Elias A, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Critchlow J, Flaherty M, Mick R, Schnipper LE, Frei E III. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. *J Natl Cancer Inst* 1988; 80:1221-6. [PMID: 3138431](#)
11. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. *J Clin Oncol* 1989; 7:126-31. [PMID: 2491883](#)
12. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E III, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. *J Clin Oncol* 1989; 7:651-61. [PMID: 2651580](#)

13. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide & dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol* 1989; 7:1208-16. [PMID: 2504890](#)
14. Sullivan R, Fredette JD, Griffin JD, Socinski MA, Elias A, Antman KH, Schnipper LE. The production of superoxide anion is enhanced in granulocytes harvested from patients infused with granulocyte-macrophage colony-stimulating factor. *Brit J Hematol* 1989; 475-479. [PMID: 2540792](#)
15. Elias AD, Eder JP, Shea T, Begg CB, Frei E III, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. *J Clin Oncol* 1990; 8: 170-178. [PMID: 2104923](#)
16. Tondini C, Pap SA, Hayes DF, Elias AD, Kufe DW. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of bone marrow. *Cancer Research* 1990; 50: 1170-1175. [PMID: 2404589](#)
17. Morris SW, Daniel L, Ahmed CMI, Elias A, Lebowitz P. Relationship of Bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. *Blood* 1990; 75: 2035-41. [PMID: 2337672](#)
18. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. *J Clin Oncol* 1990; 8:1699-1706. [PMID: 2213105](#)
19. Eder JP, Elias A, Shea TC, Schryber SM, Teicher B, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E III, Antman K. A phase I/II study of cyclophosphamide, thioTEPA, and carboplatin with autologous bone marrow transplantation in solid tumor patients. *J Clin Oncol* 1990; 8: 1239-1245. [PMID: 2162912](#)
20. Doyle LA, Borges M, Hussain A, Elias A, Tomiyasu T. An adherent subline of a unique small cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule. *J Cell Invest* 1990; 86:1848-1854. [PMID: 1701450](#)
21. Elias AD, Ayash L, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, Frei E III, Antman KH. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. *J Clin Oncol* 1991; 9:320-7. [PMID: 1846407](#)
22. Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E III, Antman KH. A phase I trial of continuous infusion cyclophosphamide in refractory cancer patients. *Cancer Chemother Pharmacol* 1991;29:61-5. [PMID: 1742850](#)
23. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. *J Clin Oncol* 1992;10:102-10. [PMID: 1727912](#)
24. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E III. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. *J Clin Oncol* 1992; 10: 995-1000. [PMID: 1588381](#)
25. Elias AD, Ayash L, Anderson K, Hunt M, Wheeler C, Schwartz G, Teppler I, Mazanet R, Lynch C, Pap S, Pelaez J, Schnipper L, Griffin J, Frei E III, Antman K. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. *Blood* 1992; 79: 3036-44. [PMID: 1350229](#)

26. Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E III, Antman K. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: a comparison of four chemotherapy regimens. *Bone Marrow Transplantation* 1992; 10: 57-63. [PMID: 1515880](#)
27. Southee AE, Kaplan WD, Gonin R, Jochelson MS, Dwyer JP, Antman KH, Elias AD. Gallium imaging in metastatic and recurrent soft tissue sarcoma. *J Nuclear Med* 1992; 9: 1594-1599. [PMID: 1517831](#)
28. Lynch TJ, Clark JR, Kalish L, Fallon BG, Elias AD, Skarin A, Frei E III. Continuous infusion cisplatin, 5-fluorouracil and bolus methotrexate in the treatment of advanced non-small cell lung cancer. *Cancer* 1992; 70: 1880-1885. [PMID: 1326396](#)
29. Elias AD, Ayash L, Frei E III, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, McCauley M, Herman T, Schnipper L, Antman KH. Intensive combined modality therapy for limited stage small cell lung cancer. *J Natl Cancer Inst* 1993; 85: 559-566. [PMID: 8384264](#)
30. Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, Weinstein H, Schwartz G, Ferrara J, Mazanet R, Rimm I, Tepler I, McCarthy P, Mauch P, Ault K, Gaynes L, McCauley M, Schnipper LE, Antin J. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine and etoposide. *J Clin Oncol* 1993; 11: 1085-1091. [PMID: 8099120](#)
31. Antman KH, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamon GH, Baker LH. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 1993; 11: 1276-1285. [PMID: 8315425](#)
32. Lynch TJ, Kass F, Kalish LA, Elias AD, Strauss G, Shulman LN, Sugarbaker DJ, Skarin A, Frei E III. Cisplatin, 5-fluorouracil and etoposide for advanced non-small cell lung cancer. *Cancer* 1993; 71(10): 2953-7. [PMID: 8387871](#)
33. Tepler I, Cannistra SA, Frei E III, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Antman KH. Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. *J Clin Oncol* 1993; 11: 1583-1591. [PMID: 8101563](#)
34. Kirn DH, Lynch TJ, Mentzer SJ, Lee TH, Strauss GM, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality therapy of patients with stage IIIA, N2 non-small cell lung cancer: Impact of preoperative chemotherapy on resectability and downstaging. *J Thorac Cardiovasc Surg* 1993; 106: 696-702. [PMID: 8412265](#)
35. Ayash LJ, Elias A, Wheeler C, Tepler I, Schwartz G, Schnipper L, Frei E, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Experience. *J Hematotherapy* 1993; 2: 507-511. [PMID: 7916250](#)
36. Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E III, Antman K. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. *J Hematotherapy* 1993; 2: 377-382. [PMID: 7522891](#)
37. Elias AD, Skarin AT, Gonin R, Oliynyk P, Stomper P, O'Hara C, Socinski MA, Sheldon T, Maggs P, Frei E III. Neoadjuvant treatment of stage IIIA non-small cell lung cancer: Long term results. *Am J Clin Oncol* 1994; 17: 26-36. [PMID: 8311004](#)

38. Ayash L, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E III, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. *J Clin Oncol* 1994; 12: 37-44. [PMID: 7505807](#)
39. Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E III. High dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy: Analysis by age. *J Natl Cancer Inst* 1994; 16: 91-94. [PMID: 7528031](#)
40. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman L, Posner M, Frei E III. A phase II study of topotecan in metastatic non-small cell lung cancer. *J Clin Oncol* 1994; 12: 347-352. [PMID: 8113842](#)
41. Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, Antman K, Anderson KC. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. *Br J Haematol* 1994; 87: 153-161. [PMID: 7947240](#)
42. Tepler I, Elias A, Kalish L, Shulman L, Strauss G, Skarin A, Lynch T, Levitt D, Resta D, Demetri G, Gaynes L, Schnipper L. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. *Br J Haematol* 1994; 87: 678-686. [PMID: 7986706](#)
43. Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E. Continuous infusion cisplatin, 5-fluorouracil, and leukovorin for advanced non-small cell lung cancer. *Cancer* 1994; 73: 1171-6. [PMID: 8313319](#)
44. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E III, Antman KH. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. *Bone Marrow Transplantation* 1995; 15: 373-379. [PMID: 7599561](#)
45. Wright JE, Tretyakov O, Ayash LJ, Elias A, Rosowsky A, Frei E III. Analysis of 4-hydroxycyclophosphamide in human blood. *Analytical Biochem* 1995; 224: 154-158. [PMID: 7710063](#)
46. Wright JE, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C, Schwartz G, Tepler I, Antman K, Rosowsky A, Frei E III, Ayash LJ. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. *Cancer Chemother Pharm* 1995; 36: 345-351. [PMID: 7628055](#)
47. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schipper L, Antman K, Frei E III, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer. *J Clin Oncol* 1995; 13: 2043-2049. [PMID: 7636547](#)
48. Benjamin RJ, Linsley L, Axelrod JD, Churchill WH, Sieff C, Shulman LN, Elias A, Ayash L, Malachowski ME, Uhl L, Gaynes L, McCauley M, Thompson L, Mazanet R, Antman K, Schnipper L, Tepler I, Antin JH, Wheeler C. The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high-dose chemotherapy support. *Transfusion* 1995; 35: 837-844. [PMID: 7570914](#)
49. Webb IJ, Eickhoff CE, Elias A, Ayash LJ, Wheeler C, Schwartz G, Demetri G, Anderson KC. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony stimulating factor (G-CSF): implications for timing and yield of hematopoietic progenitor cell collections. *Transfusion* 1996; 36(2): 160-167. [PMID: 8614968](#)

50. Kumar P, Herndon J II, Langer M, Kohman L, Shennib H, Elias A, Kass F, Eaton W, Seagren S, Green M, Sugarbaker D. Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2) - Analysis of Cancer and Leukemia Group B Protocol 8935. *Cancer* 1996; 77(11): 2393-2399. [PMID: 8635112](#)
51. Webb IJ, Coral FS, Anderson JW, Elias AD, Finberg RW, Nadler LM, Ritz J, Anderson KC. Sources and sequelae of bacterial contamination of hematopoietic stem cell products: Implications for safety of hematotherapy and graft engineering. *Transfusion* 1996; 36: 782-788. [PMID: 8823450](#)
52. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher B, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E III, Antman A. Double dose-intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in PFS by the sequence of high-dose melphalan followed by CTCb. *J Clin Oncol* 1996; 14: 2984-2992. [PMID: 8918496](#)
53. Chen L, Pulsipher M, Chen D, Sieff C, Elias A, Fine HA, Kufe D. Adenovirus mediated transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. *J Cell Invest* 1996; 98: 2539-2548. [PMID: 8958216](#)
54. Elias AD, Marks EJ. Case 25-1997: Acute and chronic pneumonitis after high dose chemotherapy with hematopoietic stem cell support. Clinicopathologic Conference, Massachusetts General Hospital. *New Engl J Med* 1997; 337: 480-489. [PMID: 9250852](#)
55. Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E III, Sugarbaker DJ. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). *Lung Cancer* 1997;17: 147-161. [PMID: 9194034](#)
56. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IF, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei III E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes. *Biol of Blood and Marrow Transplantation* 1997; 3: 98-106. [PMID: 9267670](#)
57. Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral blood progenitor cells and filgrastim in advanced breast cancer patients. *J Clin Oncol* 1997; 15: 674-683. [PMID: 9053493](#)
58. Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. *J Clin Oncol* 1997; 15: 723-734. [PMID: 9053498](#)
59. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. *Semin Oncol.* 1997 Aug;24(4 Suppl 12):S12-73-S12-80. [PMID: 9331127](#)
60. Sehn LH, Antin JH, Shulman LN, Elias A, Kadin M, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic stem cell transplantation. *Blood* 1998; 91: 717-723. [PMID: 9427731](#)
61. Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E III, Antman K. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast carcinoma. *J Clin Oncol* 1998; 16: 1000-1007. [PMID: 9508183](#)

62. [Elias AD](#), Ayash LJ, Wheeler C, Schwartz G, Ibrahim J, McCauley M, Teicher BA, Coleman N, Newquist E, Schnipper L, Antman KH, Frei E III. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide and autologous hematopoietic stem cell support. *Clin Cancer Res* 1998; 4: 1443-1449. [PMID: 9626461](#)
63. Avigan D, Richardson P, [Elias A](#), Demetri G, Shapiro M, Frei E III, Schnipper L, Wheeler C. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue for solid tumors: case series with review of the literature. *Cancer* 1998; 83: 409-414. [PMID: 9690531](#)
64. Frei E III, [Elias A](#), Wheeler C, Richardson P, Hyrniuk W. The relationship between high dose treatment and combination chemotherapy: the concept of summation dose intensity. *Cancer Res* 1998; 4: 2027-2037. [PMID: 9748116](#)
65. Richardson PG, [Elias AD](#), Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in efficacy without significant toxicity in a high risk population. *Blood* 1998; 92: 737-744. [PMID: 9680339](#)
66. [Elias A](#), Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E III. Dose intensive therapy for limited stage small cell lung cancer: long-term outcome. *J Clin Oncol* 1999; 17: 1175-1184. [PMID: 10561176](#)
67. Frei E III, Richardson P, Avigan D, Bunnell C, Wheeler C, [Elias A](#). The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. *Bone Marrow Transplantation* 1999; 24: 939-945. [PMID: 10556951](#)
68. Avigan D, Wu Z, Gong J, Joyce R, Levine J, [Elias A](#), Richardson P, Milano J, Kennedy L, Anderson K, Kufe D. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. *Clin Cancer Res* 1999; 5: 2735-2741. [PMID: 10537336](#)
69. Frei E III, Richardson P, Ara G, Teicher B, Wheeler C, [Elias A](#). Tandem high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer – effect of sequence. *Cancer Chemother Pharmacol* 2000; 45: 239-246. [PMID: 10663642](#)
70. Kraeft S-K, Sutherland R, Gravelin L, Hu G-H, [Elias A](#), Chen LB. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. *Clinical Cancer Res* 2000; 6: 434-442. [PMID: 10690521](#)
71. Avigan D, Wu Z, Joyce R, [Elias A](#), Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. *Bone Marrow Transplant* 2000; 26: 169-176. [PMID: 10918427](#)
72. Wheeler C, Khurshid A, Ibrahim J, [Elias A](#), Mauch P, Ault K, Antin J. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine and etoposide (CBV). *Leuk Lymphoma* 2001; 40: 499-509. [PMID: 11426523](#)
73. [Elias AD](#), Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Hieng S, Reich E, Frei E III, Ayash L. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy-naïve metastatic breast cancer. *Bone Marrow Transplantation* 2001; 27: 269-278. [PMID: 11277174](#)

74. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E III. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: Sequential phase I/II studies. *Bone Marrow Transplantation* 2001; 28: 447-454. [PMID: 11593317](#)
75. Salgia R, Harpole D, Herndon JE II, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. *Anticancer Res* 2001; 21: 1241-1246. [PMID: 11396194](#)
76. Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zaccarola P, Dang NH, Leong T, Salgia R, Skarin AT. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. *Cancer Chemother Pharmacol* 2001; 48: 151-159. [PMID: 11561781](#)
77. Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E III. The impact of induction duration and the number of high dose cycles on the long-term survival of women with metastatic breast cancer treated with high dose chemotherapy with stem cell rescue: An analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. *BBMT* 2002; 8: 198-205. [PMID: 12017145](#)
78. Rizzo JD, Elias AD, Stiff PJ, Lazarus HM, Zhang M-J, Oblon DJ, Pecora AJ, Hale GA, Horowitz MM. Autologous stem cell transplantation for small cell lung cancer. *BBMT* 2002; 8: 273-280. [PMID: 12064365](#)
79. Elias A, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E III. Dose intensive therapy for extensive stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. *Biol Blood Marrow Transplant.* 2002; 8: 326-333. [PMID: 12108918](#)
80. Elias AD, Kumar P, Herndon J, Skarin AT, Sugarbaker DJ, Green M. Radiotherapy versus chemotherapy plus radiotherapy in surgically staged and treated IIIA N2 non-small cell lung cancer (NSCLC). *Clinical Lung Cancer* 2002; 4: 95-103. [PMID: 14653865](#)
81. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-Institutional Use of Defibrotide In 88 Patients Post Stem Cell Transplant With Severe Venous Occlusive Disease and Multi-System Organ Failure; Response Without Significant Toxicity In a High Risk Population and Factors Predictive of Outcome. *Blood* 2002; 100:4337-4343. [PMID: 12393437](#)
82. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. *Breast Cancer Res Treat.* 2003; 77: 245-252. [PMID: 12602924](#)
83. Ramaswamy B, Elias AD, Kelbick N, Morrow M, Hauger M, Rhoades C, Kendra K, Allen J, Chen H, Eckhardt G, Shapiro CL. Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. *Clin Cancer Res* 2006; 12: 3124-3129. [PMID: 16707611](#)
84. Moore HCF, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow W, Hudis C, Wolff AC, Ingle JN, Gandara DR, Elias AD, Livingston RB, Martino S. Intensive Dose-Dense Versus High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. *J Clin Oncol* 2007; 25: 1677-1682. [PMID: 17404368](#)
85. Harvell DME, Richer JK, Spoelstra N, Singh M, Borges V, Finlayson C, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant hormone therapy of breast cancers: dominance of tamoxifen agonist effects in the presence of an aromatase inhibitor. *Breast Cancer Research and Treatment* 2008, epub 3/9/08. [PMID: 18338247](#)

86. Harvell DM, Spoelstra NS, Singh M, Finlayson C, Phang T, Trapp S, Hunter L, Borges VB, Elias A, Horwitz KB, Richer JK. Molecular signatures of response to neoadjuvant endocrine therapies for breast cancer. *Breast Cancer Research and Treatment* 2008, epub 3/13/08. [PMID: 18327671](#)
87. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Baum CM, Miller KD. A phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2008; 26:1810-1816. Epub 2008 Mar 17. [PMID: 18347007](#)
88. Regan MM, Pagani O, Walley B, Torrasi R, Perez EA, Francis P, Fleming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD; SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? *Ann Oncol*. 2008 Jul;19(7):1231-41. doi: 10.1093/annonc/mdn037. Epub 2008 Mar 5. [PMID: 18325918](#) (A Elias other author).
89. Maki RG, Keohan ML, Undevia S, Livingston M, Cooney M, Elias A, Saulle M, Wright JJ, D'Adamo DR, Schuetze S. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol* 2009; 27: 3133-3140. [PMID: 19451436](#)
90. Lamont EB, Landrum MB, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, Keating NL, McNeil BJ for the Cancer and Leukemia Group B. Differences in Clinical Trial Patients Attributes and Outcomes According to Enrollment Setting. *J Clin Oncol* 2009; 11/23 epub. [PMID: 19933919](#)
91. Pippin J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Gralow J. A phase 2 trial of pemetrexed and gemcitabine in metastatic breast cancer in patients who have received prior taxane therapy. *Clin Breast Cancer* 2010; 10: 148-153. [PMID: 20299319](#)
92. Weitzel L-R B, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Singh M, Duncan MW, Elias A. Discovery and verification of protein differences between ER positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. *Breast Can Res Ther* 2010; Jan 20 (epub). [PMID: 2087651](#)
93. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. *Breast Cancer Res Treat* 2010; 128: 45-55. Jul 28. Epub ahead of print. [PMID: 20665103](#)
94. Cochrane DR, Cittelly DM, Howe EH, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor alpha Status and Dicer Level in Breast Cancer. *Hormones and Cancer* 2011; 1: 306-319. [PMID: 21761362](#)
95. *Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med*. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: *N Engl J Med*. 2011 Oct 6;365(14):1361. [PMID: 21639806](#) (A Elias, other author).
96. Morrow PK, Murthy FK, Ensor JE, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase II trial of Angiozyme (RPI.4610) in the treatment of metastatic breast cancer. *Cancer* 2012 Jan 26, epub ahead of print. [PMID: 22281842](#)

97. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. *Breast Cancer Res Treat* 2012, epub 7/24. [PMID: 22821401](#)
98. Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, MD^d, Liu E, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H, for the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group. Reducing Breast Cancer Recurrence with Weight Loss, a Vanguard Trial: The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial. *Contemporary Clinical Trials* 2013; 34: 282-295. [PMID: 23266440](#)
99. Schöffski P, Adkins D, Blay J-Y, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO. An Open-label, Phase 2 Study Evaluating the Efficacy and Safety of the Anti-IGF-1R Antibody Cixutumumab in Patients with Previously-treated Advanced or Metastatic Soft-tissue Sarcoma or Ewing Family of Tumours. *Eur J Cancer* 2013; Oct;49(15):3219-28. doi: 10.1016/j.ejca.2013.06.010. Epub 2013 Jul 5. [PMID: 23835252](#)
100. Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruzolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. *Breast Journal* Oct;22(5):650-6. doi: 10.1016/j.breast.2013.07.037. Epub 2013 Aug 17. [PMID: 23958375](#)
101. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the Androgen Receptor in Breast Cancer and Preclinical Analysis of Enzalutamide. *Breast Cancer Research* 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599. [PMID: 24451109](#)
102. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. *Neuro Oncol.* 2014 Feb 3. [Epub ahead of print] [PMID: 24497407](#)
103. Rusthoven CG, Liu AK, Bui MM, Schefter TE, Elias AD, Lu X, Gonzalez RJ. Sarcomas of the Aorta: A systematic review and pooled analysis of published reports. *Ann Vasc Surg* 2014; 28: 515-525. [PMID: 24485779](#)
104. Pathiraja TN, Nayak S, Xi Y, Jiang S, Garee JP, Edwards DP, Lee A, Shea MJ, Santen R, Gannon F, Kangaspeska S, Jelinek J, Issa J-P, Richer J, Elias A, McIlroy M, Young L, Davidson N, Normolle D, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine resistant breast cancer. *Science Translational Medicine* 2014, Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326. [PMID: 24670685](#)
105. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribí K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med.* 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. [PMID: 24881463](#)

106. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs B, Heinz RE, [Elias AD](#), Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple negative breast cancer critically rely on androgen receptor and respond to Enzalutamide in vivo. *Molecular Cancer Therapeutics* 2015; 14: 769-778. [PMID: 25713333](#)
107. Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker GA, Sedjo RL, Wyatt H. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: a Behavioral weight loss intervention in overweight or obese breast cancer survivors. *J Clin Oncol* 2015; 33(28): 3169-76. PMCID: PMC4582146 [PMID: 26282657](#)
108. Barton VN, Gordon MA, Christenson JL, D'Amato NC, Elias A, Richer JK. Androgen receptor biology in triple negative breast cancer: a case for AR+ and quadruple negative disease subtypes. *Horm Cancer* 2015; 6: 206-213. [PMID: 26201402](#)
109. Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple hepatic lesions in a patient with history of DCIS. *Oncology (Williston Park)* 2015; 29: 669-670, 678-679. [PMID: 26384804](#)
110. Demark-Wahnefried W, Colditz GA, Rock CL, Sedjo RL, Liu J, Wolin KY, Krontiras H, Byers T, Pakiz B, Parker BA, Naughton M, Elias A, Wyatt H, Ganz PA. Quality of Life Outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY) Randomized Weight Loss Trial among Breast Cancer Survivors. *Breast Cancer Res Treat* 2015; 154: 329-337. [PMID 26518022](#)
111. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma following failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. *J Clin Oncol* 2015 Sept 14. Epub ahead of print. *J Clin Oncol* 2016; 34: 786-793. [PMID: 26371143](#)
112. Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Elias A. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in Her2-positive metastatic breast cancer. *Breast Cancer Res* 2016; 18: 34. [PMID: 26979312](#).
113. Sedjo RL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Wyatt H, Rock CL. Impact of a behavioral weight loss intervention on comorbidities in overweight or obese breast cancer survivors. *Supportive Care in Cancer* 2016; March 5, 2016 [PMID: 26945570](#).
114. Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer expression in estrogen receptor positive vs. triple-negative breast cancer: an antibody comparison. *Hum Pathol* 2016; 56: 40-51. May 31. pii: S0046-8177(16)30095-8. doi: 10.1016/j.humpath.2016.05.014. [Epub ahead of print] [PMID: 27260947](#)
115. Jasem J, Amini A, Fisher C, Rabinovitch R, Borges V, Elias A, Kabos P. 21-gene recurrence score (RS) assay as the strongest predictor of adjuvant chemotherapy administration for early breast cancer: a comprehensive analysis of use, therapeutic implications, and disparity profile. *J Clin Oncol* 2016; 3/21/16. [PMID: 27001563](#).
116. Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Liu MC, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD,

Northfelt DW, Puzstai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Lyandres J, David SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the phase 2 randomized I-SPY2 trial. *NEJM* 2016; 375: 11-22. [PMID: 27406346](#)

117. Rugo HS, Olopade OI, DeMichele A, Yau C, van't Veer LJ, Buxton MB, Hylton N, Paoloni M, Symmans F, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Liu MC, Issacs C, Albain KS, Chui SY, Moulder SL, Lang J, Viscusi RK, Khan Q, Tripathy D, Elias A, Edmiston K, Nanda R, Euhus D, Northfelt D, Lyandres J, Davis S, Hirst GL, Sanil A, Berry DA, Esserman LJ. First results from the Phase 2, adaptively randomized, I-SPY 2 trial for high risk early stage breast cancer: efficacy of veliparib plus carboplatin when added to standard neoadjuvant chemotherapy. *NEJM* 2016; 375: 23-34. [PMID: 27406347](#)
118. Ryan DW, Merimsky O, Agulnik M, Blay J-Y, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, del Muro XG, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schoffski P. A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma: The PICASSO III study. *J Clin Oncol* 2016, Sep 12. pii: JCO676684. [Epub ahead of print] PMID: 27621408
119. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney M, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma: an open-label phase 1b and randomized phase 2 trial. *Lancet*. 2016; 388: 488-497. Jun 9. pii: S0140-6736(16)30587-6. doi: 10.1016/S0140-6736(16)30587-6. [Epub ahead of print] [PMID: 27291997](#) Erratum in: *Lancet*. 2016 Jul 30;388(10043):464.
120. Overholser L, Shagisultanova E, Rabinovitch R, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast cancer following radiation for Hodgkin lymphoma: clinical scenarios and risk-reducing strategies. *Oncology (Williston Park)* 2016; 30 December: 2-9, PMID: 27987198.
121. Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. *Clin Cancer Res* 2016, Oct 4. pii: clincanres.2851.2015. [Epub ahead of print] PMID: 27702820
122. D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. *Mol Cancer Res*. 2016; 14: 1054-1067. Aug 26. pii: molcanres.0167.2016. [Epub ahead of print] PMID: 27565181 (Figure on cover).
123. Jasem J, Amini A, Fisher CM, Rabinovitch R, Shagisultanova E, Borges VF, Elias A, Kabos P. The 21-gene recurrence score (RS) assay for node-positive early breast cancer and impact of RxPONDER trial on chemotherapy decision-making: have the clinicians already decided? *JNCCN* 2017 Apr;15(4):494-503. PMID: 28404760
124. Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA, Traina TA. A phase 1/1b study of enzalutamide alone and in combination with hormonal therapies in women with advanced breast cancer. *Clin Cancer Res* 2017 Aug 1;23(15):4046-4054. doi: 10.1158/1078-0432.CCR-16-2339. Epub 2017 Mar 9. PMID: 28280092

125. Gordon MA, D'Amato NC, Gu H, Babbs B, Petricoin EF, Wulfkuhle J, Torkko K, Elias A, Richer JK. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. *Molecular Cancer Res* 2017; 16: 1389-1400. PMID: 28468774
126. Barton V, Christenson J, Rogers T, Butterfield C, Kiel T, Babbs B, Spoelstra N, D'Amato N, Elias A, Richer JK. Androgen receptor supports a cancer stem cell-like population in triple-negative breast cancer. *Cancer Research* 2017; 77: 3455-3466. PMID: 28512248
127. Villalobos VM, Hall F, Jimeno A, Gore L, Schowinsky JT, Kern K, Cesari R, Huang B, Blatchford P, Hoffner B, Elias A, Messersmith W. Long term follow up of desmoid fibromatosis treated with PF-02084014, a gamma secretase inhibitor. *Annals Surg Oncol* 2018 Mar;25(3):768-775. doi: 10.1245/s10434-017-6082-1. Epub 2017 Sep 8. PMID: 28887726
128. Wang G, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh L-E, Liu Y-T, Elias A, Simberg D. Isolation of breast cancer CTCs with multitargeted buoyant immunomicrobubbles. *Colloids and Surfaces B: Biointerfaces*. 2018 Jan 1;161:200-209. doi: 10.1016/j.colsurfb.2017.10.060. Epub 2017 Oct 23. PMID: 29080504
129. Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. *Ann Oncol* 2018; 29: 1995-2002. PMID: 30084934
130. Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechtbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. *JCI Insight* 2018; 3: e120594. <https://doi.org/10.1172/jci.insight.120594>. PMID: 30046001
131. Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson D, Capasso A, Sams S, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. The Aurora and angiogenic kinase inhibitor ENMD-2076 has clinical activity in previously treated, locally advanced or metastatic triple-negative breast cancer. *Breast Cancer Res*. 2018 Aug 2;20(1):82. doi: 10.1186/s13058-018-1014-y. PMID: 30071865
132. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med*. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. PMID: 29863451
133. Boughhey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. *NPJ Breast Cancer*. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: *NPJ Breast Cancer*. 2019 Jan 2;5:2

134. Yee D, DeMichele A, Yau C, Isaacs C, Symmans WF, Albain K, Chen Y-Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, LeBeau L, Sahoo S, Vinh T, Yang SE, Adams A, Chien A, Forero-Torres A, Stringer-Reasor E, Wallace A, Pusztai L, Boughey J, Ellis E, Elias A, Lu J, Lang J, Han H, Clark A, Korde L, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Wood W, Park J, Liu M, Oolopade O, Leyland-Jones B, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton N, van't Veer L, Perlmutter J, Melisko M, Wilson A, Peterson G, Asare A, Buxton M, Paoloni M, Clennell J, Hirst G, Singhrao R, Steeg K, Matthews J, Asare S, Sanil A, Berry S, Esserman L, Berry D. Pathologic complete response is a robust predictor of long-term outcome in the adaptively randomized I-SPY2 trial of stage 2/3 breast cancer. *JAMA Oncol* 2020. doi: [10.1001/jamaoncol.2020.2535](https://doi.org/10.1001/jamaoncol.2020.2535)
135. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paolini M, Clennell J, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ. MK-2206 and standard neoadjuvant therapy improves response in patients with Her2-positive and/or HR-negative breast cancers in the I-SPY 2 trial. *J Clin Oncol* 2020; 38: 1059-1069. PMID: 32031889.
136. Nanda R, Liu M, Yau C, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey J, Jaskowiak NT, Elias A, Isaacs C, Kermmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singrao R, Steeg K, Asare A, Matthews JB, Schwab R, Symmans F, van't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo H, Berry D, Esserman LJ. Effect of Pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial. *JAMA Oncology*, 2020; 13: 1-9. PMID: 32053137.
137. Brechbuhl HM, Paul KV, Gillen AE, Kopin EG, Corby K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. *Molecular Carcinogenesis* 2020; 59: 1129-1139. PMID: 32822091
138. Somaiah N, Van Tine BA, Milhem MM, Schuetze S, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Garrett-Mayer E, Armeson K, Hill EG, Wahlquist AE, Kraft AS. A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine with Pazopanib or Gemcitabine with Docetaxel in Advanced Soft Tissue Sarcoma. *Cancer*. 2021 Mar 15;127(6):894-904. doi: 10.1002/cncr.33216. Epub 2020 Nov 24. PMID: 33231866
139. Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, **Elias AD**, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. *J Natl Cancer Inst* 2020 Jul 1;112(7):698-707. PMID: 31693129 doi: 10.1093/jnci/djz215.
140. Chawla SP, Van Tine BA, Pollack S, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. A phase 2 randomized study of CMB305 and atezolizumab vs atezolizumab in + soft tissue sarcomas expressing NY-ESO-1. *J Clin Oncol* 2022 Apr 20;40(12):1291-1300. doi: 10.1200/JCO.20.03452. Epub 2021 Jul 14. PMID: 34260265

141. Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR-1-mutant breast cancer. *Cancer Res* 2021; Feb 1;81(3):732-746. doi: 10.1158/0008-5472.CAN-20-1200. Epub 2020 Nov 12. PMID: 33184106 PMCID: [PMC7854521](#)
142. Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at the University of Colorado Cancer Center. *Cancer Medicine* 2020; 9: 8801-8808. PMID: 33063469
143. I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Puztai L, Boughey JC, Ellis ED, **Elias AD**, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. *JAMA Oncol* 2020 Sep 1;6(9):1355-1362. PMID: 32701140 PMCID: [PMC7378873](#) DOI: [10.1001/jamaoncol.2020.2535](#)
144. Clark AS, Yau C, Wolf DM, Petricoin EF, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Albain KS, Tripathy D, Ellis ED, Forero-Torres A, Yung R, Han HS, Lang JE, Viscusi RK, Haley BB, Kemmer K, Elias AD, Nanda R, Boughey JC, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Robinson P, Buxton M, Clennell JL, Paolini M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare AL, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Yee D, van 't Veer LJ, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial: Efficacy and biomarkers of response. *Nature Communications* 2021, in press.
145. DeMichelle AM, Moulder S, Yau C, Wolf DM, Petricoin EF, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Clark AS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Korde L, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab R, Symmans WF, Yee D, Hylton NM, van't Veer LJ, Berry DA, Esserman LJ. Neoadjuvant T-DM1+pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial: efficacy and biomarkers of response. 2020 submitted.
146. Puztai L, Yau C, Wolf D, Han HS, Du L, Wallace AM, Stringer-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu M, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Campbell M, Asare SM, Wilson A, O'Grady N, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with Olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. *Cancer Cell*. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17. PMID: 34143979

147. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Forero-Torres A, Chien AJ, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann P, Tripathy D, Clark AC, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson C, Majure M, Mukhtar RA, Helsten RL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer: results from the I-SPY2 adaptively randomized platform trial. *NPJ Breast Cancer*. 2021 Oct 5;7(1):131. doi: 10.1038/s41523-021-00337-2.PMID: 34611148
148. Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Kordestani LA, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0. *J Clin Oncol* 2021; May 18: JCO2003613. doi: 10.1200/JCO.20.03613. Online ahead of print. PMID: 34003702.
149. Symmans WF, Yau C, Chen Y-Y, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhaweche-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau L, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu M, Haley BB, Elias AD, Clark AS, Kenmmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asard AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van't Veer LJ, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer. *JAMA Oncol*. 2021 Nov 1;7(11):1654-1663. doi: 10.1001/jamaoncol.2021.3690. PMID: 34529000
150. Christenson JL, O'Neill KI, Williams MM, Spoelstra N, Jones KL, Trahan GD, Reese JM, Van Patten E, Elias AD, Eisner JR, Richer JK. Activity of combined androgen receptor antagonism and cell cycle inhibition in androgen receptor-positive triple-negative breast cancer. *Mol Cancer Ther*. 2021 Jun;20(6):1062-1071. doi: 10.1158/1535-7163.MCT-20-0807. Epub 2021 Mar 15. PMID: 33722849
151. Gounder M, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, del Muro XG, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay J-Y, Chevreau C, Morales CMV, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Groschel S, Hatcher H, Duffaud F, Herraes AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, Von-Mehren M, Van Tine B, Gotze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson M, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in advanced, metastatic dedifferentiated liposarcoma. *J Clin Oncol*. 2022 Apr 8:JCO2101829. doi: 10.1200/JCO.21.01829. Online ahead of print.PMID: 35394800
152. Marczyk M, Mrukwa A, Yau C, Chen Y-Y, Balassanian R, Klein ME, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhaweche-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab JB, Helsten T, Hylton N, Perlmutter J, DeMichele AM, Yee D, Berry DA, Wolf D, van't Veer L, Symmans WF, Esserman L, Pusztai L. Treatment efficacy score – continuous RCB-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer. *Ann Oncol* 2022 Aug;33(8):814-823. doi: 10.1016/j.annonc.2022.04.072. Epub 2022 May 2. PMID: 35513244

153. Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, **Elias A**, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. *Mol Carcinog*. 2022 Mar;61(3):359-371. doi: 10.1002/mc.23377. Epub 2021 Dec 2. PMID: 34856027
154. Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. *J Clin Oncol*. 2022 Sep 20;40(27):3205-3221. doi: 10.1200/JCO.22.01063. Epub 2022 Jun 27. PMID: 35759724
155. Subbiah V, Tabernero J, Longhi A, Boni V, Delord J-P, Awada A, Alexandre J, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Siguiero M, Zeaiter A, Chawla SP. Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing Sarcoma Family of tumors: results of a basket phase II study. *Clin Cancer Res*. 2022 Jul 1;28(13):2762-2770. doi: 10.1158/1078-0432.CCR-22-0696. PMID: 35486638
156. Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, **Elias AD**, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. *Eur J Cancer*. 2022 Oct 7;176:155-163. doi: 10.1016/j.ejca.2022.09.003. Online ahead of print. PMID: 36215947
157. Li Z, Spoelstra NS, Sikora MJ, Sams SB, **Elias A**, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. *NPJ Breast Cancer*. 2022 May 10;8(1):62. doi: 10.1038/s41523-022-00426-w. PMID: 35538119
158. Albain KS, Yau C, Petricoin EF, Wolf DM, Leyland-Jones B, Lang JE, Campbell M, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Chui SY, Godellas C, Boughey JC, Isaacs C, Tripathy D, Edmiston KK, Yung FL, Viscusi RK, Northfelt DW, Gallagher RI, Wulfschlegel JD, Brown-Swigart L, Krings G, Chen YY, Potter D, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY 2 trial – efficacy and predictive biomarker discovery.
159. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Yu L, Westin S, Xing Y, Dumbrova EI, Karp D, Piha-Paul S, Tsimberidou A, Ahnert JR, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. A multicenter phase 2 trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring *CCNE1* amplification. *Clin Cancer Res*, submitted.
160. Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfschlegel JD, Buxton M, Clennell JL, Sunil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Safety and efficacy of neoadjuvant HSP90 inhibitor ganetespib in stage II/III breast cancer in the adaptively randomized I-SPY2 trial. Submitted 2021.
161. Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL,

van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin EF III, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. Submitted *Npj Breast Cancer* 2022.

162. Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Borges VF, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: a SEER-Medicare study. Submitted *Eur J Cancer*, 2022.
163. Sullivan K, Ludwig M, Galbraith MD, Eduthan N, Hill A, Clay MR, Moreno Tellez C, Wilky BA, Elias A, Espinosa JM. Proteasome inhibition sensitizes liposarcoma to nutlin-3-induced apoptosis via the ATF4/CHOP axis. Submitted, *Cancer Research*, 2022.

Proceedings of Meetings:

1. Antman K, Eder P, Henner WD, Teicher B, Shea T, Elias A, Schryber S, Siegel B, Schnipper S, Frei E III. High dose therapy and autologous bone marrow transplantation in breast cancer: the Beth Israel-Dana Farber Cancer Institute experience. In: Dicke K, Spitzer G, eds. Autologous bone marrow transplantation: Proceedings of the 3rd International Symposium. Houston, Texas: University of Texas, MD Anderson Hospital and Tumor Institute, 1987:481-4.
2. Elias AD, Cohen BF, Bernal SD. Monoclonal antibodies recognizing cytoskeletal proteins of small cell lung carcinoma. Lung Cancer 1988; 4:92-5.
3. Bernal SD, Cualing HM, Elias AD. Stability and shedding of small cell carcinoma membrane antigens: applications to detection of antigens in marrow and serum. Lung Cancer 1988; 4:79-80.
4. Bernal SD, Cualing HM, Elias AD, Schwartz G, McCluer RM. Classification of small cell carcinoma antigens by their association with subcellular components. Lung Cancer 1988; 4:99-102.
5. Antman K, Eder JP, Elias A, Shea TC, Teicher BA, Henner WD, Schryber S, Finberg R, Critchlow J, Begg C, Hunt M, Anderson K, Schnipper L, Frei E III. STAMP studies of high dose chemotherapy in breast cancer. In: Dicke K, Spitzer G, eds. Autologous bone marrow transplantation: Proceedings of the 4th International Symposium. Houston, Texas: University of Texas, MD Anderson Hospital and Tumor Institute, 1989:377-83.
6. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E III, Henner WD. A phase I trial of high dose carboplatin. In: Dicke KA, Spitzer G, Jagannath S, eds. Autologous bone marrow transplantation. Houston, Texas: U. of Texas, M.D. Anderson Hospital & Tumor Institute, 1989:519-24.
7. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. The in vivo effect of granulocyte-macrophage colony stimulating factor on circulating progenitor cells in man. Autologous bone marrow transplantation: Proceedings of the 4th International Symposium. In: Dicke K, Spitzer G, eds. Houston, Texas: University of Texas, MD Anderson Hospital and Tumor Institute, 1989:677-83.
8. Elias AD, Pap SA, Bernal SD. Purging of small cell lung cancer - contaminated bone marrow by monoclonal antibodies and magnetic beads.in bone marrow purging and processing. In: Gee AP, Gross S, eds. Clinical and biological research. Alan R. Liss Inc., 1990: 263-75. [PMID: 2155434](#)
9. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA, Schnipper LE, Frei E III. High-dose thiotepa alone and with bone marrow support. Sem Oncol 1990;17: Suppl 3: 33-8. [PMID: 2106166](#)
10. Elias AD, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Science and Medicine Symposium "Current developments and future directions with ifosfamide," Sem Oncol 1990;17: Suppl 4: 41-9. [PMID: 2110385](#)
11. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard and high-dose schedules. Sem Oncol 1990;17: Suppl 4: 68-73. [PMID: 2110386](#)
12. Antman KH, Cabanillas F, Elias A, Johnson DH, Loehrer PJ, Pratt CB, Shepherd FA, Sutton GP, Thigpen T, Van Oosterom AT. Current developments and future directions with ifosfamide: a panel discussion. Sem Oncol 1990;17: Suppl 4: 74-9.
13. Wheeler C, Eder JP, Elias A, Ayash L, Schryber SM, Shea TC, Begg C, Teicher B, Critchlow J, Burke J, Schnipper LE, Frei E III, Antman K. High dose combination alkylating agent therapy. In: Rubinstein E,

Adam D, eds. Proceedings of the 13th International Congress of Chemotherapy, Recent Advances in Chemotherapy. Jerusalem: Lewin Epstein Ltd, 1990.

14. Antman K, Ryan L, Borden E, Wood WC, Lerner HL, Corson JM, Carey R, Suit H, Balcerak S, Elias A, Baker L. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature. In: Salmon S, ed. Adjuvant therapy of cancer VI. Orlando: Grune and Stratton, 1990: 529-43.
15. Antman K, Eder JP, Elias A, Ayash L, Wheeler C, Hunt M, Schwartz G, Tepler I, Mazanet R, Pap S, Critchlow J, Shea TC, Teicher BA, Gonin R, Schnipper LE, Frei E III. Dose intensive regimens in breast cancer: the Dana-Farber Cancer Institute and Beth Israel experience. In: Dicke KA, Armitage J, Dicke-Evinger MJ, eds. Autologous bone marrow transplantation, Proceedings of the Fifth International Symposium, 1991: 305-13.
16. Elias A, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Pelaez J, Gonin R, Schnipper L, Griffin J, Frei E, Antman K. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: Two protocols. Breast Cancer Treat Res 1991; 20:S25-9. [PMID: 1687204](#)
17. Elias A, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Gonin R, Critchlow J, Schnipper L, Griffin J, Frei E, Antman K. Peripheral blood progenitor cells (PBPC): two protocols using GM-CSF potentiated progenitor cell collection. In: Dicke KA, Armitage J, Dicke-Evinger MJ, eds. Autologous bone marrow transplantation, Proceedings of the Fifth International Symposium, 1991: 875-80.
18. Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Hunt M, Critchlow J, Schnipper L, Frei E III, Antman KH. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. J Cancer Res Clin Oncol 1991; 117 (suppl IV): S208-13. [PMID: 1795009](#)
19. Elias A, Mazanet R, Anderson K, Ayash L, Wheeler C, Schwartz G, Tepler I, Hunt M, Critchlow J, Schnipper L, Frei E III, Antman K. GM-CSF mobilized peripheral blood stem cell autografts: the DFCI/BIH experience. Int J Cell Cloning 1992; 10 (suppl 1): 149-51.
20. Elias AD, Ayash L, Frei E III, Skarin AT, Wheeler C, Schwartz G, Mazanet R, Tepler I, McCauley M, Schnipper L, Antman KH. Intensive combined modality therapy for responding small cell lung cancer. In: Dicke KA, Armitage J, Dicke-Evinger MJ, eds. Autologous bone marrow transplantation, Proceedings of the Sixth International Symposium, Arlington, TX, 1992, pp 161-173.
21. Elias AD, Ayash L, Frei E III, Skarin AT, Wheeler C, Hunt M, Schwartz G, Mazanet R, Tepler I, Eder JP, McCauley M, Herman T, Schnipper L, Antman KH. High dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small cell lung cancer. Chest 1993; 103 (suppl): 433S-435S. [PMID: 8096454](#)
22. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. High-dose ifosfamide, carboplatin, etoposide with autologous hematopoietic stem cell support - Safety and future directions. Semin Oncol 1994; 21(5 Suppl 12): 83-85. [PMID: 7992072](#)
23. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ, Skarin AT. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Semin Oncol 1995; 22 (4 Suppl 9): 70S-74S. [PMID: 7544029](#)
24. Elias AD. Dose-Intensive Therapy for Small-Cell Lung Cancer. Chest 1995; 107: 261S-266S.

25. Richardson P, Elias A. Dose intensive therapy in small cell lung cancer. In: Dicke KA, Armitage J, Dicke-Evinger MJ, eds. Autologous bone marrow transplantation, Proceedings of the Eighth International Symposium. Carden Jennings, Charlottesville, VA, 1997; pp. 361-374.
26. Elias A. Dose-intensive therapy in lung cancer. *Cancer Chemother Pharmacol* 1997; 40 (suppl): S64-S69. [PMID: 9272137](#)
27. Elias A. Dose intensive therapy in small cell lung cancer. Proceedings of the International Symposium on Thoracic Malignancies, Pittsburgh, PA. *Chest*, in press 1998.
28. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. *Chest* 1999; 116 (6 Suppl): 531S-538S. [PMID: 10619526](#)
29. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. *JNCCN* 2018; 16: 605-610. [PMID: 29784737](#)
30. Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Mamounas ET, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). *Breast Cancer Res Treat* 2018; <https://doi.org/10.1007/s10549-018-4662-9>. PMID: 29352368
31. Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Mamounas ET, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer: a roundtable discussion. *Breast Cancer Res Treat* 2018; <https://doi.org/10.1007/s10549-018-4783-1>. PMID: 29725889

Reviews, Chapters, and Editorials

1. Antman K, Eder JP, Schryber S, Anderson J, Peters WP, Henner WD, Finberg R, Elias AD, Shea T, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Come S, Bast R, Schnipper L, Frei E III. A preparative regimen of combination alkylating agents with autologous bone marrow transplant (ABMT) for solid tumors: phase II. In: Gale R, Champlin R, eds. Progress in bone marrow transplantation. New York: Alan R. Liss Inc., 1987:855-64.
2. Antman K, Peters WP, Eder JP, Schryber S, Andersen J, Henner WD, Elias A, Shea T, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Come S, Gorgone B, Bast R, Schnipper L, Frei E III: Treatment of 58 patients on a phase I and II protocol using high dose combination alkylating agent preparative regimen with autologous bone marrow support. In: Fortner JG, Rhoads JE, eds. Accomplishments in Cancer Research. New York: JB Lippincott Company, 1987:152-65.
3. Antman K, Henner D, Teicher B, Eder P, Shea T, Elias A, Schryber S, Siegel B, Schnipper L, Frei E. High dose combination chemotherapy with thiotepa and autologous bone marrow transplantation. In: Herzig GP ed. High-dose thioTEPA and autologous marrow transplantation: Proceedings of a Symposium, advances in cancer chemotherapy. New York, NY: John Wiley & Sons, 1987:35-7.
4. Bernal S, Speak J, Stahel R, Elias A, Mabry M, Cualing H. Small cell carcinoma antigens. In: Rosen S, Mulshine J, Cuttita F, Abrams P, eds. Biology in lung cancer: diagnosis and treatment. New York: Marcel Dekker Inc., 1988:213-35.
5. Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: a critical appraisal. Seminars in Surgical Oncology. 1988; 4:59-65. [PMID: 3281213](#)
6. Antman KH, Elias AD. Chemotherapy of advanced soft tissue sarcomas. Seminars in Surgical Oncology. 1988; 4:53-8. [PMID: 3281212](#)
7. Bernal SD, Elias AD. Editorial: Early lung cancer detection: monoclonal antibody staining of exfoliated cells in sputum. J Clin Oncol. 1988; 6:1676-8. [PMID: 2460593](#)
8. Elias AD. Review and Commentary on Loehrer PJ, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989; 7:1655-9. Oncology Journal Forum 1990;1:#5; LP Communications, New York. [PMID: 2681554](#)
9. Elias AD, Antman KH. Soft tissue and bone sarcoma. In: Wittes RE, ed. Manual of Oncologic Therapeutics 1989/1990. JB Lippincott Co., chapter 34, 1989:292-303.
10. Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: an approach in search of an effective regimen. Sem Oncol. 1989; 16:1-7.
11. Elias AD, Antman KH. Treatment of advanced sarcomas. Advances in Oncology 1989;5:11-8.
12. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Sem Oncol 1990; 17: Suppl 2: 1-9.
13. Elias AD. Advances in the diagnosis and management of sarcomas. Current Opinion in Oncology 1990;2:474-80. [PMID: 2092763](#)
14. Elias AD, Antman KH. Soft-tissue and bone sarcomas. In: Manual of Oncologic Therapeutics 1991/1992, 2nd Edition; Philadelphia: J.B. Lippincott Company, 1991: 212-20.

15. Elias AD. Advances in the diagnosis and management of sarcomas. *Current Opinion in Oncology* 1991; 3: 671-6. [PMID: 1932226](#)
16. Elias AD. Future directions in the management of soft tissue sarcomas. *Hematologic Oncology* 1992; 10: 53-60. [PMID: 1563704](#)
17. Elias AD. Advances in the diagnosis and management of sarcomas 1991. *Current Opinion in Oncology* 1992; 4: 681-8. [PMID: 1511024](#)
18. Elias AD. The clinical management of soft tissue sarcomas. *Semin Oncol* 1992;19:19-25. [PMID: 1411616](#)
19. Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non-small cell lung carcinoma: a critical review of the literature and strategies for future research. *J Clin Oncol* 1992; 10: 829-838. [PMID: 1314892](#)
20. Antman KH, Elias A, Ryan L. Six Dana-Farber Cancer Institute studies in patients with sarcoma. *Chinese Journal of Cancer* 1992; 11:187-191.
21. Elias AD. Chemotherapy and radiotherapy for regionally advanced non-small cell lung cancer. *Chest* 1993; 103 (suppl): 362S-366S. [PMID: 8384971](#)
22. Elias AD. Chemotherapy for soft-tissue sarcomas. *Clinical Orthopaedics & Related Research* 1993; 289: 94-105. [PMID: 8472436](#)
23. Demetri GD, Elias AD. Current understanding of PBPCs and hematopoietic growth factors. *Advances in Oncology* 1994; 10: 11-19.
24. Demetri GD, Elias AD. Clinical applications of peripheral blood progenitor cells. *Advances in Oncology* 1994; 11: 12-20.
25. Elias AD. Salvage therapy for soft tissue sarcomas. *Seminars in Oncology* 1994; 21(Suppl 7): 76-81. [PMID: 8091245](#)
26. Antman KH, A Elias, HA Fine. Dose-intensive therapy with autologous bone marrow transplantation in solid tumors. In *Bone Marrow Transplantation*, S Forman, K Blume, ED Thomas, Blackwell Scientific Press, Boston, 1994 pp 767-88.
27. Elias A, Cohen BF. Dose intensive therapy in lung cancer. In: *High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells*, 2nd Edition. Eds: Armitage JO, Antman KH. Williams and Wilkins, Baltimore, 1995. Chapter 45, pp 824-846.
28. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. In: *Hematology/Oncology Clinics of North America Vol 9, #4 (August): Sarcomas Part II*. Guest Eds: Patel SR, Benjamin RS. WB Saunders Co., Philadelphia, PA, 1995, pp. 765-785. [PMID: 7490240](#)
29. Suit HD, Mankin HJ, Corson JM, Elias A, Singer S, Garcea MD. Sarcoma of bone and soft tissue. *ACS Manual on Oncology (RJ Osteen, ed)*. 1995.
30. Elias AD, Antman KH. Soft-tissue and bone sarcomas. In: *Manual of Oncologic Therapeutics*, 3rd Edition; Philadelphia: J.B. Lippincott Company, 1995: 226-236.
32. Lerner A, Elias A. "Sarcomas of Soft Tissue and Bone". In *Current Practice of Medicine (ed Bone, RC), Oncology volume (ed, Ettinger D)*. Philadelphia, PA, 1996.

33. Lazarus HM, Elias AD. Editorial: Autologous bone marrow and peripheral blood progenitor cell transplants in small cell lung cancer. *Bone Marrow Transplantation* 1996; 17: 1-3. [PMID: 8673040](#)
34. Salgia R, Skarin AT, Elias AD. Management of limited stage small cell lung cancer. *Advances in Oncology* 1996; 12: 8-15.
35. Elias AD. Preface. In *Multidisciplinary Care of Lung Cancer Patients, Part I*. In *Hematology/Oncology Clinics of North America* (ed Cullen H), April 1997; volume 11, Number 2, WB Saunders Company, Philadelphia, PA, pp xiii-xv.
36. Elias AD. Future Directions in Lung Cancer Research and Therapeutics. In *Multidisciplinary Care of Lung Cancer Patients, Part II*. In *Hematology/Oncology Clinics of North America* (ed Cullen H), June 1997; volume 11, Number 3, WB Saunders Company, Philadelphia, PA pp 519-527. [PMID: 9209908](#)
37. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. *Chest* 1997; 112 (4 Suppl): 251S-258S. [PMID: 9337299](#)
38. Elias A. Dose-intensive therapy in small cell lung cancer. *Chest* 1998; 113 (suppl 1): 101S-106S. [PMID: 9438698](#)
39. Elias A. High dose therapy for adult soft tissue sarcomas: dose response and survival. *Semin Oncol* 1998; 25 (suppl 4): 19-23. [PMID: 9578058](#)
40. Elias AD. Chapter 88: Hematopoietic stem cell transplantation for small cell lung cancer. In: Forman S, Blume K (eds). Blackwell Science Inc, Malden, MA, 1999, pp 1043-1048.
41. Elias AD. Cyclophosphamide. In *Oncology Therapeutics: A Quick Reference Guide*. eds, Ratain MJ, Tempero M. WB Saunders. 2000.
42. Elias AD. Ifosfamide. In *Oncology Therapeutics: A Quick Reference Guide*. eds, Ratain MJ, Tempero M. WB Saunders. 2000.
43. Elias AD. High-dose therapy for small-cell lung cancer with stem cell support. In *Multimodality Treatment of Lung Cancer*. Ed. Arthur T Skarin. Volume 140 *Lung Biology in Health and Disease*. Exec Ed. Claude Lenfant. Marcel Dekker, NY, 2000, pp. 405-421.
44. Elias AD. High dose therapy with stem cell support for SCLC. In *Lung Cancer: Controversies and Dilemmas*. Eds: Movsas/Langer/Goldberg. Marcel Dekker, Inc. New York, NY. 2000.
45. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JJ, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EJ. Status of high-dose chemotherapy for breast cancer: a review. *Biol Blood Marrow Transplant* 2000; 6: 476-495. [PMID: 11063377](#)
46. Elias AD. High Dose Chemotherapy with stem cell rescue for breast cancer: current status and future directions. *Breast Disease* 2001; 14: 51-68. [PMID: 15687636](#)
47. Eisenberg RE, Finlayson C, Rabinovitch R, Seligman P, Robinson W, Singh M, Lewin J, Elias AD. Breast Cancer: Case Presentation (Crawford E, ed). A 42-year-old woman with breast cancer. *Oncology (Williston Park)* 2003; 17: 614-620.
48. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. *Breast CA Res* 2004; 6: 93-101. [PMID: 14979914](#)

49. Elias A, ed. Breast Cancer I. In: Johnson DH, ed. 2004 Annual Meeting Summaries. Alexandria, VA: ASCO; 204: pages TK.
50. Elias A, ed. Breast Cancer II. In: Johnson DH, ed. 2004 Annual Meeting Summaries. Alexandria, VA: ASCO; 204: pages TK.
51. Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. *Oncology (Williston Park)* 2005; 19: 278-287 passim. [PMID: 15828548](#)
52. Menter A, Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Finlayson C, Hardesty L, Elias A. University of Colorado Mult-disciplinary tumor board: A woman with primary breast cancer and a solitary sternal metastasis. *Oncology (Williston Park)* 2006; 20: 1068-71, 1075, 1079-80. [PMID: 16986350](#)
53. Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. University of Colorado Mult-disciplinary tumor board: A Young Woman with a Small Estrogen Receptor-Positive Breast Cancer, a Micrometastatic Axillary Lymph Node, and an Intermediate Oncotype DX Recurrence Score. *Oncology (Williston Park)* 2007; 21: 1212-1217. [PMID: 17926799](#)
54. Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. A perimenopausal woman with a small ER/Her2-positive node negative breast cancer. *Oncology (Williston Park)* 2008; 22: 1270-1276. [PMID: 18980024](#)
55. Diamond JR, Finlayson CA, Thienalt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early stage BRCA-2 associated breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. *Oncology (Williston Park)* 2009; 23 (August 17). [PMID: 19777765](#)
56. Elias AD, Kabos P, Bowles DW. Adjuvant Treatment of Breast Cancer: Chapter 20. In: Finlayson, editor. Elsevier, 2010.
57. Elias AD. The Use of Molecular Profiles in the Management of Breast Cancer. In: Finlayson, editor. Elsevier, 2010.
58. Elias AD. Triple negative breast cancer: a short review. *Am J Clin Oncol* 2009 Dec 17 epub. *Am J Clin Oncol* 2010 Dec; 33: 637-645. [PMID: 20023571](#)
59. Gadjos C, Elias A. Trabectedin: safety and efficacy in the treatment of advanced sarcoma. *Clin Med Insights Oncol* 2011; 5: 35-43. [PMID: 21499557](#)
60. Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein CE, Elias A, Finlayson C, Borges VF. Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. *Oncology (Williston Park)* 2011; 25: 351-356. [PMID: 21618957](#)
61. Borges VF, Elias AD. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest. *J Clin Oncol* 2011; Jul 18, epub. [PMID: 21768457](#)
62. Kessler ER, Elias AD. Resistance to HER2-targeted therapy in HER2+ breast cancer. *Clinical Medicine Reviews in Women's Health, Libertas Academica*, 2012; 4: 1-12.
63. Fini, MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. *Clinical and Translational Medicine* 2012; 1: 16. [PMID: 23369448](#)

64. Elias AD. Management of Small T1ab N0 Breast Cancers. Proc ASCO Educational Book 2012.
65. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytton N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Puzstai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive Trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012; 30: 4584-4586. [PMID: 23169510](#)
66. Diamond JR, Elias AD. The Development of Targeted Therapies for Triple-Negative Breast Cancer: Can We Harness Tumor Heterogeneity to Improve Patient Outcomes. Breast Cancer Management. Breast Cancer Management 2013; 2: 175-178.
67. Elias AD, Sams S. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR. Oncology (Williston Park). 2013 Jun;27(6):526-7, 566. [PMID: 23909065](#)
68. Lopez JP, Gajdos C, **Elias A**. Trabectedin: novel insights in the treatment of advanced sarcoma. Curr Oncol Rep. 2014 Jun;16(6):387. doi: 10.1007/s11912-014-0387-z. [PMID: 24756367](#)
69. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr;12(4):542-90. [PMID: 24717572](#)
70. Fisher C, Diamond JR, Kounalakis N, Kabos P, Mayordomo J, Rabinovitch R, Murphy C, Finlayson C, Borges VF, Elias AD. The Integration of Locoregional with Systemic Adjuvant Therapy for Early Stage Breast Cancer: the Shifting Sands of Decision Making. Breast Cancer Management 2014; 3: 1-8, in press.
71. Kabos P, Elias AD. Breast Diseases: A Year Book Quarterly comment on sHer2 in Gepar Quinto. Breast Diseases 2014.
72. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res 2015; 21: 2911-2915. PMID: 25712686
73. Fisher CM, Klein C, Kondapalli L, Elias A, Borges V. Management of young breast cancer patients with de novo genetic mutations. Clinical Quandaries. Oncology 2014; Oct; 28(10). Pii: 201947. [PMID: 25323616](#)
74. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo

- G, Telli M, Ward JH, Shead DA, Kumar R. **Breast** Cancer Version 2.2015. *J Natl Compr Canc Netw*. 2015 Apr;13(4):448-75. PMID: 25870381
75. Yadav BS, Sharma SC, Robin TP, Sams S, Elias AD, Kaklamani V, Marcom PK, Schaefer S, Morris GJ. Synchronous primary carcinoma of breast and ovary versus ovarian metastases. *Semin Oncol* 2015 Apr;42(2):e13-24. PMID 25843740
76. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. **Breast** Cancer Version 2.2015. *J Natl Compr Canc Netw*. 2015 Dec;13(12): 1475-1485. PMID: 26656517
77. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016 Mar;14(3):324-54. PMID: 26957618
78. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer, Version 1.2016. *J Natl Compr Canc Netw*. 2015 Dec;13(12):1475-85. PMID: 26656517.
79. Gordon JA, Harrison B, Richer JK, Elias A. Anti-androgen therapy in breast cancer. *AJHO* 2016.
80. Elias AD, Wang W-S, Hardesty L. A 55-Year-Old woman with new triple-negative breast mass, less than 2 cm on both mammogram and ultrasound: Clinical Quandaries. *Oncology* 2016; 30: 258-262. PMID 26984221.
81. Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple negative breast cancer. *Ther Adv Med Oncol* 2016; 8: 305-308. PMID: 27482289.
82. Villalobos VM, Hoffner B, Elias AD. We CAN study ultra-rare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas. Editorial for "Phase II Study of Dasatinib in Patients with Alveolar Soft Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid Sarcoma or Solitary Fibrous Tumor" (CNCR-16-1729). *Cancer* 2016, Oct 3. doi: 10.1002/cncr.30377. [Epub ahead of print] PMID: 27696384
83. Shagisultanova E, Mayordomo J, Elias AD. Triple negative breast cancer in the elderly. *The Breast Journal* 2017; Nov;23(6):627-629. doi: 10.1111/tbj.12814. No abstract available. PMID: 29112794
84. Elias AD, Kabos P. Triple negative breast cancer: a review. *Internal Medicine Review* 3/2017, in press.
85. Elias AD. How I Manage: Adjuvant therapy in Her2-positive breast cancer. *Clinical Oncology News* 2017, July, p 19-23.
86. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,

Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. *J Natl Compr Canc Netw*. 2017 Apr;15(4):433-451. PMID: 28404755

87. Christenson JL, Trepel JB, Eli HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a different dependency: how to identify and target androgen receptor-positive versus quadruple-negative breast cancer. *Horm cancer* 2018 Jan 16. doi: 10.1007/s12672-017-0314-5. [Epub ahead of print] Review. PMID: 29340907
88. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2018 Mar;16(3):310-320. doi: 10.6004/jncn.2018.0012. PMID: 29523670
89. Hoffner B, Elias AD, Villalobos VM. Targeted therapies in the treatment of sarcomas. *Targeted Oncology* 2018; 13: 557-565. <https://doi.org/10.1007/s11523-018-0583-0> Published online 8/24/18.
90. Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. *J Natl Compr Canc Netw*. 2019 Feb;17(2):118-126. doi: 10.6004/jncn.2019.0009. PMID: 30787125
91. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. *Breast Cancer Res Treat*. 2019 Jan;173(1):37-48. doi: 10.1007/s10549-018-4921-9. Epub 2018 Sep 28. Review. PMID: 30267249
92. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2020 Apr;18(4):452-478. doi: 10.6004/jncn.2020.0016. PMID: 32259783
93. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, **Elias AD**, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. *J Natl Compr Canc Netw*. 2021 May 1;19(5):484-493. doi: 10.6004/jncn.2021.0023. PMID: 34030128
94. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, **Elias AD**, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. *J Natl Compr Canc Netw*. 2022 Jun;20(6):691-722. doi: 10.6004/jncn.2022.0030. PMID: 35714673

Books and Monographs

1. Antman K, Elias A. Clinical considerations in using Ifex (sterile ifosfamide) for the management of sarcomas. Bristol-Myers Company monograph, 1989.
2. Elias A. Autologous bone marrow transplantation. In: Future opportunities: the experts speak - chemical, materials, medical/health care. Venture Capital Forum 1989.
3. Eder JP, Shea TC, Henner WD, Elias AD, Teicher BA, Weissman L, Wheeler C, Ayash L, Schryber SM, Deary J, Schnipper LE, Frei E III, Antman KH. High dose combination alkylating agent therapy with carboplatin and autologous bone marrow transplantation (ABMT) in solid tumors. In: Bund PA, Cantetta R, Ozols RF, Rozenzweig M, eds. Carboplatin JM-8: current perspectives and future directions. Philadelphia, PA: WB Saunders Co., 1990:353-62.
4. Antman KH, Eder JP, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Critchlow J, Begg C, Schnipper LE, Frei E III. High dose chemotherapy in breast cancer. In: Ariel I, Ragaz J, eds. High risk breast cancer II. Springer-Verlag Berlin Heidelberg, 1991: 447-70.
5. Elias A (Guest Editor). Multidisciplinary Care of Lung Cancer Patients, Part I. In Hematology/Oncology Clinics of North America (ed Cullen H), April 1997; volume 11, Number 2, WB Saunders Company, Philadelphia, PA.
6. Elias A (Guest Editor). Multidisciplinary Care of Lung Cancer Patients, Part II. In Hematology/Oncology Clinics of North America (ed Cullen H), June 1997; volume 11, Number 3, WB Saunders Company, Philadelphia, PA.

Clinical Communications, Letters

1. Elias AD, Elias ER. (Letter) Matching of couples in the NRMP. New Engl J Med. 1980; 302:1425-6. [PMID: 7374708](#)
2. Antman K, Elias A, Cannistra SA, Socinski MA, Schnipper LE, Frei E III, Griffin JD. (Letter) Recombinant human GM-CSF in myelosuppression of chemotherapy. New Engl J Med. 1989; 320:253-4.
3. Antman KH, Elias AD, Cannistra SA, Frei E III, Schnipper LE, Griffin JD. (Letter) Recombinant human GM-CSF in myelosuppression of chemotherapy (Continued). New Engl J Med. 1989; 320:939-40.
4. Elias AD. Book Review: Treatment of soft tissue sarcomas. J Natl Cancer Inst. 1989; 81:1329-30.
5. Antman KH, Elias A, Colvin MO. Mesna, continuous or bolus infusion? (Letter). J Clin Oncol 1989; 7: 817-818.
6. Antman K, Ayash L, Elias A, Wheeler C, Frei E III. High dose chemotherapy for the treatment of advanced breast cancer (letter). J Clin Oncol 1992; 10: 1025-1026.
7. Elias A. Tumor Board (Sarcoma management). Oncology Times 1993;15 (July): 11.
8. Elias AD. (Letter) Bone marrow transplantation. New Engl J Med. 1994; 331:617.
9. Demetri G, Grecula J, Mittal B, Raschko J, Robertson J, Fossella F, Gershenson D, Elias A. NCCN Small-Cell Lung Cancer Practice Guidelines. Oncology 1996;10 (11 Suppl): 179-194. [PMID: 8953602](#)

10. Elias A. Dose intensification in SCLC valuable, but new approach to radiotherapy is needed – editorial comment. Abstracts in Hematology & Oncology, Medscape, Darien, CT. 2000 Fall, pp. 16-17.

Nonprint Materials:

1. Video: One Step at a Time: An orientation program for patients and their families about Bone Marrow Transplantation. Dana Farber Cancer Institute, 1993.
2. Video: Stem Cell Transplantation: A Video Guide for Patients and Families. Dana Farber/Partners Cancer Care, 2000.
3. Kelly K, Elias A. Treatment of small cell carcinoma of the lung. A. Elias only author 1998-2001. Since 2002, with Dr. Karen Kelly as first author. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 1998-2010.
4. Elias A. Pathobiology and staging of small cell carcinoma of the lung. UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2001-2014.
5. Elias A, Baldini E. Patient Information: Treatment of small cell lung cancer (Beyond the Basics). UPTODATE in Pulmonary and Critical Care Medicine. Ed Weinberger S et al. American Lung Association. 2004-2016.
6. NCCN Breast Cancer guidelines version 2014.1
7. NCCN Breast Cancer guidelines version 2015.1
8. NCCN Breast Cancer guidelines version 2016.1
9. NCCN Breast Cancer guidelines version 2017.1
10. NCCN Breast Cancer guidelines version 2018.1
11. NCCN Breast Cancer guidelines version 2019.1

Patents:

1. Duncan M, Weitzel L, Byers T, Elias A.
Title: *Biomarkers for Diagnosis of Breast Cancer* 2011
2. Richer J, Elias A, Gertz J, Jacobsen B.
Title: *Unique vulnerabilities estrogen receptor mutations predict sensitivity to agents that target androgen receptors.*

Abstracts

1. Antman K, Eder JP, Schryber S, Andersen J, Peters WP, Henner WD, Elias A, Shea T, Finberg R, Kruskall MS, Anderson K, Gorgone B, Schnipper L, Frei III E. A high dose combination alkylating agent preparative regimen with autologous bone marrow transplant (ABMT): the DFCI/BIH experience. *Blood* 66; 1985:248A, Supplement 1.
2. Eder JP, Antman KH, Elias A. High dose combined alkylating agents (HDCA) with autologous bone marrow transplantation (ABMT) in metastatic breast cancer. 8th Annual Breast Cancer Symposium, Breast Cancer Research and Treatment, 1985.
3. Bernal SD, Stahel RA, Elias A, Weinberg K, Speak J. Membranes and cytoskeletal composition of lung cancer. 4th World Congress on Lung Cancer, Toronto, Canada. *Lung Cancer* 1985; 4:131.
4. Antman K, Eder JP, Schryber S, Andersen J, Peters WP, Henner WD, Finberg R, Elias AD, Shea T, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Come S, Bast R, Schnipper L, Frei E III. A preparative regimen of combination alkylating agents with autologous bone marrow transplant (ABMT) for solid tumors: phase II. 1986 UCLA Symposia: Recent advances in bone marrow transplantation, Los Angeles, CA. *J Cell Biochem.* 1986; (Suppl 10D):254.
5. Antman K, Eder JP, Schryber S, Andersen J, Peters WP, Henner WD, Elias AD, Shea T, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Come S, Bast R, Schnipper L, Frei

E III. 58 solid tumor patients treated with a high dose combination alkylating agent preparative regimen with autologous bone marrow support: The DFCI/BIH experience. Proc. ASCO 1986; 5:40 (C-154).

6. Klegar K, Ryan L, Elias AD, Schwenn M, Antman K. Ifosfamide (IFF) for advanced previously treated sarcomas: phase II. Proc ASCO 1986; 5:132 (C-514).
7. Elias AD, Antman K, Ryan L. Doxorubicin (DOX), Ifosfamide (IFF), and DTIC with Mesna uroprotection for advanced untreated sarcoma. Proc ASCO 1986; 5:134 (C-522).
8. Bosserman L, Tanaka I, Elias AD, Skarin A, Cualing H, Dreyfuss A, Bernal SD. Serum radioimmunoassay detects SM1 antigen in lung cancer patients: potential serum marker for small cell lung cancer (SCLC). Proc ASCO 1986; 5:C-683.
9. Elias AD, Cohen BF, Weinberg K, Bernal SD. The cytokeratins of small cell lung cancer (SCLC): evidence for epithelial origin. Proc AACR 1986; 27:C-169.
10. Elias AD, Ryan L, Aisner J, Antman KH. Doxorubicin, Ifosfamide, and DTIC (AID) for advanced untreated sarcomas. Proc ASCO 1987; 6:134 (C-524).
11. Eder J, Antman K, Elias A, Shea T, Siegel R, Schryber S, Mick R, Schnipper L, Frei E III. High dose combination chemotherapy with continuous infusion (CI) cyclophosphamide (CPA) and thiotepa (TSPA) with autologous bone marrow reinfusion (ABMT). Proc ASCO 1987; 6:154.
12. Henner WD, Shea TC, Furlong EA, Flaherty M, Elias A, Eder JP, Antman K. Pharmacokinetics of high dose continuous infusion thiotepa. Proc ASCO 1987; 6:47.
13. Antman K, Griffin J, Elias A, Socinski M, Whitley M, Ryan L, Cannistra S, Oette D, Frei E, Schnipper L. Use of rGM-CSF to ameliorate chemotherapy induced myelosuppression in sarcoma patients. Blood. 1987; 70 (Suppl 1):129a (373).
14. Eder JP, Antman K, Elias A, Shea T, Henner D, Teicher BA, Schryber S, Holden SA, Mick RM, Schnipper L, Frei E III. High dose combination alkylating agents (HDCAA) and autologous bone marrow support (ABMS) for metastatic breast cancer (BC). 10th annual San Antonio Breast Cancer Symposium, Breast Cancer Research and Treatment, 1987; 10:89 (19).
15. Elias AD, Antman KH, Eder JP, Shea T, Schryber S, Bernal SD, Skarin, AT, Schnipper L, Frei E III. Consolidation of responding small cell lung cancer (SCLC) with high dose combination alkylating agents and autologous bone marrow transplant (ABMT): a pilot study. Proc ASCO 1988; 7:219 (C-850).
16. Cannistra SA, Socinski MA, Groshek P, Elias A, Antman K, Schnipper L, Griffin JD. In vivo administration of human granulocyte-monocyte colony stimulating factor (rGM-CSF) enhances monocyte tumoricidal activity. Proc ASCO 1988; 7:167 (C-645).
17. Antman K, Griffin J, Elias A, Socinski M, Whitley M, Ryan L, Cannistra S, Frei E, Schnipper L. Effect of GM-CSF on chemotherapy induced myelosuppression in sarcoma patients. Proc ASCO 1988; 7:160 (C-619).
18. Socinski MA, Cannistra SA, Elias A, Antman K, Schnipper L, Griffin J. In vivo administration of GM-CSF induces expression of the CD11b surface adhesion protein on granulocytes. Proc ASCO 1988; 7:159 (C-612).
19. Socinski MA, Cannistra SA, Elias A, Antman K, Schnipper L, Griffin J. In vivo administration of GM-CSF increases the number of peripheral blood (PB) progenitor cells and the cycling fraction of bone marrow (BM) CFU-GM. Proc ASCO 1988; 7:159 (C-613).

20. Whitley MJ, Antman K, Griffin J, Socinski M, Elias A, Ryan L, Oette D, Schnipper L. Recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) reduces chemotherapy associated myelosuppression. ONS Congress, May, 1988.
21. Antman K, Elias A, Ryan L. Three Dana Farber Institute Ifosfamide studies. Satellite Symposium, National Cancer Institute of Canada, Toronto, April 24, 1988.
22. Elias A, Ryan L, Aisner J, Antman K. Mesna, Adriamycin, Ifosfamide & DTIC: (MAID) in 127 untreated sarcomas. Cancer Investigation 1988; 6:553-554 (Abstract 15).
23. Bernal S, Wong Y-C, Kakefuda M, O'Hara C, Tsao S-W, Wang Y-H, Elias A. A novel membrane protein associated with differentiation of normal and neoplastic bronchial epithelial cells. 5th World Conference on Lung Cancer, August, 1988. Lung Cancer 1988; 4 (Suppl):A39.
24. Morris SW, Elias A, Daniel L, Ahmed CMI, Liebowitz P. Relation of BCR Breakpoint to time to blast crisis and to survival in BCR-positive CML patients presenting in chronic phase. ASH abstract, Blood. 1988; 72 (Suppl 1):182a (640).
25. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Bast R, Schnipper L, Frei E III, and the Solid Tumor Autologous Bone Marrow Team. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: The Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treatment Reports 71: 119-125, 1987. Abstracted in 1989 Year Book of Hematology (Wiernik P, ed), Year Book Publishers, 1989.
26. Eder JP, Elias AD Teicher BA, Weissmann LB, Wheeler CA, Schryber SM, Schnipper LE, Frei E III, Antman KH. High dose combination alkylating agents & autologous bone marrow transplant (ABMT) for metastatic breast cancer. Bone Marrow Transplantation 1989; 4 (suppl 2): 57.
27. Elias AD, Pap S, Bernal SD. Removal of small cell lung cancer cell lines (SCLC) from bone marrow (BM) by magnetic bead immunoconjugates. 2nd International Bone Marrow Purging Conference, Cancun, Mexico, April 26-29, 1989.
28. Elias A, Antman K, Eder J, Frei E III. High-dose ifosfamide (IFF) with mesna uroprotection: phase I study. Proc ASCO 1989; 8:C-264.
29. Elias AD, Skarin AT, Socinski MA, Kalish L, Frei E III. Neoadjuvant therapy for stage IIIA non-small cell lung cancer (NSCLC). Proc ASCO 1989; 8:C-941.
30. Elias AD, Skarin AT, Socinski MA, Kalish L, Frei E III. Neoadjuvant therapy for unresectable stage IIIB non-small cell lung cancer (NSCLC). Proc ASCO 1989; 8:C-942.
31. Eder JP, Elias AD, Teicher BA, Weissmann LB, Wheeler CA, Schryber SM, Schnipper LE, Frei E III, Antman KH. High dose combination alkylating agents (HDCAA) & autologous bone marrow transplant (ABMT) for metastatic breast cancer. EBMT, 1989; 72 (Abstr 128).
32. Elias AD, Pap S, Bernal SD. Use of magnetic bead immunoconjugates to remove bone marrow contamination with small cell lung cancer cell lines. Proc AACR 1989; 30:236 (C-940).
33. Tondini C, Pap SA, Hayes DF, Elias AD, Kufe DW. DF3 antibody conjugated with holoricin for in vitro purging of bone marrow. Proc AACR 1989; 30:394 (1563).

34. Wong Y-C, Tsao S-W, Kakefuda M, Elias A, O'Hara C, Bernal S. Cloning and sequence analysis of a new membrane protein in respiratory carcinomas reveals partial homology with human EGF receptor. Proc AACR 1989; 30:51 (201).
35. Samuels B, Elias A, Vogelzang N, Williams S, Mick R, Antman K. High-dose chemotherapy with autologous bone marrow reinfusion for refractory sarcoma. Proc AACR 1989; 30:273 (1086).
36. Antman KH, Eder JP, Elias A, Weissman L, Wheeler C, Ayash L, Teicher BA, Schnipper LE, Frei E III. Preclinical & clinical considerations in the design of high-dose regimens for solid tumors. Cancer Update, Tokyo, Japan, July 14-16, 1989.
37. Elias A, Ryan L, Siegel R, Antman K. Ifosfamide and mesna: Responses in sarcoma. ECCO meeting, September, 1989.
38. Ayash L, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin J, Greenough T, Eder JP. Hepatic veno-occlusive disease (VOD) in autologous bone marrow transplantation (BMT) of solid tumors and lymphomas. Blood 1989;74:242a (906).
39. Elias A, Ayash L, Wheeler C, Deary J, Schryber S, Critchlow J, Hunt M, Eder JP, Frei E III, Antman K. High-dose ifosfamide (IFX) with escalating doses of carboplatin (Cb) and autologous bone marrow support (ABMT). Proc ASCO 1990; 9: 11 (C-35).
40. Antman K, Eder J, Elias A, Ayash L, Wheeler C, Schnipper L, Frei E III. High-dose cyclophosphamide, thioTEPA, and carboplatin intensification with autologous bone marrow support in patients with breast cancer responding to standard dose induction therapy. Proc ASCO 1990; 9: 10 (C-33).
41. Wright JE, Antman KH, Willingham LA, Wilson E, Eder JP, Ayash L, Elias AD, Rosowsky A, Frei E III. Carboplatin infusion pharmacokinetics in the autologous bone marrow transplant setting. Proc AACR 1990;31:182 (A-1080).
42. Elias AD, Ayash L, Anderson K, Wheeler C, Schwartz G, Tepler I, Lynch C, Hunt M, Pap S, Schryber S, Deary J, Pelaez J, Schnipper L, Griffin J, Frei III E, Antman KH. Hematologic support during high dose intensification for breast cancer: recruitment of peripheral blood progenitor cells (PBPC) by GM-CSF and chemotherapy. Blood 1990; 76 (Suppl 1): 536 (2135a).
43. Antman K, Elias AD, Hunt M, Ayash L, Anderson K, Wheeler C, Schwartz G, Tepler I, Mazanet R, Critchlow J, Schnipper L, Demetri G, Griffin J, Frei III E. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection and use after high dose chemotherapy. Blood 1990; 76 (Suppl 1): 526 (2094a).
44. Ayash L, Elias AD, Demetri G, Deary J, Wheeler C, Tepler I, McCauley M, Schnipper L, Frei III E, Antman KH, Anderson K. Recombinant human erythropoietin (EPO) in anemia associated with autologous bone marrow transplantation (ABMT). Blood 1990; 76 (Suppl 1): 131 (513a).
45. Demetri G, Spertini O, Pratt ES, Kim E, Elias AD, Antman KH, Tedder, TF, Griffin JD. GM-CSF and G-CSF have different effects on expression of neutrophil adhesion receptors in vivo. Blood 1990; 76 (Suppl 1): 178 (704a).
46. Southee AE, Elias AD, Antman KH, Jochelson MS, Gonin R, Dwyer JP, Kaplan WD. Gallium scanning in metastatic or recurrent soft tissue sarcoma. Society Nuclear Medicine, Washington DC. 6/19-6/22/90.
47. Lynch TJ, Skarin A, Elias AD, Kass F, Shulman L, Frei E. A phase II trial of PFL in advanced NSCLC. Proc ASCO 1991; 10: 259 (C-894).

48. Mazanet R, Elias A, Hunt M, Ayash L, Anderson K, Wheeler C, Schwartz G, Tepler I, Critchlow J, Schnipper L, Demetri G, Griffin J, Frei E III, Antman K. Peripheral blood progenitor cells (PBPCs) added to bone marrow (BM) for hemopoietic rescue following high dose chemotherapy for solid tumors reduces morbidity and length of hospitalization. Proc ASCO 1991; 10: 324 (C-1140).
49. Elias AD, Skarin AT, Herman T, Hunt M, Ayash L, Wheeler C, Frei III E, Antman K. High dose combined alkylating agents with autologous bone marrow support (AMBT) followed by consolidative radiotherapy for responding small cell lung cancer (SCLC). 6th World Conference on Lung Cancer, Melbourne, Australia. Lung Cancer 1991; 7 (Suppl):109 (A-399).
50. Elias A, Ayash L, Anderson K, Wheeler C, Mazanet R, Schwartz G, Tepler I, Reich E, Hunt M, Pap S, Pelaez J, Lynch C, Schnipper L, Griffin J, Frei E III, Antman K. GM-CSF-mobilized peripheral blood progenitor cells (PBPC) support after high dose chemotherapy for breast cancer: effect of GM-CSF post reinfusion. Blood 1991; 78 (Suppl 1): 400a (A-1590).
51. Wheeler C, Eder JP, Churchill WH, Ault K, Ayash L, McCarthy P, Elias A, Schwartz G, Tepler I, Antman K, Mazanet R, Schnipper L, Antin J. Cyclophosphamide (C), Carmustine (B) and Etoposide (V) with autologous stem cell support (ASCS) in non Hodgkin's lymphoma (NHL). Blood 1991;78 (suppl 1): 235a (A-932).
52. Tepler I, Elias A, Young D, Gaynes L, Demetri G, Kalish L, Strauss G, Shulman L, Lynch T, Skarin A, Oldham F, Nadler P, Schnipper L. Effect of recombinant human interleukin-3 (IL-3) on hematologic recovery from chemotherapy-induced myelosuppression - a phase I/II study. Blood, 1991; 78(Suppl.1):162a (A-639).
53. Elias AD, Ayash L, Mazanet R, Anderson K, Hunt M, Wheeler C, Schwartz G, Tepler I, Lynch C, Pap S, Pelaez J, Critchlow J, Demetri G, Schnipper L, Griffin JD, Frei III E, Antman KH. Peripheral blood progenitor cell mobilization by chemotherapy and GM-CSF for hematologic support of high dose intensification chemotherapy. Cancer Investigation 1992; 10 (suppl 1): 6-8.
54. Elias AD, Ayash L, Wheeler C, Hunt M, Schwartz G, Mazanet R, Tepler I, Herman T, Skarin AT, Frei E III, Antman K. High dose combination alkylating agents supported by autologous marrow (ABMT) with chest radiotherapy for responding limited stage (LD) small cell lung cancer (SCLC). Proc ASCO 1992; 11: 296 (991).
55. Mazanet R, Elias A, Ayash L, Anderson K, Wheeler C, Schwartz G, Tepler I, Critchlow J, Schnipper L, Frei E III, Antman K. Stimulated peripheral blood progenitor cells (PBPCs) added to bone marrow (BM) for hemopoietic rescue following high dose chemotherapy for small cell lung cancer (SCLC) reduces time of aplasia and length of hospitalization. Proc ASCO 1992; 11: 385 (1336).
56. Tepler I, Elias A, Young D, Levitt D, Gaynes L, Demetri G, Kalish L, Strauss G, Shulman L, Lynch T, Skarin A, Oldham F, Nadler P, Schnipper L. Use of recombinant human interleukin-3 (IL-3) after "ICE" chemotherapy for non-small cell lung cancer (NSCLC): effect on hematologic recovery. Proc ASCO 1992; 11: 296 (990).
57. Lynch TJ, Shefner J, Wen P, Coral F, Elias AD, Skarin A, Epstein C, Blattler WA, Colinson AR, Ritz J. Immunotoxin therapy with N901-blocked ricin (N901-BR) for small cell lung cancer (SCLC): a phase I study. Proc ASCO 1992; 11: 314 (1063).
58. Tepler I, Cannistra S, Anderson K, Niloff J, Goodman H, Sheets E, Elias A, Mazanet R, Ayash L, Wheeler C, Schwartz G, McCauley M, Gaynes L, Schnipper L, Frei E III, Antman K. Repetitive dose-intensive chemotherapy (x4) made possible by initial collection and repetitive rescue with peripheral blood progenitor cells (PBPC) in previously untreated outpatients with ovarian cancer. Proc ASCO 1992; 11: 239 (768).

59. Wright JE, Tretyakov O, Ayash LJ, Elias AD, Wheeler C, Tepler I, Schwartz G, Mazanet R, Holden SA, Rosowsky A, Antman KH, Frei E III. Platinum rebound after dialysis for renal failure during high dose ifosfamide-carboplatin-etoposide treatment. Proc AACR 1992; 33: 530 (3170).
60. Wright JE, Tretyakov O, Ayash LJ, Elias AD, Eder JP, Wheeler C, Rosowsky A, Antman KH, Frei E III. Correlation of stable response to high dose carboplatin-thiotepa-cyclophosphamide with cyclophosphamide clearance. Proc AACR 1992; 33: 248 (1484).
61. Wheeler C, Hunt M, Ayash L, Gaynes L, McCauley M, Eder JP, Ault K, Mauch P, Antman K, Guinan E, Elias A, Rimm I, Schwartz G, Gilliland G, Weinstein H, Gonin R, Schnipper L, Antin J. Autologous bone marrow transplantation (ABMT) for Hodgkin's disease (HD): prognostic factors for failure free survival. Blood 1992; 79 (Suppl 1): 69a (A-265).
62. Tepler I, Cannistra S, Anderson K, Demetri G, Gonin R, Niloff J, Goodman H, Muntz M, Muto M, Sheets E, Elias A, Mazanet R, Ayash L, Wheeler C, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper L, Frei E III, Antman K. Use of peripheral blood progenitor cells (PBPC) for support of repetitive high-dose carboplatin chemotherapy (x4) in previously untreated outpatients with cancer. Blood 1992; 79 (Suppl 1): 71a (A-275).
63. Wheeler C, Guinan E, Sieff C, Gaynes L, McCauley M, Ayash L, Bierer B, Elias A, Rimm I, Antman K, Schwartz G, Weinstein H, Ferrara J, Tepler I, Brugnera C, Mazanet R, Schnipper L, Gonin R, Oette D, Antin J. Interleukin 3 (IL-3) before marrow harvest and GM-CSF post-autotransplant (ABMT) in patients with relapsed lymphoma: no enhancement of hematopoietic recovery. Blood 1992; 79 (Suppl 1): 85a (A-330).
64. Wheeler C, Kadin M, Pinkus G, Shulman L, Ayash L, Antman K, Eder JP, Guinan E, Elias A, Ferrara J, Schaffer K, Mauch P, Gonin R, Schnipper L, Antin J. Relapsed mediastinal B-cell lymphoma with sclerosis: favorable outcome after autotransplantation with cyclophosphamide (C), carmustine (B) and etoposide (V) in patients with sensitive relapse. Blood 1992; 79 (Suppl 1): 536a (A-2136).
65. Sugarbaker DJ, Kirn DH, Mentzer SJ, Lynch TJ, Strauss GM, Elias AD, Lee TH, Skarin AT. Neoadjuvant chemotherapy downstages patients with stage IIIA non-small cell lung cancer (NSCLC). Amer Coll Surgeons, 1992.
66. Tepler I, Hamm JT, Shulman L, Ritch P, Nemunaitis J, Fitch T, Young DC, Felser J, Resta D, Gaynes L, Millenson M, Strauss G, Lynch T, Skarin A, Schnipper LE, Elias AD. Combination cytokine therapy with recombinant interleukin-3 (IL-3) and granulocyte colony stimulating factor (G-CSF) after "ICE" chemotherapy for lung cancer: Sequential and simultaneous schedules. Proc ASCO 1993; 12: 333 (C-1110).
67. Schwartz G, Elias A, Wheeler C, Eder JP, Ayash L, Mazanet R, Tepler I, Gonin R, Antman K, Schnipper L, Frei E III. Carmustine (BCNU) dose and treatment era predict incidence (INC) of noninfectious pneumonitis (NP) in solid tumor patients undergoing high dose chemotherapy with autologous stem cell support. Proc ASCO 1993; 12: 154 (C-414).
68. Elias A, Kantoff P, Ayash L, Schwartz G, Wheeler C, Tepler I, Mazanet R, McCauley M, Warren D, Frei E III, Antman K. High-dose ifosfamide, carboplatin, & etoposide (ICE) with autologous marrow support for germ cell carcinoma. Proc ASCO 1993; 12: 231 (C-710).
69. Mazanet R, Seidenberg S, Bartel S, Elias A, Saletan S. A phase I Study of liposomal encapsulated doxorubicin (TLC D-99) with G-CSF. Proc ASCO 1993; 12: 154 (C-415).

70. Ayash L, Lynch J, Cruz J, Reich E, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Warren D, Shapiro C, Schnipper L, Frei E, Hurd D, Weiner R, Antman K. High-dose multimodality therapy for locally unresectable or inflammatory (stage IIIB) breast cancer. Proc ASCO 1993; 12: 89 (C-158).
71. Ayash L, Elias A, Reich E, Wheeler C, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell (PBPC) support for metastatic breast cancer. Proc ASCO 1993; 12: 65 (C-61).
72. Elias AD, Skarin AT, Strauss G, Lynch T, Shulman L, Frei E III, Jacobs C, Abner A, Mentzer S, Sugarbaker D. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Proc ASCO 1993; 12: 332 (C-1106).
73. Lynch TJ, Coral F, Shefner J, Elias AD, Skarin A, Mentzer S, Sugarbaker D, Epstein C, Blattler WA, Colinson AR, Ritz J. Phase one trial of the novel immunotoxin N901-blocked ricin (N901-BR): demonstration of clinical activity in small cell lung cancer. Proc ASCO 1993; 12: 293 (954).
74. Bolcsak L, Youngster S, Swenson C, Saletan S, Elias A, Mazanet R. Plasma levels of free and liposome-encapsulated doxorubicin after administration of TLC D-99 (liposomal doxorubicin) in humans. Proc AACR 1993; 34: 364 (2171).
75. Ayash L, Elias A, Cruz J, Lynch J, Wheeler C, Schwartz G, Tepler I, Schnipper L, Frei E, Weiner R, Hurd D, Antman K. High-dose multimodality therapy for locally unresectable or inflammatory (Stage IIIB) breast cancer. 16th Annual San Antonio Breast Cancer Symposium 1993.
76. Ayash L, Elias A, Reich E, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell (PBPC) support for metastatic breast cancer. 16th Annual San Antonio Breast Cancer Symposium 1993.
77. Wheeler C, Axelrod J, Sieff C, Shulman LN, Elias A, Churchill WH, Antman K, Ayash L, Mazanet R, Tepler I, Schnipper L, Wegner S, Schwartz G, Antin JH. Cyclophosphamide and G-CSF mobilized peripheral blood progenitor cells (PBPC) to support intermediate dose ifosfamide, carboplatin, etoposide, and dexamethasone (SPICE) induction therapy in relapsed lymphoma: timing of progenitor cell collection. Keystone, 1/94.
78. Elias AD, Skarin AT, Strauss G, Propert K, Shulman L, Coleman N, Frei E III. Modulation of drug resistance with etanidazole: dose escalation in combination with multiagent chemotherapy for advanced lung cancer. Proc ASCO 1994; 13: 326 (1077).
79. O'Day SJ, Mazanet R, Skarin AT, Salgia R, Gordon D, Elias AD. Dose escalation of liposome-encapsulated doxorubicin (D-99) with granulocyte stimulating factor (G-CSF) support in patients with advanced malignancies. Proc ASCO 1994; 13: 153 (406).
80. Salgia R, Skarin AT, O'Day SJ, Lucca DA, Propert KJ, Elias A. CA-125: A useful tumor marker and an indicator of response to therapy in lung cancer. Proc ASCO 1994; 13: 347 (1158).
81. Shapiro CL, Hurd D, Clark P, Blumsack R, Gelman R, McKenney-Tedder S, Demetri G, Ayash L, Elias A, Hayes D, Duggin D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification with peripheral blood progenitor cells (PBPC) and filgrastim (G-CSF) in advanced breast cancer patients (Pts). Proc ASCO 1994; 13: 66 (67).
82. Lynch TJ, Skarin A, Elias AD, Jacobs C, Frei E. PFL with ifosfamide (FLIP) in advanced NSCLC: a phase I study. Proc ASCO 1994; 13: 327 (1081).

83. Tretyakov OI, Wright JE, Ayash LJ, Elias A, Rosowsky A, Frei E III. Sensitive determination of hydroxylated metabolites of cyclophosphamide and ifosfamide in human blood. *Proc AACR* 1994; 35: 298 (1774).
84. Elias AD, Skarin AT, Strauss G, Shulman L, Teicher BA, Coleman N, Frei E III. ICE chemotherapy with dose escalation of the drug resistance modulator etanidazole for advanced lung cancer. 7th World Conference on Lung Cancer. *Lung Cancer* 1994; 11 (Suppl 1): 124 (A-475).
85. Elias AD. Dose intensive combined modality therapy for small cell lung cancer. International Association for the Study of Lung Cancer, 7th World Conference on Lung Cancer. *Lung Cancer* 1994; 11 (Suppl 1): 124 (A-475).
86. O'Day SJ, Mazanet R, Salgia R, Skarin A, Gordon G, Elias A. A phase I study of liposome-encapsulated doxorubicin (D-99) and granulocyte colony stimulating factor (G-CSF) in patients with advanced solid tumors. *Lung Cancer* 1994; 11 (Suppl 1): 97 (A-367).
87. Salgia R, Skarin AT, O'Day SJ, Lucca DA, Propert KJ, Elias A. CA 125: a useful clinical tumor marker in lung cancer. *Lung Cancer* 1994; 11 (Suppl 1): 48 (A-182).
88. Tepler I, Demetri G, McCauley M, Gaynes L, Harvey S, Skarin A, Strauss G, Ayash L, Wheeler C, Schwartz G, Schnipper L, Frei E III, Elias A. Outpatient-based treatment with multiple cycles of dose-intensified ifosfamide, carboplatin and etoposide (ICE) chemotherapy supported by peripheral blood progenitor cells (PBPC) mobilized by G-CSF: Efficient collection of progenitor cells with rapid hematologic recovery. *Blood* 1994; 84:211a (abstract # 830).
89. Kumar P, Sugarbaker D, Herndon J, Langer M, Elias AD, Kohman L, Jaklitsch M, Kass FC, Eaton WL, Seagren S, Green MR. Efficacy and safety of tri-modality treatment in patients with pathologically staged IIIA (N2) non-small cell lung cancer (NSCLC) utilizing consolidative thoracic irradiation: results of Cancer and Leukemia Group B (CALGB) trial 8935. *Proc Amer Soc Therapeutic Radiation Oncology* 1994; 30 (suppl 1).
90. Kumar P, Sugarbaker D, Herndon J, Langer M, Elias AD, Kohman L, Jaklitsch M, Kass FC, Eaton WL, Seagren S, Green MR. Patterns of relapse following tri-modality treatment in patients with pathologically staged IIIA(N2) non-small cell lung cancer (NSCLC): analysis of Cancer and Leukemia Group B (CALGB) protocol 8935. 5/3/95, American Radium Society, 78th Annual Meeting, p. 31.
91. Webb IJ, Ayash LJ, Eickhoff CE, Wheeler C, Schwartz G, Mazanet R, Demetri G, Antman K, Schnipper L, Frei E III, Elias A. Strategies for mobilization of peripheral blood stem cells for use in high dose chemotherapy. *Blood* (ASH abstr 408) 1994.
92. Wheeler C, Shulman LN, Elias A, Sieff C, Churchill L, Ayash L, Uhl L, Benjamin R, Gaynes L, McCauley M, Thompson L, Mazanet R, Antman K, Richardson P, Schnipper L, Wegner S, Tepler I, Schwartz G, Antin J. Sequential ifosfamide, carboplatin and etoposide with steroids and cyclophosphamide/G-CSF mobilized peripheral blood progenitor cell support (SPICE) in relapsed lymphoma. *Proc ASCO* 1995; 14: 312 (913).
93. Ayash L, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with dose-intensive chemotherapy with autologous stem cell support for advanced breast cancer. *Proc ASCO* 1995; 14: 318 (937).
94. Elias A, Ayash L, Wheeler C, Schwartz G, McCauley M, Teicher BA, Coleman N, Eickhoff C, Warren D, Schnipper L, Antman K, Frei III E. Phase I dose escalation of the hypoxic cell sensitizer etanidazole (ETA) combined with high dose ifosfamide, carboplatin & etoposide (ICE) & autologous stem cell support. *Proc ASCO*; 1995; 14: 180 (405).

95. Ayash L, Antman K, Wheeler C, Schwartz G, Shapiro C, Richardson P, Fairclough D, Reich E, Warren D, Lynch C, Schnipper L, Frei E, Elias A. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer: the DFCI/BIH experience. Proc ASCO 1995; 14: 318 (936).
96. Lynch TJ, Grossbard M, Fidiias P, Bartholomay M, Coral F, Salgia R, Elias AD, Skarin A, Sheffner J, Wen P, Arinello P, Bramen G, Esseltine D, Ritz J. Immunotoxin therapy of small cell lung cancer (SCLC): clinical trials of N901-blocked ricin (N901-bR). Proc ASCO 1995; 14: 424 (1350).
97. Soiffer R, Murray C, Richardson P, Ayash L, Elias A, Ritz J. Prolonged subcutaneous administration of low dose IL-2 following bone marrow and peripheral blood stem cell transplantation. ASH, 1995.
98. Richardson P, Krishnan A, Wheeler C, Ayash L, Hoppensteadt D, Fareed J, Schnipper L, Kufe D, Frei E III, Elias A. The use of defibrotide in BMT-associated veno-occlusive disease. ASH, 1995.
99. Elias AD. Dose intensive therapy in lung cancer. 3rd International Conference: Clinical Applications of Cytokines and Growth Factors in Hematology and Oncology, June 8-10, 1995, Atlanta, GA, p. 41-3.
100. Elias A, Li Y, Wheeler C, Richardson P, Ayash L, McCauley M, Newquist E, Cap B, Tuchin J, Webb I, Schnipper L, Frei E III, Skarin AT, Chen LB. CD34-selected peripheral blood progenitor cell (PBPC) support in high dose therapy of small cell lung cancer (SCLC): use of a novel detection method for minimal residual tumor (MRT). Proc ASCO 1996; 15: 341 (A-991).
101. Richardson P, Krishnan A, Wheeler C, Fyfe H, Hoppensteadt D, Fareed J, Guinan E, Grupp S, Twist C, Antin J, Bierer B, Kufe D, Frei E III, Elias A. The use of defibrotide in BMT-associated veno-occlusive disease. Proc ASCO 1996; 15: 87 (A-13).
102. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Young ML, Kwiatkowski DJ, Shulman LN, Carey RS, Grossbard ML, Sugarbaker DJ, Mathiesen DJ, Frei E, Skarin AT. Phase I study of ICE-T (ifosfamide, carboplatin, etoposide, and taxol) in advanced lung cancer. Proc ASCO 1996; 15: 375 (A-1114).
103. Chen L, Pulsipher M, Chen D, Elias A, Sieff C, Fine H, Kufe D. A gene therapy strategy for in vitro purging: adenovirus mediated prodrug activation (AMPA) for elimination of breast cancer cells in hematopoietic progenitor products. Proc AACR 1996; 37: 344 (A-2346).
104. Richardson P, Krishnan A, Wheeler C, Hoppensteadt D, Tuchin J, Fyfe H, Bierer B, Guinan E, Antin J, Frei E III, Fareed J, Elias A. Elevation of plasminogen activator inhibitor-1 (PAI-1) levels in BMT-associated veno-occlusive disease (VOD) and changes seen with the use of defibrotide (DF). ASH 1996.
105. Ayash L, Elias A, Ibrahim J, Wehswartz G, Wheeler C, Reich E, Lynch C, Shapiro C, Richardson P, Schnipper L, Frei E, Antman K. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer: the DFCI/BIH experience. Proc ASCO 1997; 16: 90a (A-318).
106. Elias AD, Herndon J, Kumar P, Sugarbaker D, Green MR. For the CALGB. A phase III comparison of "best local-regional therapy" with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results. Proc ASCO 1997; 16: 448a (A-1611).
107. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Waller EK, Antin JH, Soiffer RJ, Vredenburgh J, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease (VOD) with defibrotide (DF): compassionate use results in efficacy without significant toxicity in a high risk population. Blood, ASH 1997.
108. Richardson R, Hoppensteadt D, Elias A, Frei E III, Iacobelli M, Guinan E, Fareed J. Elevation of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM), and plasminogen activator inhibitor-1 (PAI-1)

levels in stem cell transplant (SCT) - associated venoocclusive disease (VOD) and changes seen with the use of defibrotide (DF). Blood, ASH 1997.

109. Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Antin J. Low incidence of post-transplant myelodysplasia/acute leukemia (MDS/AML) in NHL patients autotransplanted after cyclophosphamide, carmustine and etoposide (CBV). Blood, ASH 1997.
110. Avigan D, Wu Z, Gong J, Wheeler C, Elias A, Joyce R, Richardson P, Demetri G, Bunnell C, Kufe D. Immune reconstitution following high dose chemotherapy with stem cell rescue for advanced breast cancer. ASBMT 1998.
111. Elias AD, Wheeler C, Richardson P, Reich E, Hu P, Avigan D, Bunnell C, Demetri G, Joyce R, Levine J, Warren D, Teicher B, Ayash L, Frei E III. A Phase I trial of double transplant for metastatic breast cancer: sequence and interval considerations. ASBMT 1998.
112. Herbst R, Dang N, Lynch C, Teicher B, Strauss G, Elias A, Anderson I, Salgia R, Jacobs C, Skarin A. Phase I study of combination weekly gemcitabine and vinorelbine in patients with lung cancer. Proc ASCO 1998; 17: 488a (1877).
113. Demetri GD, Geiger EA, Xu G, Stefanowicz L, Joyce R, Richardson P, Elias AD. Outpatient tolerability of high-dose liposome-encapsulated daunorubicin (DaunoXome™) with filgrastim support in patients with solid tumors. 10th NCI-EORTC symposium on new drugs in cancer therapy. June 16-19, 1998; abstract 490.
114. Elias A. High dose therapy for small cell lung cancer: future strategies. July 29, 1998. 9th International Symposium on Autologous Blood and Marrow Transplantation, Dallas, Texas.
115. Elias AD, Richardson P, Avigan D, Ibrahim J, Bunnell C, Joyce R, Demetri G, Levine J, Warren D, Hieng S, Reich E, Frei E. Phase I development of double cycle stem cell supported high dose chemotherapy (HDC) for metastatic breast cancer (BC): the DFCI/BIDMC experience. Proc ASCO 1999; 18: 123a (A-466).
116. Rizzo D, Stiff P, Elias A. Autologous stem cell transplantation for small cell lung cancer. Proc ASCO 1999; 18: 469a (A-1811).
117. Avigan D, Wu Z, Gong J, Wheeler C, Elias A, Joyce R, Richardson P, Demetri G, Bunnell C, Kufe D. Immune reconstitution following high dose chemotherapy with stem cell rescue for advanced breast cancer. Proc ASCO 1999;18:55a (A-202).
118. Strauss GM, Lynch TJ, Leong T, Elias AD, Jacobs C, Kwiatkowski D, Grossbard ML, Sugarbaker DJ, Mathisen DJ, Skarin AT. Phase II study of ICE-T (Ifosfamide, carboplatin, etoposide, and taxol) in stages IIIB and IV NSCLC: are dose intense regimens effective in advanced lung cancer? Proc ASCO 1999; 18: 481a (A-1855).
119. Shapiro G, Patterson A, Lynch C, Lucca J, Anderson I, Boral A, Elias A, Lu H, Salgia R, Skarin A, Panek-Clark C, McKenna R, Rabin M, Vasconcelles M, Eder P, Supko J, Lynch T, Rollins B. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer. Proc ASCO 1999; 18: 522a (A-2013).
120. Elias AD, Richardson P, Tretyakov O, Avigan D, Warren D, Arthur T, McCauley M, Wright J, Frei E. Amifostine with high dose ifosfamide, carboplatin, and etoposide (ICE) with hematopoietic stem cell support. Proc ASCO 2000; 19: 51a (197).

121. Bunnell CA, Parker L, Matulonis UA, Shulman LN, Elias AD, Harris L, Scheib RG, Burstein HJ, Campos SM, Younger J, Kuter I, Winer EP. A phase I study of cyclophosphamide, doxorubicin, and eniluracil/5-FU in women with advanced breast cancer: preliminary results. Proc ASCO 2000; 19: 115a (444).
122. Kumar P, Herndon J II, Sugarbaker DJ, Kohman L, Elias AD, Green MR. Long term survival outcome of a sequential trimodality trial in pathologically staged IIIA(N2) non-small cell lung cancer (NSCLC): final results of Cancer and Leukemia Group B (CALGB) protocol 8935. Proc ASCO 2000; 19: 496a (1939).
123. Richardson PG, Murakami C, Warren D, Jin Z, Neuberg D, Elias AD, Antin J, Soiffer R, Bearman SI, Vredenberg J, Vogelsang G, Hoppensteadt D, Fareed J, Iacobelli M, McDonald GB, Guinan EC. Multi-institutional emergency use of defibrotide (DF) in 75 pts post SCT with severe VOD and multi-system organ failure (MOF): response without significant toxicity in a high risk population. Proc ASH 2000, in press.
124. Salgia R, Harpole D, Herndon JA, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA125 and CEA in non-small cell lung cancer. Proc IASLC 2000, in press.
125. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Elias A, Rabinovitch R, Matthes S, Razook C, Chao N, Jones RB. Pilot phase II study of concurrent administration of trastuzumab and high-dose chemotherapy (HDCT) in advanced her2+ breast cancer. Proc ASCO 2002; 21: 416a (1663).
126. Hortobagyi G, Weng D, Elias A, Rugo H, Urba W, Margolin K, Radka S, Aitchison R, Wolin M, Gordon G. Assessment of serum markers of angiogenesis in Stage IV metastatic breast cancer patients following treatment with ANGIOZYME - a chemically stabilized synthetic ribozyme targeting VEGFR-1. ESMO 2002.
127. Richardson PG, Murakami C, Warren D, Jin Z, Neuberg D, Elias AD, Antin J, Soiffer R, Bearman SI, Vredenberg J, Vogelsang G, Hoppensteadt D, Fareed J, Iacobelli M, McDonald GB, Guinan EC. Defibrotide (DF) Appears Effective and Safe in a Phase II, Randomized Study of Patients (pts) with Severe Venous Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post Stem Cell Transplantation (SCT). ASH, 2002
128. Finlayson CA, Lewin JM, Rabinovitch R, Robinson WA, Seligman PA, Elias AD, Arya J, Isaacs P. MRI is a potential intermediate marker for tamoxifen response in breast cancer prevention. Breast CA Res & Treat 2003; 82 (Suppl 1): S178 (A-1033).
129. Ramaswamy B, Rhoades CA, Kendra K, Hauger M, Allen J, Jhaveri S, Chen H, Cagnoni P, Eckhardt GS, Elias A, Shapiro CL. CTEP-sponsored phase II trial of bevacizumab (Avastin) in combination with docetaxel (Taxotere) in metastatic breast cancer. Breast CA Res & Treat 2003; 82 (Suppl 1): S50 (A-224).
130. Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients with previously treated metastatic breast cancer (MBC). Proc ASCO 2005; 23: 19s (A563).
131. AD Elias, KD Miller, HJ Burstein, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, M Collier, BJ Adams, CM Baum. Sunitinib malate (SU11248), a multitargeted tyrosine kinase inhibitor: safety and efficacy as second-line therapy in metastatic breast cancer. AACR: Advances in Breast Cancer Research: LaJolla, CA 9/23/05.
132. Richer JK, Harvell DME, Spoelstra NS, Singh M, Elias AD, Horwitz KB. Molecular changes in response to pre-operative endocrine therapy. Abstract 5080. SABCS, 12/05.

133. Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). Abstract 1066, SABCs, 12/05.
134. Harvell DME, Richer JK, Spoelstra N, Singh M, Elias A, Horwitz KB. Estrogen-regulated genes involved in response to neoadjuvant therapy for breast cancer. Endocrine Society 2006.
135. Deprimo SE, Friece C, Huang X, Smeraglia J, Sherman L, Collier M, Baum C, Elias AD, Burstein HJ, Miller KD. Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. Proc ASCO 2006; 24: 22s (A578).
136. Harvell DME, Spoelstra N, Singh M, Finlayson C, Elias A, Horwitz KB, Richer JK. Breast cancer androgen receptors are implicated in anti-estrogen therapy failure. Endocrine Society 2007.
137. Maki RG, Keohan ML, Undevia S, Livingston M, Cooney M, Elias A, Saule M, Wright JJ, D'Adamo DR, Schuetz S, CTEP Sorafenib Sarcoma Study Group. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. Proc ASCO 2008.
138. Kabos P, Dye WW, Elias A, Sartorius CA, Horwitz KB. The chemoresistant population of luminal subtype human breast cancer cells expresses a basal phenotype. *31st San Antonio Breast Cancer Symposia*, December 2008 (oral presentation).
139. Kabos P, Dye WW, Elias A, Horwitz KB, Sartorius CA. Rare ER-/CK5+ cells in luminal type human breast cancers are resistant to hormone therapy and chemotherapy and repopulate ER+ tumors. Proc AACR 2009 (oral presentation).
140. Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, Rea D, Wardley A, Britten C, Elias A. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. Proc ASCO 2009; 27: 60s (A1081).
141. Diamond JR, Amaria R, O'Donnell CI, Meltesen L, Swisshelm K, Malancon D, McGavran L, Singh M, Elias A, Borges VF. The incidence of low-level HER2 gene amplification and chromosome 17 polysomy in cases of newly diagnosed breast cancer and their association with clinical prognostic markers. J Clin Oncol 2009; 27 (suppl) abstr e22012.
142. Schwartz GN, Borges VF, Weiselberg LR, Elias AD, Budman DR. Lapatinib restores endocrine sensitivity in selected patients with estrogen receptor (ER) positive metastatic breast cancer. Proc SABCs 2009. Cancer Res 2009; 69 (suppl): 24: 675s (A-3089).
143. Cochrane DR, McKinsey E, Cittelly D, Spoelstra SN, Tan A-C, Elias A, Richer JK. Dicer1 is targeted by two EMT-associated microRNAs in breast cancer. Keystone Conference, 2010.
144. Krop IE, Modi S, Elias A, LoRusso P, Choi YJ, Lu M. A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with Her2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. SABCs 2010; P3-14-10.
145. Lu D, Krop I, Modi S, Elias A, LoRusso P, Huang J, Lu M, Girish S. Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with Her2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. SABCs 2010; P3-14-22.

146. Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. A randomized phase II study of sunitinib vs. standard of care for patients with previously treated advanced triple-negative breast cancer. SABCS 2010; P6-12-02.
147. Cochrane DR, Jacobsen BM, Jean A, Elias A, Richer JK. The Role of Androgen Receptor in Postmenopausal Breast Cancer. Era of Hope 2011.
148. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Zojwala NJ, Willey R, Grebennik DO. Phase II trial of anti-IGF-1R antibody cixutumumab in patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumor. Proc ASCO 2011; A-10004. Oral presentation.
149. Kabos P, Li C, Finlay-Schultz J, Kline E, Edgerton S, Wissel J, Finlayson C, Elias A, Sartorius C. A patient-derived tumor model to study hormone receptor action and luminal specific stem/progenitor cells in estrogen receptor positive breast cancer. AACR, San Francisco, October 2011.
150. Lu D, Modi S, Elias A, Agarwal P, Yi J-H, Guardino AE, Althaus B, Girish S. Pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and paclitaxel or docetaxel in patients with Her2-positive MBC previously treated with a trastuzumab-containing regimen. SABCS 2011.
151. Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Bernales S, Protter AA, Elias AD, Richer JK. MDV3100, an androgen receptor signaling inhibitor, inhibits tumor growth in breast cancer preclinical models regardless of estrogen receptor status. AACR 2012 LB-109.
152. Elias AD, Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Bernales S, Protter AA, Richer JK. MDV3100, an androgen receptor signaling inhibitor, inhibits tumor growth in AR-positive breast cancer cell lines in vivo: evidence to justify clinical trials. ASCO 2012, A-564.
153. Modi S, Elias A, LoRusso PM, Samant M, Guardino E, Althaus B, Krop IE. Results from a dose-escalation study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in patients with HER2-positive MBC previously treated with a trastuzumab-containing regimen. ASCO 2012, A-528.
154. Elias A, Richer JK, LoRusso P, Peterson AC, Steinberg J, Mordenti J, Lopez C, Hudis C, Traina T. MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer. ASCO 2012, TPS668.
155. Tap WD, Van Tine BA, Elias A, Livingston M, Agulnik M, Cooney M, Chmielowski B, Brenner A, Pennock GK, Somaiah N, Dang L, Tian GG, Jones RL, Okuno S, Loizos N, Nippgen J, Schwartz GK. A phase Ib/II study evaluating the efficacy of doxorubicin with or without a human anti-PDGFR alpha monoclonal antibody (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS). ASCO 2012, TPS10099.
156. Richard D. Carvajal, Rashmi Chugh, Mohammed M. Milhem, Christopher W. Ryan, Suzanne George, Bartosz Chmielowski, Mark Agulnik, Eve T. Rodler, Anthony D. Elias, G. Thomas Budd, Hussein Tawbi, Sujana Movva, Brian Andrew Van Tine, Mark Andrew Dickson, Martee Leigh Hensley, Mary Louise Keohan, William D. Tap, Cathryn M. Bennett, Robert G. Maki, Gary K. Schwartz. Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy. ASCO 2012, TPS10103.
157. Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Goddard E, Connaghan KD, Jedlicka P, Elias A, Bain D, Richer JK. microRNAs and Hormone Receptor Action in Breast Cancer. Endocrine Society 2012.
158. D'Amato NC, Bernales S, Jacobsen BM, Cochrane DR, Guerrero J, Gómez F, Protter AA, Elias AD, Richer JK. Preclinical Evaluation of Enzalutamide in Breast Cancer Models. SABCS 2012 P2-14-02.

159. Borges VF, Ramirez O, Borakove M, Manthey E, Diamond JR, Elias AD, Finlayson C, Kounalakis N, Jordan K. Young Women's Breast Cancer Is Characterized by Increased Immune Suppression Through Circulating Myeloid Derived Suppressor Cells. SABCS 2012 P4-04-06.
160. Sartorius CA, Finlay-Schultz J, Li C, Rosen RB, Hendricks P, Wisell J, Finlayson C, Elias A, Kabos P. Progestins Exert Divergent Growth Effects and Regulate Tumor-Unique Gene Cohorts in Patient Derived Breast Cancer Xenografts. SABCS 2012 P6-05-10.
161. Traina TA, Yardley DA, Patel M, Schwartzberg L, Elias A, Gucalp A, Peterson AC, Hannah A, Gibbons J, Khondker Z, Hudis CA, LoRusso P. A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer. SABCS 2013 PD3-6 (A938), accepted, poster discussion.
162. Elias A, Modi S, Krop IE, Pegram M, Ipe D, Guardino E, Althaus B, LoRusso PM. Results from a Phase 2a Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer. SABCS 2013 P4-12-09 (A1520) accepted, poster presentation.
163. Lin N, Schwartzberg L, Kesari S, Elias A, Anders C, Raizer J, Kozloff, Amiri-Kordestani L. A phase II study of ANG1005, a novel, brain-penetrant taxane derivative, in breast cancer patients with brain metastases. AACR-NCI-EORTC 2013, Abstract B76/989 accepted.
164. D'Amato NC, Cochrane DR, Barton VN, Thor AD, Elias AD, Richer JK Targeting the androgen receptor in multiple breast cancer subtypes, Invited symposium presentation. AACR Advances in Breast Cancer. October 2013, 1A18.
165. Traina TA, Yardley DA, Patel MR, Schwartzberg LS, Elias A, Gucalp A, Blaney ME, Gibbons J, Hudis CA, LoRusso P. A phase 1 open-label study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer. IMPAKT 2014 Breast Cancer Conference May 2014, Abstract 214.
166. Gralow JR, Barlow WE, Paterson A, Lew DL, Stopeck A, Hayes DF, Hershman D, Schubert M, Clemons M, van Poznak C, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino M, Margolis J, Dakhil S, Chew H, Livingston RB, Hortobagyi GN. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery (ClinicalTrials.gov Identifier: NCT00127205). Proc ASCO 2014.
167. Lin N, Gabrail N, Sarantopoulos J, Schwartzberg L, Kesari S, Bates S, Anders C, Elias A, Castaigne J-P, Iordanova V, Lawrence B, Kurzrock R. Evaluation of CNS and peripheral anti-tumor activity of ANG1005 in patients with brain metastases arising from breast tumors and other advanced solid tumors. Proc ASCO 2014.
168. Trivalent Ganglioside Vaccine in Metastatic Sarcoma Patients Rendered Disease-Free by Surgery: A Randomized Phase 2 Trial. Proc ASCO 2014.
169. Schwartzberg LS, Yardley DA, Elias A, Patel MR, Gucalp A, Burris HA, Peterson AC, Hannah AL, Blaney ME, Gibbons J, Tudor IC, Steinberg JL, LoRusso P, Infante JR, Hudis CA, Traina TA. Enzalutamide plus exemestane: a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer. Proc ASCO 2014.
170. D'Amato N, Spoelstra N, Elias A, Cox MB, Richer JK. Androgen Receptors in Estrogen Receptor Positive Breast Cancer. Endocrine Society 2014.

171. Diamond JR, Tan AC, Pitts TM, van Bokhoven A, Aisner D, Elias AD, Borges VF, Miller KD, Eckhardt SG, Tentler JJ. A phase II clinical trial of ENMD-2076 in metastatic triple –negative breast cancer: translating a p53-based biomarker from bench to bedside. Proc TAT, 2014.
172. Gordon MA, D’Amato N, Gu H, Elias A, Richer JK. Targeting multiple pathways in breast cancer: androgen receptor, Her2, and mTOR. Keystone Conference 2014.
173. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Elias A, Sartorius CA, Kabos P. CD146 positive and negative stroma direct breast tumor estrogen receptor levels, therapeutic response and metastatic potential. Proc SABCS 2014, P4-04-06.
174. D’Amato NC, Jacobsen BM, Cochrane DR, Spoelstra NS, Babbs BL, Elias A, Richer JK. Inhibiting androgen receptor nuclear localization decreases estrogen receptor (ER) activity and tumor growth in ER+ breast cancer. Proc SABCS 2014, P3-04-06
175. Gordon MA, D’Amato N, Gu H, Wong D, Elias A, Richer JK. Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR. Proc SABCS 2014, P6-03-07.
176. Gordon MA, D’Amato N, Gu H, Liu B, Elias A, Richer JK. The anti-androgen enzalutamide synergizes with trastuzumab and everolimus to inhibit breast cancer growth via distinct mechanisms. Endocrine Society 2015.
177. Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker GA, Sedjo RL, Wyatt H. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: a Behavioral weight loss intervention in overweight or obese breast cancer survivors. Proc ASCO 2015, oral presentation.
178. Gralow JR , Barlow WE, Paterson A, Lew DL, Stopeck A, Hayes DF, Hershman D, Schubert M, Clemons M, Van Poznak C, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino M, Margolis J, Dakhil S, Chew H, Livingston RB, Hortobagyi GN. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307 (NCT00127205). Proc ASCO 2015, oral presentation.
179. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NA, Park YC, Knoblauch R, Parekh TV, Maki RG, Patel SR. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of advanced liposarcoma or leiomyosarcoma. Proc ASCO 2015, oral presentation.
180. Tap W, Jones RL, Chmielowski B, Elias AD, Adkins D, Van Tine BA, Agulnik M, Cooney M, Livingston MB, Pennock G, Qin A, Shahir A, Ilaria R, Conti I, Cosaert J, Schwartz GK. A randomized phase 1b/2 study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti–platelet-derived growth factor α (PDGFR α) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). Proc ASCO 2015, oral presentation.
181. Von Mehren M, Demetri GD, Schuetze SM, Jones RL, Milhem M, Elias A, Van Tine BA, Hamm J, Khokhar NZ, McCarthy S, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (≥ 65 years) with advanced

leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. Proc ESMO, 2015 and Proc CTOS, 2015.

182. Jones RL, Tap W, Chmielowski B, Elias AD, Adkins D, Van Tine BA, Agulnik M, Cooney M, Livingston MB, Pennock G, Qin A, Shahir A, Ilaria R, Conti I, Cosaert J, Schwartz GK. A randomized phase 1b/2 study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFR α) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). Proc CTOS 2015, and British Cancer Society 2015 and DKK cancer society 2015 and AIOM 2016.
183. Blay JY, Tap W, Jones RL, Chmielowski B, Elias AD, Adkins D, Van Tine BA, Agulnik M, Cooney M, Livingston MB, Pennock G, Qin A, Shahir A, Ilaria R Jr, Conti I, Schwartz GK. Evaluation de l'efficacite de doxorubicine +/- olaratumab dan les STM. Proc SFC, 2015.
184. von Mehren M, Demetri GD, Schuetze SM, Jones R, Milhem M, Elias A, Van Tine BA, Hamm J, Khokhar NA, McCarthy S, Wang G, Knoblauch R, Parekh T, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine in advanced liposarcoma or leiomyosarcoma after prior chemotherapy: elderly patient (age >65 Years) subgroup analysis. Proc CTOS 2015, oral presentation.
185. Elias AD, Burris HA, Patel MR, Schwartzberg LS, Richer JK, Kavalierchik E, Stopatschinskaja S, Gibbons J, Markova D, Steinberg JL, Traina TA. MDV3100-08: a phase I study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer. Proc SABCS 2015, accepted poster presentation.
186. Albain KS, Leyland-Jones B, Symmans F, Paoloni M, van't Veer L, Yau C, Chien AJ, Wallace A, Forero-Torres A, Yee D, Kaplan H, Nanda R, Moulder S, Haley B, Elias A, Boughey J, Lang J, DeMichele A, Isaacs C, Kemmer K, Godellas C, Buxton M, Hogarth M, Hylton N, Perlmutter J, Edmiston K, Korde L, Viscusi R, Khan Q, Northfelt D, Alvarado M, Melisko M, Schwab R, Helsten T, Krontiras H, Beckwith H, Ellis ED, Jaskowiak N, Murthy R, Unni N, Haddad T, Tripathy D, Russel K, Clark A, Clennell JL, Sanil A, I-SPY2 TRIAL investigators, Berry D, Esserman L. The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial. Proc SABCS 2015.
187. Buxton M, DeMichele A, Chia S, van't Veer L, Chien J, Wallace A, Kaplan H, Lang J, Yee D, Isaacs C, Moulder S, Albain K, Boughey J, Kemmer K, Haley B, Minton S, Forrero A, Nanda R, Elias A, Korde L, Viscuzi R, Rugo H, Schwab R, Symmans F, Paoloni M, Hylton N, Hogarth M, Lyandres J, Perlmutter J, Sanil A, Yau C, Esserman L, Berry D. Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for Her2+ breast cancer: results from the neoadjuvant I-SPY2 trial. Proc ASCO 2016, in press.
188. DeMichele A, Moulder S, Buxton M, Yee D, Wallace A, Chien J, Isaacs C, Albain K, Boughey J, Kemmer K, Haley B, Lang J, Kaplan H, Minton S, Forrero A, Elias A, Nanda R, Korde L, Schwab R, Melisko M, Sanil A, Hogarth M, Hylton N, Paoloni M, Symmans F, Perlmutter J, Lyandres J, Yau C, Berry D, Esserman L. Efficacy of T-DM1+pertuzumab over standard therapy for Her2+ breast cancer: results from the neoadjuvant I-SPY2 trial. Proc ASCO 2016, in press.
189. Villalobos VM, Jimeno A, Gore L, Elias A, Hoffner B, Messersmith W. Long term follow up of desmoids treated with PF-03084014, a gamma secretase inhibitor. CTOS 11/2016.

190. Gucalp A, Bardia A, Gabrail N, DaCosta N, Danso M, Elias AD, Ali H, Lemon SJ, Riley EC, Eisner JR, Fleming RA, Kurman MR, Moore WR, Traina TA. Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor antagonist, in patients with advanced androgen receptor positive triple negative or estrogen receptor positive breast cancer. Proc SABCS 2016, P2-08-04.
191. Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, Kaplan HG, Albain KS, Wallace AM, Haley BB, Isaacs C, Korde LA, Nanda R, Lang JE, Kemmer KA, Hylton NM, Paoloni M, van't Veer L, Lyandres J, Perlmutter J, Hogarth M, Yau C, Sanil A, Berry DA, Esserman LJ. Efficacy of Hsp90 inhibitor Ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY2 trial. Proc SABCS 2016, in press.
192. Yee D, Paoloni M, van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, Kaplan HG, Elias AD, Haley BB, Boughey JC, Kemmer KA, Korde LA, Isaacs C, Minton S, Nanda R, DeMichele A, Lang JE, Buxton MB, Hylton NM, Symmans WF, Lyandres J, Hogarth M, Perlmutter J, Esserman LJ, Berry DA. The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY2 trial. Proc SABCS 2016, in press.
193. Gordon MA, D'Amato N, Christenson J, Babbs B, Gu H, Wulfkuhle J, Petricoin E, Elias A, Richer JK. Synergy between androgen receptor (AR)-targeting agents seviteronel (SEVI) or enzalutamide (ENZA) and mTOR or HER2 pathway-targeting agents in breast cancer. Proc AACR 2017, in press.
194. Gucalp A, Danso M, Elias A, Bardia A, Ali H, Potter D, Gabrail N, Haley B, Khong H, Riley E, Ervin L, Eisner J, Baskin-Bey E, Moore W, Traina TA. Phase 2 Stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor inhibitor, in women with advanced AR+ triple negative or estrogen receptor positive breast cancer: CLARITY-01. Proc ASCO 2017, A-1102.
195. Nanda R, Liu MC, Yee D, DeMichele AM, Yau C, Asare SM, Hylton NM, van't Veer LJ, Perlmutter J, Wallace AM, Chien J, Forero-Torres A, Ellis ED, Han HS, Clark AS, Albain KS, Boughey JC, Elias AD, Berry DA, Esserman LJ, I-SPY 2 Investigators. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. Proc ASCO 2017, A-506 (oral).
196. Elias A, Gucalp A, Van Poznak DH, Bardia A, Resaul A, Eisner J, Baskin-Bey E, Traina TA. Initial phase (Ph)2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in men with advanced breast cancer (BC). Proc SABCS 2017, P5-23-04, poster.
197. Mayordomo J, Falkson C, Kepes J, Poage GM, Israel MA, Schroeder BE, Schnabel CA, Elias A. Correlation of breast cancer index (BCI) prognostic and predictive results to clinicopathologic risk groups in early stage HR+ breast cancer. Proc SABCS 2017, P1-07-12, poster.
198. Elias A, Israel MA, Schroeder BE, Zhang Y, Schnabel CA, Mayordomo J. Correlation of breast cancer index (BCI) predictive (HoxB13/IL17BR) results to nodal status and hormone receptor expression in early stage HR+ breast cancer. Proc SABCS 2017, P4-09-09, poster.
199. Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson D, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Clinical safety and efficacy of the

Aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, local advanced or metastatic triple-negative breast cancer. Proc SABCS 2017, PD3-16, poster discussion.

200. Chawla S, Van Tine B, Pollack S, Ganjoo K, Elias A, Riedel R, Attia S, Choy E, Okuno S, Agulnik M, Von Mehren M, Livingston M, Keedy V, Verschraegen C, Philip T, Bohac C, Lu H, Chen M, Maki R. A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: interim analysis of immunogenicity, tumor control and survival. Proc ESMO and CTOS 2017.
201. Yee D, DeMichele A, Isaacs C, Symmans F, Yau C, Albain KS, Hylton NM, Forero-Torres A, van't Veer LJ, Perlmutter J, Rugo HS, Melisko M, Chen Y-Y, Balassanian R, Krings G, Datnow B, Hasteh F, Tipps A, Weidner N, Zhang H, Tickman R, Thornton S, Ritter J, Amin K, Klein M, Chen B, Keeney G, Ocal T, Feldman M, Klipfel N, Sattar H, Mueller J, Gwin K, Baker G, Kallakury B, Zeck J, Duan X, Ersahin C, Gamez R, Troxell M, Mansoor A, Grasso LeBeau L, Sams S, Wisell J, Wei S, Harada S, Vinh T, Stamatakos MD, Tawfik O, Fan F, Adams A, Rendi M, Minton S, Magliocco A, Sahoo S, Fang Y, Hirst G, Singhrao R, Asare SM, Wallace AM, Chien AJ, Ellis ED, Han HS, Clark AS, Boughey JC, Elias AD, Nanda R, Korde L, Murthy R, Lang J, Northfelt D, Khan Q, Edmiston KK, Viscusi R, Haley B, Kemmer K, Zelnak A, Berry DA, Esserman LJ. GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. Proc SABCS 2017, GS3-08.
202. Association of NY-ESO-1 expression with baseline immunity and clinical outcomes in soft tissue sarcoma (STS) patients (PTS) treated with CMB305 + Atezolizumab or atezolizumab alone. Toronto Sarcoma Symposium 2018.
203. Hylton NM, Symmans WF, Yau C, Li W, Hatzis C, Isaacs C, Albain KS, Chen Y-Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhaweche-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, Grasso LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace A, Boughey JC, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen PK, van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Sanil A, Berry SM, Abe H, Wolverton D, Crane EP, Ward KA, Nelson M, Niell BL, Oh K, Brandt KR, Bang DH, Ojeda-Fournier H, Eghtedari M, Sheth PA, Bernreuter WK, Umphrey H, Rosen MA, Dogan B, Yang W, Joe B, I-SPY 2 TRIAL Consortium, Yee D, Pusztai L, DeMichele A, Asare SM, Berry DA, Esserman LJ. Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden. Proc SABCS 2018: P2-07-03.
204. Silverstein J, Suleiman L, Yau C, Price ER, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain KS, Chien AJ, Forero-Torres A, Wallace AM, Pusztai L, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, I-SPY 2 TRIAL Consortium, Berry DA, Asare SM, Esserman LJ, Boughey JC, Mukhtar RA. The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL. Proc SABCS 2018: P2-14-01.

205. Reese JM, Babbs BL, Christenson JL, Spoelstra NS, Elias A, Eisner JR, Baskin-Bey ES, Gertz J, Richer JK. Targeting the androgen receptor with seviteronel, a CYP17 lyase and AR inhibitor, in triple negative breast cancer. Proc SABCS 2018: P5-05-05.
206. Williams MM, Christenson JL, Spoelstra NS, Babbs BL, O'Neill, K, Reese JM, Arnesen S, Blanchard ZD, Hanamura T, Eisner JR, Elias A, Gertz J, Jacobsen BM and JK Richer. Enhanced expression and reliance on androgen receptors in *ESR1* mutant breast cancer is revealed by clinically relevant culture conditions and biopsies of metastatic disease. Proc AACR 2019.
207. Schwab R, Clark AS, Yau C, Hylton N, Li W, Wolfe D, Chien AJ, Wallace AM, Forero-Torres A, Stringer-Reasor E, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han HS, Lee C, Albain K, Isaacs C, Elias AD, Ellis ED, Shah P, Lang JE, Lu J, Tripathy D, Kemmer K, Yee D, Haley B, Majure M, Roesch E, Vaklavas C, Ewing C, Helsten T, Symmans WF, Perlmutter J, Rugo HS, Melisko M, Wilson A, Singhrao R, van 't Veer L, DeMichele A, Asare S, Berry D, Esserman LJ. Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. CT136 / 2. Proc AACR 2019.
208. Williams MM, Spoelstra NS, Arnesen S, Christenson JL, Babbs BL, O'Neill, K, Reese JM, Blanchard ZD, Hanamura T, Elias A, Gertz J, Jacobsen BM, Richer JK. Unique response of *ESR1* mutant breast cancer to stress associated with disease progression. International Association of Breast Cancer Research April 2019 The Netherlands.
209. Fu S, Taylor M, O'Reilly EM, Druta M, Elias A, Tap WD, Ingham M, Esquibel V, Ben Y, Sharp LL, Boyle WJ, Chang C, Frey G, Chen W, Melnick M, Short JM, Burris H. A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-ROR2 humanized monoclonal antibody drug conjugate (BA3021) in patients with advanced solid tumors. Proc ASCO 2019.
210. Chawla SP, Van Tine BA, Pollack S, Ganjoo K, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Lu H, Chen M, Maki RG. A phase 2 randomized study of CMB305 and atezolizumab in NY-ESO-1⁺ soft tissue sarcoma: analysis of immunogenicity, tumor control and survival. Proc ASCO 2019.
211. Somaiah N, Hill B, Kraft A, Van Tine B, Reuben D, Elias A, Read W, Meyer C, Schuetze S, Milhem M, Chawla S, Wahlquist AH, Garrett-Mayer E. Phase II Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine with Docetaxel (T) in Advanced Soft Tissue Sarcoma (STS). Proc ASCO 2019.
212. Weiss J, Gao D, Elias A, Borges V, Kabos P, Davis SL, Leong S, Diamond JR. Patients with Metastatic Breast Cancer Enrolled in Phase I Clinical Trials: Clinical Outcomes and Cohort Trends. Proc ASCO 2019.
213. Williams MM, Spoelstra NS, Arnesen S, Christenson JL, O'Neill K, Reese JM, Blanchard ZD, Hanamura T, Jacobsen BM, Gertz J, Elias A, Richer JK. Preclinical and Clinical Analyses of Estrogen Receptor Mutant Metastatic Breast Cancer. SABCS 2019.
214. Li W, Onishi N, Newitt DC, Harnish R, Jones EF, Wilmes LJ, Gibbs J, Price E, Joe BN, Albain KS, Berry DA, Boughey JC, Chien A, Clark AS, Edmiston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Isaacs C, Khan QJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yee D, Yung R, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Symmans W, van't

Veer LJ, Esserman LJ, Hylton NM. The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI. SABCS 2019.

215. Li W, Onishi N, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Joe BN, Sit LS, Yau C, Brown T, Albain KS, Berry DA, Boughey JC, Chien A, Clark AS, Edmiston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Isaacs C, Khan QJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yee D, Yung R, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Symmans W, van't Veer LJ, Esserman LJ, Hylton NM. Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial. SABCS 2019.
216. Ingham M, Mahoney MR, Remotti F, Shergill A, Dickson MA, Riedel RF, Attia S, Elias AD, Liebner DA, Agulnik M, Thornton KA, Monga V, Van Tine BA, Schwartz GK, Tap WD. A randomized phase II study of MLN0128 (M) vs. pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304). Proc ASCO 2020, abstract 11562.
217. Elias AD, Fournier M, Vidal GA, Sams S, Spoelstra N, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Carter L, Zolman K, Armstead S, Winchester A, Borges V, Wulfkuhle J, Petricoin E, Gao D, Richer J. Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer. SABCS 2020, PS12-06.
218. Elias AD, Spoelstra N, Vidal GA, Sams S, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, Wulfkuhle J, Petricoin E, Hill S, Zolman K, Armstead S, Winchester A, McSpadden T, Crawford G, Borges V, Gao D, Richer J. Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer. SABCS 2020, PS12-14.
219. Richer JK, Spoelstra N, Winchester A, Wulfkuhle J, Sams S, Vidal G, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges VF, Gao D, Petricoin E, Elias AD. Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide. Proc AACR 2021, poster.
220. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin SN, Xing Y, Dumbrava EI, Karp D, Piha-Paul S, Tsimberidou AM, Ahnert JR, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase 2 trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. Proc AACR 2021, poster.
221. Gabrail N, Hamilton E, Elias A, Rimawi M, Li C, Corvez M, Li W, Feng Y, Wei J, Greene S, Patterson J, Zeng Q, Hui A-M. A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in pts with advanced solid tumors. Proc ASCO 2021.
222. Updated analysis of a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC). Proc ASCO 2021.
223. Chien AJ, Soliman H, Ewing C, Boughey JC, Campbell MJ, Rugo HS, Wallace A, Albain KS, Stringer-Reasor E, Church AL, Kalinsky K, Elias A, Mitri Z, Clark AS, Nanda R, Thomas A, Yau C, I-SPY 2 Consortium, Berry DA, Esserman LJ. Evaluation of Intra-tumoral (IT) SD-101 and Pembrolizumab (Pb) in combination with

paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Proc ASCO 2021, A-508.

224. Schreiber AR, Kagihara J, Nickbowski A, Gao D, Afghahi A, Elias A, Kabos P, Shagisultanova E, Pitts T, Lang J, Karam S, Borges V, Fisher C, Diamond JR. Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer. Proc AACR, 2022.
225. Van Tine BA, Tap WD, Ratan R, Attia S, Elias AD, Monga V, Hartner L, Agulnik M, Schwartz GK, Ali A, Mintautas I, Lobbaridi R, Schoenborn-Kellenberger O, Hurh E, Crystal AS, Cote GM. A phase 1/2 study of CFT8634, a novel bifunctional degradation activating compound (BIDAC) degrader of BRD9, in synovial sarcoma and SMARCB1-null tumors. CTOS 2022.